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Thesis Abstract 
Introduction 
Substance misuse in Ireland has a long history. Alcohol was recognised as 
the main concern, but it was not until the 1960s that other dependence-
forming substances have been recognised as problematic in Ireland. Since 
then, the number of misused substances has risen sharply to include novel 
synthetic compounds and prescription-only medicines. Many attempts have 
been made to reduce the misuse of these substances: restricting growth and 
manufacture of substances, criminalising possession, increasing prescribing 
requirements, and using treatment centres to assist those who wish to stop 
misusing. Despite enormous expense and effort, substance misuse is still a 
problem. The mechanism by which these substances excite the brain’s 
natural reward pathways means it can be difficult for misusers to stop 
desiring the effects of the substances. Much has been discovered about how 
misused substances create their dependence-forming effect, but there is still 
much unsolved in such a complex area. 
 
Methods 
A systematic review was undertaken on the prevalence of substance misuse 
amongst young people in Ireland between 2000 and 2012 to create a context 
in which later research among substance misusers can be compared, and to 
put benzodiazepine misuse in the context of other misused substances.  
 
xvi 
 
Data from national reimbursement claims were analysed to examine trends 
in: (i) the prescribing of benzodiazepines nationally and internationally and 
(ii) the prescribing of benzodiazepines to patients younger than 18 years 
between 2009 and 2012, to monitor adherence to benzodiazepine 
prescribing guidelines and to highlight areas in prescribing where the 
potential for misuse could be decreased.  
 
The differences between urban and rural attendees of a substance misuse 
treatment centre in Cork were compared to examine whether there were 
differences in substance misuse between the groups. This was followed by a 
comparison of regular and non-regular benzodiazepine misusers from the 
substance misuse treatment centre and their self-reported misuse-related 
symptoms. 
  
The next stage involved qualitative research using semi-structured interviews 
with young people who had misused benzodiazepines in their adolescence. 
This approach was used to describe the experiences and causes of youth 
benzodiazepine misuse in Cork and to guide future interventions to reduce 
misuse. This approach was also utilised for interviews conducted with youth 
counsellors (YCs) and general practitioners (GPs). As substance misuse in 
adolescence can lead to damaged brain development, which may result in a 
lack of insight into their behaviours, it was important to gain this information 
from those who have worked with young benzodiazepine misusers. 
xvii 
 
 Results 
The systematic review returned 18 articles that matched the inclusion criteria 
for the study. The review showed that tobacco, alcohol and cannabis use 
levels in Ireland have reduced in the period between 2000 and 2012. Lifetime 
tobacco use reported at the beginning of the review period ranged from 
approximately 61-67%, and decreased to 43-48% at the end of the study 
period. Lifetime alcohol levels similarly decreased from 71-92% at the 
beginning of the review period to 58-81%. Lifetime cannabis misuse 
decreased from 29-39% to approximately 18%. Lifetime benzodiazepine 
misuse was the only parameter which did not decrease over the study 
period. Research conducted into the comparison of Irish prescribing data 
relative to European counterparts found that Ireland had the fourth highest 
level of benzodiazepine prescribing among those countries surveyed 
between 2009 and 2012. However Irish prescribing did decrease by 16% 
over this time. Approximately 15% of Irish people aged 17 and under were 
prescribed benzodiazepines for greater than four weeks, whilst 
approximately 40% were prescribed hypnotics, both in contravention of the 
Good Practice Guideline for Clinicians. 
 
Data comparing urban and rural treatment centre attendees showed that a 
greater percentage of rural service-users were employed (p = 0.015), more 
urban service-users were unemployed (p = 0.015), while there were similar 
levels of students from urban and rural areas. A greater proportion of urban 
service-users had taken multiple substances in their lifetime (73.7% vs. 
xviii 
 
52.2%, p = 0.001) and continued to use multiple substances regularly (49.3% 
vs. 31.3%, p = 0.003) compared with their rural counterparts. The study 
comparing regular and non-regular benzodiazepine usage showed that 
benzodiazepines had ever been used by 51.0% treatment centre attendees, 
and of these, 55.8% were regular benzodiazepine users. The mean age of 
first use was 14.9 ± 1.4 years. Regular users of benzodiazepines were 
regular users of significantly more substances (3, IQR = 2-3) when compared 
with non-regular benzodiazepine users (1, IQR = 1-2). Regular 
benzodiazepine users reported more behavioural signs (12, IQR = 10-14) 
than non-regular users (9, IQR = 7-12). Physical signs were significantly 
different between regular (8, IQR = 6-11) and non-regular (5, IQR = 3-10) 
users.  
 
Interviews with benzodiazepine misusers highlighted that benzodiazepines 
are used by young people coping with the pressures of life, and its use is 
encouraged and/or normalised by those around them. Participants said that 
they took benzodiazepines to escape negative feelings, to “not feel anything 
at all”, and that they were taken in a group setting. The majority of 
participants indicated that they had no knowledge of benzodiazepines when 
they started taking them.  
 
The YC/GP interviews confirmed these findings and added the importance of 
family and community attitudes on the potential for young people to misuse 
benzodiazepines. GPs and YCs felt that doctors were more aware of the 
xix 
 
risks of prescribing to young people and prescribed less than in the past. 
Participants suggested that public awareness campaigns and stricter 
prescribing regulations could reduce the levels of misuse. 
 
 
Conclusion 
This thesis provides a comprehensive overview of the issues of 
benzodiazepine misuse by young people in Ireland. Quantitative analysis has 
demonstrated that while prescribing of benzodiazepines to young people has 
decreased over the last number of years, approximately 15% of those aged 
17 and under were prescribed benzodiazepines for greater than four weeks, 
whilst approximately 40% were prescribed hypnotics. Qualitative research 
with young people, GPs and substance misuse counsellors has highlighted 
the many factors that can influence misuse and makes recommendations on 
what can be done to reduce it, which ultimately will benefit the individual and 
society. 
 
  
xx 
 
Acknowledgements 
 
I want to express my gratitude to my supervisors; Stephen, Laura, and 
Suzanne for their unceasing support to me from day one of my studies. I 
have learned much since January 2011 and it is due to their foresight, 
guidance and encouragement that I got the most from my PhD. 
 
I would also like to thank Sharon for guiding me through the world of youth 
substance misuse and for sharing her enthusiasm for helping all the young 
people who pass through the doorway of Matt Talbot Services. 
 
Many thanks to everyone who worked in Room 2.01; Richie, James, Shane, 
Marion, Dónal Óg, Dave O’ Riordan and Maria. Their friendship and support 
kept my spirits high throughout the PhD.  
 
I want to give a special thanks to Dave O’ Sullivan and Aoife. Dave was my 
mentor at the beginning of my studies; he was always patient and gave his 
time freely to help me. Aoife and I were at similar stages of our studies and it 
was reassuring to share my difficulties with her. 
 
I also want to thank the staff of Matt Talbot Services; Ger, Ciara, Sarah (who 
has gone on to greater things), the two Pats, Suzanne, Tara, Edel, and the 
xxi 
 
staff of the day program and residential unit. You welcomed me into your 
family and I felt at home among you. 
 
I thank the staff of the School of Pharmacy for helping me ensure that the 
little things did not become time-consuming. 
 
I would like to thank my family for their support and understanding 
throughout. I want to also thank my friends for reminding me that there was 
life outside of the PhD. 
 
The final thanks must go to Wei for her unconditional and inexhaustible 
support. 
 
xxii 
 
 Thesis Introduction 1.
 
 
1 
 
1.1 Drugs Policy in Ireland 
The beginning of drug policies in Ireland originates with legislation enacted 
before Irish independence. Prior to the first legislation in 1851, all substances 
were relatively freely available in Ireland. The Arsenic Act, 1851 controlled 
the supply of arsenic to the public (1). Following this was the introduction of  
the Pharmacy Act (Ireland), 1875 which made changes such that the 
preparation or sale of opium could only be performed by a registered 
pharmacist, and medicines containing opium were required to be labelled 
“Poison” (1). The next significant legislation was the Poisons and Pharmacy 
Act, 1908 which added coca and its derivatives to the list of pharmacist-
controlled substances. The Dangerous Drugs Act, 1920 put these 
substances under stricter control. The Act required those in possession of 
the above substances and the synthetic opioid heroin to have a prescription 
from a doctor or dentist. It also restricted their importation and exportation (2) 
The first legislation drafted by the Irish Free State was the Dangerous Drugs 
Act, 1934, which replaced the Dangerous Drugs Act, 1920. It included other 
legislation to comply with the International Convention for Limiting the 
Manufacture and Regulating the Distribution of Narcotic Drugs in 1931. The 
commencement order for the act [Dangerous Drugs Act, 1934 
(Commencement) Order, 1937] was not enacted until the 1st April 1937. 
From this time, there was a prohibition of the possession of the above 
substances, cannabis, and other natural or synthetic opioids that were known 
at the time. Exceptions to this were provided for specified medicinal products 
that contained morphine.  
 
2 
 
The Misuse of Drugs Act, 1977 which was commenced on 1st May 1979, 
created four schedules into which prohibited substances were placed 
(updated schedules Appendix I). A person may only legally possess a 
Schedule 1 substance if they have been licenced by the Minister of Health. 
Substances in Schedule 1 are deemed to have little medicinal use and high 
abuse potential, and contained substances such as cannabis, coca leaf (from 
which cocaine is obtained), lysergic acid diethylamide (LSD), psilocin (the 
psychoactive chemical in magic mushrooms derived from the prodrug, 
psilocybin), and raw opium. Schedules 2 and 3 contained substances that 
were controlled less strictly than Schedule 1 as they were deemed to have 
greater medicinal properties. They may be prescribed in some circumstances 
by registered prescribers. Cocaine, codeine, heroin, methadone, and 
morphine were part of Schedule 2. The Act also updated the list of 
substances that were regulated to include novel substances such as 
amphetamines, and other synthetic opioids such as fentanyl. 
 
The next significant update was provided by the Misuse of Drugs 
Regulations, 1988. A further schedule was added to the regulations which 
were mostly populated by benzodiazepines. Schedule 4 from the previous 
Act was renamed Schedule 5 and the restrictions on benzodiazepines 
occupied the new Schedule 4. This schedule had minimal restrictions similar 
to Schedule 5, but the disposal and destruction of Schedule 4 substances 
were regulated. Amendments have been made to the schedules as set out in 
the Misuse of Drugs Act to include novel substances such as midazolam 
(Schedule 4) in 1993, or substances that were becoming more widely used in 
3 
 
Ireland such as khat (the leaves of Catha edulis) (Schedule 1) in 1993, magic 
mushrooms (Schedule 1) in 2006, zolpidem (Schedule 4) in 2010. The most 
significant of these changes was from the Misuse of Drugs (Amendment) 
Regulations 2007, which permitted nurses to prescribe medicines such as 
opioids from Schedules 2 or 3 in limited circumstances. Another significant 
piece of legislation enacted was the Criminal Justice (Psychoactive 
Substances) Act 2010. The act forced the closure of head shops i.e. 
premises where unregulated novel psychoactive substances were sold. 
 
In the near future, there are plans to more strictly regulate the prescription of 
all benzodiazepines due to the increase in illicit trading. A draft of the 
regulations include requirements for those in possession of benzodiazepines 
to have a prescription, benzodiazepine quantities to be stated in words and 
figures, and that pharmacies must notify the government of privately 
dispensed benzodiazepines as well as medicines in Schedules 1, 2 and 3 
(Appendix II) (3). It is hoped that these regulations may reduce the current 
high availability of illicit benzodiazepines. 
 
In parallel to evolution of laws to regulate substance use, there has also 
been the evolution of other methods to prevent and treat substance misuse. 
The first organised attempt to reduce substance misuse on a large scale in 
Ireland was the Cork Total Abstinence Society founded in 1835 by a Quaker 
named William Martin. The organisation, which promoted abstention from 
alcohol, became widespread when Father Theobald Mathew joined the 
4 
 
organisation in 1938 (4). The organisation spread across the country and by 
1843, 250,000 Irish people had pledged lifelong abstinence from alcohol. 
The organisation declined during the Great Famine and never recovered. 
The tradition of abstention in Ireland was continued by Fr. James Cullen 
when he founded the Pioneer Total Abstinence Association of the Sacred 
Heart in 1889 which is still in existence today (5).  
 
During this period, there was no government involvement in dealing with 
substance misuse and it was only in 1945, with the enactment of the Mental 
Treatment Act, that the government put forward legislation regarding mental 
health (6). This act provided for voluntary and/or compulsory admission of 
addicts to psychiatric hospitals. This was mainly intended for the treatment of 
alcoholism, as the 1966 Report of the Commission of Inquiry on Mental 
Illness stated that Ireland had avoided serious drug use (7). The problem of 
rising misuse was recognised soon thereafter however, and the first Irish 
statutory outpatient treatment facility was established at Jervis Street 
Hospital in 1969 (7). The government commissioned a report entitled: Report 
of the Working Party on Drug Abuse, which was published in 1971, and it 
was the first report to present recommendations for the prevention and 
treatment of substance misuse (6). Some of its recommendations such as 
differentiating between possession and possession with intent to supply, and 
penalties based on the drug possessed are still enforced to this day. 
 
5 
 
There was a dramatic rise in opiate use in Dublin at the beginning of the 
1980s, but it was not until 1985 that the National Co-ordinating Committee on 
Drug Abuse was set-up to monitor and advise on drug misuse (7). The drug 
treatment approach changed because of fears of an Acquired Immune 
Deficiency Syndrome (AIDS) epidemic in the late 1980s to incorporate a 
harm reduction approach to reduce the risk of drug misusers becoming 
infected with the disease. Examples of harm reduction approaches that were 
pursued were (i) use of a prescribed medicine; methadone, to replace the 
use of heroin from 1987, and (ii) needle exchange schemes from 1989 (6). It 
was not until 1991 that the harm reduction approach received official backing 
from the National Co-ordinating Committee on Drug Abuse in the 
Government Strategy to prevent Drug Misuse report (8). This was the first 
drugs policy that had been used in a national drugs strategy. The report 
recommended a decentralised approach to prevention and treatment, such 
as the development of community drug services and a greater role for 
general practitioners (GPs) for treatment of dependence (6). 
 
In 1998, the methadone treatment protocol was rolled out nationally. It 
created the two-tier system for methadone treatment, where Level 1 doctors 
could not initiate methadone prescriptions, but rather this could only be done 
by the specifically-trained Level 2 doctors. A new drugs strategy document 
was published in 2001 called; “Building on experience: national drugs 
strategy 2001-2008” (8). This report stratified drugs policy around four pillars, 
(i) supply reduction, (ii) prevention, (iii) treatment, and (iv) research. Regional 
drugs task forces were created to tackle alcohol and drug issues at a local 
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level. The strategy sought to increase the availability of treatment places in 
communities and prisons to reduce waiting times. The latest National Drugs 
Strategy, covering the period 2009-2016, reported that alcohol would be 
included as a substance that would be monitored in a new policy called the 
National Substance Misuse Strategy (9). Some of the initiatives suggested to 
reduce alcohol misuse include the introduction of minimum pricing and the 
phasing out of alcohol advertising at large sporting and other public events 
by 2016 (10). 
 
To understand what challenges may lay ahead, and what strategies can be 
used to prevent them, it is important to understand the source of the problem 
with all these drugs i.e. dependence. 
 
1.2 Defining addiction and dependence 
In layman’s terms “addiction” and “dependence” have essentially the same 
meaning. It becomes clear however that as more is learned about the field 
that these concepts refer to different things. Addiction is the older term and 
referred to intense liking of any activity, e.g. addicted to reading. It was only 
in the beginning of the 20th century that this word took on the specialised 
drug meaning (11). Such was the confusion that the World Health 
Organisation (WHO) abandoned the word and instead used the word 
“dependence” (12).  The use of the word addiction however, has not 
diminished and today there are a myriad of definitions for the word, with 
different yet overlapping features. A report by the European Monitoring 
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Centre for Drugs and Drug Addiction (EMCDDA) highlighted this by 
presenting a sample of nine varying definitions of addiction in their Models of 
Addiction report (13). The EMCDDA report created a definition that 
aggregated the concepts suggested by these definitions and defined 
addiction as (8): 
 “A repeated powerful motivation to engage in a purposeful behaviour 
that has no survival value, acquired as a result of engaging in that behaviour, 
with significant potential for unintended harm.” 
 
It can be seen that this definition is not restricted to legal and illegal 
substance use but can potentially include activities such as gambling and 
internet use. 
 
As stated earlier, the term ‘dependence’ was first formally used in a drug use 
context by the Expert Committee on Addiction-producing Drugs of the WHO 
in 1964 in an attempt to replace the ambiguous terms of addiction and 
habituation. The report defined dependence as “a state arising from repeated 
administration of a drug on a periodic or continuous basis” (14). The 
definition has changed subsequently and the present definition of 
dependence given by: 
“As a general term, the state of needing or depending on something or 
someone for support or to function or survive. As applied to alcohol and 
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other drugs, the term implies a need for repeated doses of the drug to feel 
good or to avoid feeling bad” (15). 
 
On its own, the term refers to the concept of dependence, but it can be 
qualified to confer greater specificity. Dependence can be divided into two 
types; (i) psychological and (ii) physiological dependence. Both of these 
terms will be explained in detail later. Dependence can also be qualified to 
include reference to a class of substances or to an individual substance, e.g. 
opioid dependence, morphine dependence. 
 
1.3 Diagnosing dependence 
The broad definitions of dependence available can make diagnosis of 
dependence more difficult in a clinical setting. To aid diagnosis, criteria have 
been developed to support mental health professionals in their diagnosis and 
treatment of those with dependence. There are two primary diagnostic 
criteria used internationally:  
 
The first of these is the Tenth Revision of the International Statistical 
Classification of Diseases and Related Health Problems (ICD-10) (16). 
Section F10-F19 covers “Mental and behavioural disorders due to 
psychoactive substance use”. Dependence in this classification falls under 
F1x.2, where ‘x’ is a digit that differs depending on the substance that the 
patient is using. The diagnostic guidelines for dependence for any 
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dependence-forming substances in general are listed in Table 1.1. The Beta 
Draft of the updated ICD criteria, ICD-11, put substance dependence at 
section 5C1.Since it is a beta draft, no criteria were described (17). The full 
diagnostic criteria are expected to be released in 2015. 
Table 1.1. ICD-10 diagnostic criteria for substance dependence 
A definite diagnosis of dependence should usually be made only if three or more of 
the following have been present together at some time during the previous year: 
(a) a strong desire or sense of compulsion to take the substance; 
(b) difficulties in controlling substance-taking behaviour in terms of its onset, 
termination, or levels of use; 
(c) a physiological withdrawal state (see F1x.3 and F1x.4) when substance 
use has ceased or been reduced, as evidenced by: the characteristic 
withdrawal syndrome for the substance; or use of the same (or a closely 
related) substance with the intention of relieving or avoiding withdrawal 
symptoms; 
(d) evidence of tolerance, such that increased doses of the psychoactive 
substances are required in order to achieve effects originally produced 
by lower doses (clear examples of this are found in alcohol-and opiate-
dependent individuals who may take daily doses sufficient to 
incapacitate or kill non-tolerant users); 
(e) progressive neglect of alternative pleasures or interests because of 
psychoactive substance use, increased amount of time necessary to 
obtain or take the substance or to recover from its effects; 
(f) persisting with substance use despite clear evidence of overtly harmful 
consequences, such as harm to the liver through excessive drinking, 
depressive mood states consequent to periods of heavy substance use, 
or drug-related impairment of cognitive functioning; efforts should be 
made to determine that the user was actually, or could be expected to 
be, aware of the nature and extent of the harm; 
 
An intermediate stage between non-use and substance dependence is 
described in the ICD-10; harmful use. Diagnosis of harmful use is made 
based on whether “…actual damage should have been caused to the mental 
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or physical health of the user”, without the diagnosis of substance 
dependence (16).  
 
The second commonly used criteria comes from the American Psychiatric 
Association’s Text revision of the Diagnostic and Statistical Manual of Mental 
Disorders IV (DSM-IV-TR) (18). The diagnostic guidelines for substance 
dependence are listed in Table 1.2.  
Table 1.2. DSM-IV-TR diagnostic criteria for substance dependence 
A maladaptive pattern of substance use, leading to clinically significant impairment 
or distress, as manifested by three (or more) of the following, occurring at any time 
in the same 12‐month period: 
1 Tolerance, as defined by either of the following: 
 a A need for markedly increased amounts of the substance to achieve 
intoxication or desired effect 
or  
 b Markedly diminished effect with continued use of the same amount of 
the substance 
2 Withdrawal, as manifested by either of the following: 
 a The characteristic withdrawal syndrome for the substance 
or  
 b The same (or a closely related) substance is taken to relieve or avoid 
withdrawal symptoms 
3 The substance is often taken in larger amounts or over a longer period than 
was intended 
4 There is a persistent desire or unsuccessful efforts to cut down or control 
substance use 
5 A great deal of time is spent on activities necessary to obtain the substance 
(e.g., visiting multiple doctors or driving long distances), use the substance 
(e.g., chain‐smoking), or recover from its effects 
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6 Important social, occupational, or recreational activities are given up or 
reduced because of substance use 
7 The substance use is continued despite knowledge of having a persistent 
physical or psychological problem that is likely to have been caused or 
exacerbated by the substance (e.g., current cocaine use despite 
recognition of cocaine‐induced depression, or continued drinking despite 
recognition that an ulcer was made worse by alcohol consumption) 
 
Much like the harmful use criteria used in the ICD-10, DSM-IV-TR has a 
stage of substance use that occurs before substance dependence; 
substance abuse. The criteria for substance abuse are listed in Table 1.3. 
Table 1.3. DSM-IV-TR diagnostic criteria for substance abuse 
A maladaptive pattern of substance use leading to clinically significant impairment 
or distress, as manifested by one (or more) of the following, occurring within a 12‐
month period: 
1 Recurrent substance use resulting in a failure to fulfil major role 
obligations at work, school, or home (e.g., repeated absences or poor 
work performance related to substance use; substance‐related 
absences, suspensions, or expulsions from school; neglect of children 
or household 
2 Recurrent substance use in situations in which it is physically hazardous 
(e.g., driving an automobile or operating a machine when impaired by 
substance use) 
3 Recurrent substance‐related legal problems (e.g., arrests for substance‐
related disorderly conduct) 
4 Continued substance use despite having persistent or recurrent social or 
interpersonal problems caused or exacerbated by the effects of the 
substance (e.g., arguments with spouse about consequence of 
intoxication, physical fights) 
The symptoms have never met the criteria for Substance Dependence for this class 
of substance. 
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A newer version of the DSM was released in May 2013 (DSM-5) and 
contains some changes from the previous iteration (19). Substance use is no 
longer a dichotomous choice between Substance Abuse and Substance 
Dependence, each with differing criteria. Instead, both have been merged 
into a single condition called Substance Use Disorder, which ranges from 
mild to severe. Substance Use Disorder comprises of a list of 11 statements. 
The list is generally the same as the items in the previous list except that 
item 3 in Substance Abuse was removed, due to “cultural considerations that 
make the criteria difficult to apply internationally”. Additionally, drug craving 
was added to the list. A diagnosis of Mild Substance Use Disorder requires 
the presence of two to three symptoms on the list, Moderate Substance Use 
Disorder requires the presence of four to five symptoms, while Severe 
Substance Use Disorder signifies the patient having six or more symptoms 
(20).  The DSM-5 is less than a year old and has yet to become widely 
referenced in scientific literature so for the purposes of this introduction the 
criteria of DSM-IV-TR are still used. Because these criteria were developed 
and are to be used by psychiatric assessment, they assume a top-down view 
of dependence; dependence at the level of the individual, their beliefs, view 
and their interactions with others. The basis for this view is discussed in the 
next section. 
 
1.4 Psychological dependence 
Psychological dependence is a state of dependence that occurs purely at the 
psychological or mental level, as opposed to the physiological level. As with 
many terms in the area of substance use, there is no single agreed definition 
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of psychological dependence, however the definitions used do overlap. 
Psychological dependence is defined by the WHO as “the experience of 
impaired control over drug use” (15). The definition used by the American 
Psychiatric Association is “dependence on a psychoactive substance for the 
reinforcement it provides” (21). Examples of alternative definitions include 
“The emotional state of craving a drug either for its positive effect or to avoid 
negative effects associated with its absence” (22), and “A non-physiological 
attachment to the availability of the prescribed medication that may be a 
natural response to effective relief of distressing symptoms” (23). Smith, et 
al. 2013 performed a systematic review of definitions of common terms used 
in substance abuse, and examined common features of definitions of these 
definitions (24). For psychological dependence, the features were: 
compulsive use and impaired control, craving, characterised by drug use to 
obtain psychotropic or euphoric effects, avoidance of negative effects and 
symptoms associated with drug absence, unpleasant emotional and 
motivational effects, and non-physiological attachment to availability of a 
drug. The main features studied in the literature were craving and 
compulsion.  
 
Craving, like addiction, is a term with many definitions and no consensus. 
The WHO definition of craving is a “very strong desire for a psychoactive 
substance or for the intoxicating effects of that substance” (15). A recent 
definition of craving came from a review of models of craving published in 
2010 (25). Craving was defined as “a desire of any intensity to consume a 
substance”. There are also perspectives on craving that are generalised 
14 
 
beyond substance use. One study wrote that “craving is the ‘grasping’ quality 
of the mind as it attempts to pursue its attachments” (26). Just as there are 
many definitions of craving there are also many explanations for it. The 
review by Skinner and Aubin in 2010 found many attempts to explain 
craving, and some are presented below (27): 
• Conditioning models work on the assumption that “craving is an 
automatic, unconscious reaction to a stimulus”. 
• Cognitive models use the principle that “craving arises from the 
operation of information processing systems”. This differs from 
conditioning models in that conscious, higher functions such as 
expectancies and concentration influence cravings (28). 
• Psychobiological models work on the premise that cravings are due to 
a combination of both physical and psychological factors. 
• Motivation models see craving as one of many factors that influence 
motivation to use a substance. Level of motivation to use a substance 
decides whether a person will actually use that substance. 
Each of these models has its strengths and weaknesses so it is difficult to 
prioritise any one of the models. 
 
Compulsion is defined by the WHO as “…a powerful urge - attributed to 
internal feelings rather than external influences - to take the substance (or 
substances) in question. The substance user may recognize the urge as 
detrimental to well-being and may have a conscious intent to refrain” (15), 
and as “repetitive, purposeful acts performed according to certain rules or in 
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a ritualized manner” (29).  There are conflicting opinions among researchers 
as to whether cravings and compulsions are separate factors in 
psychological dependence. Some view craving as the cause of the 
compulsion to misuse substances, while others view compulsion as an 
automatised behaviour (30). The latter view craving as a conscious process 
while compulsion is an unconscious process (31).  
 
1.5 Physiology of psychological dependence 
While the previous section described psychological dependence from a top-
down approach, this section uses a bottom-up approach to describe 
psychological dependence in a neurophysiological manner. The primary 
location for the rewarding effects of dependence-forming substances is the 
nucleus accumbens (NAc) (Figure 1.1) (32). An increase in the level of 
dopamine (DA) in this area results in increased reward. Increased levels of 
DA in the NAc has also been linked with other non-substance related 
activities such as seeking social approval from others (33). All substances 
which have the potential to cause psychological dependence increase DA in 
the NAc (34). 
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 Figure 1.1. Schematic diagram of the human brain that highlights some of the 
main brain areas and neurotransmitter pathways implicated in reward 
processes (35) 
 
Mesolimbic neurons that reach the NAc from the ventral tegmental area 
(VTA) are recognised as the main neurons responsible for stimulation of the 
NAc (36). Dopaminergic (DAergic) neurons from the VTA also innervate 
areas of the prefrontal cortex (PFC) (Figure 1.2) (37).  
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 Figure 1.2. Action of selected dependence-forming substances in the 
mesolimbic system (38) 
 
Stimulation of some of these areas is thought to be responsible for other 
features of psychological dependence. Other areas include; conditioning to 
cues, executive function and motivation (32). Effects on misusers’ memories 
can result in the sensation of craving when exposed to drug cues, such as 
watching others use the substance. This powerful effect is thought to be due 
to the presence of DA in the dorsal striatum, as a correlation has been 
observed between cue-induced DA increases and high scores on addiction 
severity tests (39). Indeed, in one study of cocaine addicts, the DA increase 
appeared greater for the cues than the DA increase produced by the drug 
itself (40). This suggests that at the beginning of substance misuse the DA 
increases may be linked to the effect of the substance, however after 
repeated use, the increases in DA appear to be primarily due to cues such 
as drug administration equipment or watching others use. Executive function 
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in physiology refers to cognitive processes such as planning, decision-
making and self-monitoring, and it is the PFC that is  primarily responsible for 
executive function (41). Impairments in this area of the brain are thought to 
lead to reduced self-control. This was shown in a study where lateral PFC  
activity in cigarette smokers predicted smoking behaviour over a three-week 
period (42). This is thought to occur due to damage to the PFC which 
increases subjects’ desires for immediate gratification compared with larger, 
delayed rewards (43, 44). This would suggest that a misuser would prefer 
drug use over the benefits of staying clean. 
 
Motivation to procure a substance is a defining feature of substance 
dependence; misusers are often willing to engage risky behaviour with 
severe consequences to obtain the drug they seek (45). In a dependent 
misuser, substance-seeking and substance-taking can be the biggest 
motivator in that person’s life and, in comparison, the person can lack 
motivation to pursue non-substance-related activities (46). The PFC and NAc 
are both involved in regulating motivation behaviour. Increased DA activity in 
the PFC is associated with motivation and has been observed when 
dependent subjects are exposed to substance-conditioned cues in 
comparison to the levels when exposed to non-substance-conditioned cues 
(47). Another study showed that dependent subjects showed more activity in 
the same region than nondependent subjects when administered a stimulant 
(48). The conclusion of both of these studies is that substance dependence 
can result in higher motivation to take the substance. 
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 1.6 Physical dependence 
Physical dependence is the counterpart to psychological dependence. Both 
forms of dependence can have deleterious effects on the substance misuser 
if they cannot access their drug. Psychological and physical dependence to a 
substance do not always occur together, and those who are dependent can 
experience both types of dependence with differing severities. Examples of 
substances which can result in physical dependence with little-to-no 
psychological dependence are caffeine, (49) β-blockers (50) and some 
antidepressants (51). To understand how this can be, it is helpful to look at 
definitions of physical dependence. Physical dependence as defined by the 
WHO “…refers to tolerance and withdrawal symptoms…is also used in the 
psychopharmacological context in a still narrower sense, referring solely to 
the development of withdrawal symptoms on cessation of use” (15). The 
systematic review by Smith et al. 2013, found that definitions of physical 
dependence had the following elements, “associated with withdrawal 
symptoms or a withdrawal syndrome, adaptive physiologic process, occurs 
when the drug is rapidly withdrawn, tolerance to substance effects” (24). 
Both of these highlight that tolerance and withdrawal are the essential 
features of physical dependence. Tolerance is defined as “a decrease in 
response to a drug dose that occurs with continued use” (15), while a 
withdrawal syndrome is, 
“a group of symptoms of variable clustering and degree of severity 
which occur on cessation or reduction of use of a psychoactive 
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substance that has been taken repeatedly, usually for a prolonged 
period and/ or in high doses” (15) 
 
The difficulty in defining the effects of withdrawal exist because withdrawal 
symptoms differ based on the substance in question. A brief description of 
withdrawal symptoms for different classes of misused substances will now be 
provided. 
 
Withdrawal symptoms to opioids can begin as soon as 8-12 hours for short-
acting substances such as morphine or heroin, while onset may not start until 
1-3 days after cessation of use for longer-acting opioids such as methadone 
(52). Withdrawal symptoms are generally milder for longer-acting opioids but 
can last for several weeks, while the withdrawal symptoms of short-acting 
opioid may be more severe but subside after 7-10 days. The typical 
symptoms experienced include; craving, anxiety, dysphoria, yawning, 
sweating, piloerection, lacrimation, rhinorrhoea, insomnia, nausea or 
vomiting, diarrhoea, cramps, muscle aches and fever (52).  Alcohol 
withdrawal symptoms can appear within 6-12 hours. In mild cases of 
withdrawal the symptoms include insomnia, tremor, mild anxiety, 
gastrointestinal upset, headache, perspiration, while severe withdrawal can 
lead to seizures and delirium tremens; which involves hallucinations and 
disorientation. Symptoms can persist for up to five days (53). Unsurprisingly 
as benzodiazepines have a similar mechanism of action to alcohol, 
benzodiazepine withdrawal symptoms share similar features to alcohol 
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withdrawal. Symptoms include all symptoms listed above and others 
including formication (skin crawling), tingling and numbness, and 
depersonalisation (54). 
 
Psychostimulants are a class of substances that includes amphetamines, 
cocaine, methamphetamine, and ecstasy (55). These substances have 
different mechanisms of action but all produce similar effects and likewise 
have similar withdrawal symptoms. These symptoms include; dysphoria, 
depression, poor concentration, agitation, insomnia, craving, irritability. The 
duration of withdrawals differs between psychostimulants, for example 
amphetamine withdrawal can last up to four weeks while methamphetamine 
withdrawal can last months (55). Nicotine is another substance that is 
classed as a stimulant (56), and thus the withdrawal symptoms of nicotine 
misuse are similar; irritability, anxiety, difficulty concentrating, restlessness, 
bradycardia, weight change, dysphoria and insomnia (57). The onset of 
withdrawal symptoms from cannabis misuse can begin from 1-4 days after 
cessation (58). Common withdrawal symptoms include craving, sleep 
difficulties, irritability, aggression, anxiety, and change in appetite (58). 
Withdrawal symptoms from inhalants such as acetone and toluene are not 
widely recognised because they are claimed not to be clinically significant, 
however this may be due to a paucity of research in the area (59). Examples 
of symptoms experienced as a consequence of withdrawal from inhalant use 
are headaches, nausea, hallucinations, rhinorrhoea, tachycardia, dysphoria 
and anxiety. Further research into the area could uncover further symptoms 
or re-prioritise the existing ones.  
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 The final category of misused substances is the hallucinogens. 
Hallucinogens comprise of substances that produce changes in mood and 
perception (60). Substances included in this category include LSD, peyote 
(whose active substance is mescaline), and magic mushrooms (18). There is 
conflict about whether withdrawal symptoms are a feature of hallucinogen 
misuse, as DSM-IV-TR states that withdrawal is not necessary for a 
diagnosis of hallucinogen dependence (18), while others doubt whether 
hallucinogens cause dependence (61). Others suggest that such symptoms 
exist and describe them as craving, fatigue, irritability, reduced ability to 
experience pleasure (62).  
 
1.7 Mechanisms of action of misused substances 
To understand how these substances cause their withdrawal effects and how 
they have their acute effects, it is necessary to understand how these 
substances affect the body. As described in the psychological dependence 
above, all dependence-forming psychoactive substances interact with 
DAergic neurons in the NAc and the VTA. This section will describe how this 
occurs in the human body. 
 
Opioids bind to G-protein-coupled opioid receptors in the body, of which 
there are four types: mu (μ), delta (δ), kappa (κ), and opioid receptor-like 1 
(ORL1)(61). The μ opioid receptor (MOR) is the primary opioid receptor 
responsible for substance dependence and euphoria (63). The MOR is 
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distributed throughout the central nervous system with the greatest densities 
occurring at the thalamus, dorsal striatum, and NAc (64). The dependence-
forming effects of opioids are thought to be due to the presence of MOR on 
gamma-aminobutyric acid (GABA) interneurons that project from VTA to NAc 
(65). MOR-mediated hyperpolarisation of these GABAergic interneurons 
decreases their inhibitory effect on mesolimbic DAergic neurons, and so 
causes an indirect increase in the DA levels in the reward area of the brain. 
Tolerance to the effects of opioids such as morphine generally occurs 
through desensitisation of the MOR (66). Side effects of opioid use can be 
associated with the MOR in the case of pupil constriction, other opioid 
receptors such as in the case of hallucinations (κ receptor), or through 
multiple receptors in the case of spinal analgesia (MOR, δ, and κ receptors) 
(61). 
 
As alcohol and benzodiazepines have similar pharmacological action,  they 
will be described together. They have action on the GABAA receptor, and for 
benzodiazepines it is the only site of action but alcohol binds to multiple 
receptors (61). GABAA receptors are pentamer ligand-gated ion channels 
that are predominantly located on postsynaptic neurons and activation of the 
receptor allows movement of chloride (Cl−) ions so benzodiazepines act as 
an allosteric modulator of the GABAA receptor. Benzodiazepines bind to their 
allosteric site causing the receptor to change shape to make the receptor 
sensitive to GABA (61). This leads to an increased frequency of opening of 
the receptor’s Cl− channels and subsequent hyperpolarisation of the 
postsynaptic neuron. Alcohol binds to the GABAA receptor also, however its 
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exact mechanism of action is not clear (67). It is thought that it has actions 
on the δ subunit which is found in extrasynaptic GABAA receptors and that it 
may potentiate the effect of neurosteroids (68). It is also thought that alcohol 
can act presynaptically to cause the release of GABA, potentially involving 
GABAB receptors (69). The dependence-forming ability of benzodiazepines 
derive from the presence of GABAA receptors on GABAergic interneurons in 
the VTA (70). Benzodiazepines binding to the receptors lead to 
hyperpolarisation of the interneurons, which decrease the release of GABA, 
and hence decrease the inhibition of DAergic cells in the VTA. Alcohol 
appears to decrease GABA release in the VTA (Figure 1.3), as opposed to 
increase GABA release as is in other areas (71). This paradoxical effect is 
thought to be due to alcohol-activated endogenous opioid release and 
alcohol-mediated N-methyl-D-aspartate (NMDA) channel inhibition, which 
cause decreased GABA transmission in the VTA. 
 
25 
 
 Figure 1.3. GABA receptors in the mesolimbic dopaminergic systems involved 
in addiction (70) 
 
Inhalants are a class of substance that are categorised by their method of 
administration, and include glue, shoe polish, nail varnish remover, and 
butane lighter fluid (72). Exposure of some GABAA receptors have recorded 
increased activation in the presence of inhalants (73). Activation of the MOR 
by inhalants has also been noted in the literature (74). The mechanism by 
which each of these interact with the VTA has been described already, and 
thus give an indication of how dependence to inhalants can be formed, 
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however inhalants also have a direct, excitatory effect on DAergic neurons in 
VTA (75).  
 
Psychostimulants are a class of substances that are defined by their 
subjective effects of wakefulness and alertness. Cocaine, amphetamines, 
methamphetamine, and methylenedioxymethamphetamine (MDMA, ecstasy) 
are psychostimulants. Their effects are achieved by increasing the activity of 
monoamine neurotransmitters, however psychostimulants achieve this by 
different mechanisms (76). Cocaine’s primary mechanism is blocking the DA 
reuptake channel, DAT 1, which recycles DA from the synapse. This leads to 
apparent higher concentrations of DA in the synapse (77). Amphetamine, 
methamphetamine, and ecstasy have a more complex mechanism and 
stimulate DA release in multiple ways (78). These substances can be taken 
into a neuron by DAT and this increases the likelihood of efflux of cytosolic 
DA by DAT down its concentration gradient into the synapse. Amphetamines 
can promote DA efflux by DAT through protein kinase C (PKC). 
Amphetamines can activate PKC which phosphorylates DAT and the result is 
that DA efflux is increased, without modifying its DA neuronal-uptake activity 
(78). The amphetamine-family of substances make efflux more effective by 
disrupting the formation of vesicles, which leaves a greater concentration of 
DA in the cytosol to be effluxed by DAT. Overall the effect is to increase the 
activity of DAergic neurons, and this activity in the VTA can lead to 
dependence (76). Tolerance to the effects of psychostimulants is due to 
down-regulation of neurotransmitters. Side effects of psychostimulant use 
are derived not only from their DAergic effects, but also from their adrenergic 
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effects (hypertension and tachycardia) and serotonergic effects 
(hyperlocomotion) (79, 80). 
 
Hallucinogens include LSD, peyote, and magic mushrooms. Like the 
psychostimulants, the hallucinogens act on many receptor types but their 
hallucinogenic activity is due to their agonist activity on the 5-HT2A receptor 
(81, 82). As described above, hallucinogens are not described as having 
dependence-forming ability in the majority of scientific literature, however 
excitation of 5-HT2A receptors in the medial PFC can cause DA release in the 
VTA (83), and this could possibly be a mechanism for dependence. 
 
The pharmacological effects of cannabis are primarily due to Δ9-
tetrahydrocannabinol (THC), but also Δ8-tetrahydrocannabinol, cannabinol, 
and cannabidiol (84). Cannabis elicits its psychological effects through the 
cannabinoid 1 (CB1) receptor, a G protein-coupled receptor (85). CB1 
receptors reside primarily on GABAergic but also on glutamatergic neurons 
(86), and activation causes increased DA levels in the NAc (87). THC has 
also been shown to increase DA levels in the NAc through its actions on the 
MOR (88), and both of these may account for its dependence-forming action 
(89). Tolerance to the effects of cannabis after prolonged use occurs through 
the down regulation of CB1 receptor levels and impaired G protein coupling 
(85). 
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1.8 Summary 
Substance misuse has a long history in Ireland and has evolved from alcohol 
misuse in the 1800s to the plethora of substances misused at present. Drug 
policies in Ireland have reacted to the changing nature of substance misuse 
with ever-changing laws regarding substance misuse and approaches to the 
prevention and treatment of substance misuse and dependence, but they 
have not succeeded in eliminating the problem. This is because these 
substances stimulate natural reward pathways in the brain and so create a 
desire to continue taking the substance. It is a desire that can be powerful 
and difficult to resist. Much has been learned about the mechanism of action 
of misused substances, but because of the complexity of the interactions 
with the brain, there is still more to learn. 
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The work of this chapter has been published as  Murphy, K., Sahm, 
L., McCarthy, S., Lambert, S., & Byrne, S. (2013). Substance use in 
young persons in Ireland, a systematic review. Addictive Behaviors, 
38(8), 2392-2401. doi: http://dx.doi.org/10.1016/j.addbeh.2013.03.016 
(Appendix III) 
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2.1 Introduction 
Adolescence is a time of discovery and experimentation. It is also a period of 
physical and mental development when small changes can impact on the 
rest of a person’s life. Adolescence is also the time when a large proportion 
of teenagers try alcohol (90, 91), tobacco (92), and cannabis (91) for the first 
time. Use of these substances during this period can often be detrimental to 
normal adult growth (93, 94) and may result in chronic use leading to long-
term health problems and early death (95). The number of deaths 
attributable to addictive substances worldwide in 2004 was estimated to be 
over seven and a half million people (96). The same report showed that in 
Europe, 22.5% of all deaths in the region were directly caused by addictive 
substances, the highest percentage in any World Health Organisation (WHO) 
region in the world. There were 65,087 recorded drug-induced deaths due to 
illicit drugs alone in European Union (EU) member states between 2000 and 
2008; with approximately 16% of those deaths occurring in under 25s (97). 
 
Ireland is similarly affected by substance use. Approximately 287 
adolescents under the age of 19 years died in Ireland between 1998 and 
2009, due to or as a consequence of substance use (98-100). These 
statistics highlight the magnitude of substance use amongst the adolescent 
population in Ireland. Substance use in Ireland has been on the rise over the 
past decade; lifetime use of any illegal substance has risen by nearly 10% in 
the 15-34 years age category. Increased use of cannabis (up 9.6% to 33.4%) 
and cocaine (doubled to 9.4%) are the most concerning trends identified 
from a recent report from the National Advisory Committee on Drugs (NACD) 
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(101). A recent survey from United Nations International Children’s 
Emergency Fund (UNICEF) reported that 38% of Irish 18-year-olds have 
taken drugs (defined in this survey as any substance except alcohol or 
tobacco) at some stage in their lives, and it rose to 44% for 20 year-olds 
(102). In the same survey, when asked if they were currently taking drugs, 
28% admitted that they were.  
 
This widespread substance use in Irish society is placing an undeniably large 
burden on resources. Between 2005 and 2010, there were 2,295 recorded 
cases of adolescents under the age of 18, who utilised a drug treatment 
centre for the first time (103). This reflects an increase of over 50% in 
treatment demand over this five-year period. Large amounts of public funds 
and manpower have been invested in reducing availability of illegal 
substances in our society. Figures from the Central Statistics Office (CSO) 
show that the number of cases of “possession of drugs for personal use” in 
2010 was 14,523, which is more than double the figure for 2004 (104). This 
database also shows a similar rise in the recorded number of cases of 
“possession of drugs with intent to supply”; 4,159 reported in 2010, almost 
twice the level recorded in 2004. There appears also to be a sharp increase 
in the domestic production of these substances to supply the high level of 
demand. In the same period of time as above, there was a 14-fold increase 
in the number of cases of “cultivation or manufacture of drugs”. This is a 
substantial challenge to the resources of An Garda Síochána, (Irish national 
police force). There are presently over 400 Gardaí involved in the Garda 
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National Drugs Unit and in divisional units solely working to combat drug 
crime (105). 
 
Persons who start experimenting with substances at an early age are more 
likely (i) to engage in polysubstance use (106), (ii) to have problem use later 
in life (107, 108), (iii) to suffer from health problems (109), and (iv) to 
experience psychological problems (94). Preventing or delaying the onset of 
experimentation could reduce the number of persons requiring medical 
treatment; thus potentially reducing the burden on the public health-care 
system, and related health-care expenditure. Furthermore, it would likely 
lead to a decrease in polysubstance use, which has been associated with 
increased mortality (110) and has been implicated in approximately 50% of 
all substance-related deaths in Ireland between 2004 and 2009 (100).  
 
The prevalence of substance use and the harm that is caused by young 
people is an area of concern for policy makers, health workers, the criminal 
justice system, youth workers, teachers and parents. It is therefore important 
to have a clear understanding of the extent of the problem. Whilst there have 
been studies which have examined this issue, there has not been a 
comprehensive review of the literature relating to substance use by young 
people in Ireland.Therefore a systematic review was conducted to identify, 
synthesise and summarise the existing literature on the prevalence of 
substance use among adolescents and young adults in Ireland. The review 
will look at prevalence figures for the four most-used substances across the 
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Republic of Ireland for persons between the age of 13 and 24, and compare 
usage across the years studied, 2000-2012.  
 
2.2 Methods 
This review was produced according to Preferred Reporting Items for 
Systematic reviews and Meta-Analyses (PRISMA) guidelines for systematic 
reviews and meta-analyses (111). These guidelines are primarily used for 
the reporting of controlled randomised trials (RCTs) or intervention studies, 
and so while not all items were applicable to this review of prevalence 
studies, the guidelines were adhered to as closely as possible. The articles 
were compiled from a large number of databases to ensure that as many 
relevant articles were included. The review was limited to articles reporting 
the use of cannabis, alcohol, nicotine, and benzodiazepines. These four 
substances were identified as the most widely-used substances in two recent 
large-scale studies (112, 113). An age range of 13-24 years was used as the 
criteria for searching as it encompasses the National Library of Medicine’s 
Medical Subject Headings (MeSH) definitions of an ‘adolescent’ (13-18 
years) and ‘young adult’ (19-24 years) (114). The following inclusion criteria 
were applied to the searches: English language, full-text access, and 
published since 2000. The databases searched with a Boolean string were: 
PubMed, Scopus, Web of Knowledge, Google Scholar, ERIC, Embase and 
CINAHL. The PubMed database was searched using the keywords as 
follows: adolescent or young adult, marijuana smoking, benzodiazepines, 
smoking, ethanol, Ireland. A search of the remaining databases was 
performed including the search terms: adolescent or young adult, cannabis 
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or marijuana or benzodiazepine or alcohol or nicotine or tobacco or cigarette, 
and Ireland. These searches were conducted in December 2011 and 
updated thereafter to include relevant studies that were published after 
December 2011. An additional manual search of the National Documentation 
Centre on Drug Use was necessary as it did not allow searches using 
Boolean operators (115). This website is controlled by the Health Research 
Board (HRB) in Ireland and is a “database of Irish drug and alcohol research 
– an electronic library of full-text reports, journal articles, theses, and 
conference papers” (116). This database has links to grey literature 
published by the government, national and international bodies. Personal 
contact was made with authors of some articles to obtain additional 
information. 
 
The eligibility of articles found by the database search was checked by 
searching the title and abstract of the articles. Duplicates and records that 
were found to be not relevant were excluded. Reasons for exclusion 
included: multiple papers publishing data from the same dataset, articles 
which were commentaries and not original research, articles which covered a 
range of ages but were not divided into age categories, and articles which 
were part of a multi-national study, but did not provide country-specific 
information for Ireland. If there was still doubt about the eligibility of a paper, 
it was included so that a detailed inspection could be done at the next stage. 
The next stage was to obtain full-text copies of the remaining articles, and do 
a further assessment for eligibility and relevance. The data points of interest 
were extracted from the full-text reports and compiled into summary tables 
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(see Tables 2.1-2.5). The data points assessed were divided into two 
categories: study characteristics (sample size, sampling method, age range, 
region of sampling, and any other information that might influence the 
analysis of the survey), and study results (details of alcohol, tobacco, 
cannabis, and benzodiazepines). These study results would be the outcomes 
of interest for the review. 
 
Quality of the final articles was assessed using the Methodological Index for 
NOn-Randomised Studies (MINORS) tool (117). The tool was customised for 
use in this review, and all the articles retrieved were assessed in a scale of 
0-10 based on their methodological quality. The scoring of the studies can be 
seen in Table 2.1 and Appendix IV.  
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Table 2.1. Summary of study characteristics 
Study n Region Age Gender (%) Substance(s) 
surveyed 
Sampling method MINORS 
score 
Notes 
Currie et al., 2008 4840 Republic of Ireland 11-15 M: 50.6, F: 49.4 Alcohol, Cannabis, 
Tobacco 
Stratified random 10 a 
Curtin, 2004 248 County Cork 15-16 F: 100 Tobacco, Alcohol Unable to identify 4 a 
Flanagan et al., 
2003 
1426 Cavan, Louth, 
Meath & 
Monaghan 
12-19 M: 59.7, F:39.31 Alcohol, Cannabis, 
Tobacco 
Stratified random 8 a 
Hibell et al., 2004 2407 Republic of Ireland 15-16 M: 50.6, F: 49.4 Alcohol, BZDs, 
Cannabis, Tobacco  
Stratified random 10 a 
Hibell et al., 2009 2221 Republic of Ireland 15-16 M: 45.2, F: 54.8 Alcohol, BZDs, 
Cannabis, Tobacco 
Stratified random 10 a 
Hibell et al., 2012 2207 Republic of Ireland 15-16 M: 50.3, F: 49.7 Alcohol, BZDs, 
Cannabis, Tobacco 
Stratified random 10 a 
Kabir et al., 2010 2805 Republic of Ireland 13-14 M: 40.4, F: 59.6 Tobacco Stratified random 8 a 
Kelleher et al., 
2003 
2297 Clare, Limerick & 
Tipperary 
13-19 M: 44.8, F: 53.3 Alcohol, BZDs, 
Cannabis, Tobacco 
Stratified random 6 a 
Manning et al., 
2002 
2580 Republic of Ireland 13-14 M: 45.2, F:54.8 Tobacco Stratified random 8 a 
McNeill et al., 
2011 
214 Republic of Ireland 13-15 Unable to 
identify 
Tobacco Stratified random 7 b 
Moran et al., 2000 1070 Louth 12-19 M: 100 Tobacco Unable to identify 4 a 
Morgan et al, 
2008 
1048 Republic of Ireland 18-24 M: 45.9, F: 54.1 Alcohol, BZDs, 
Cannabis, Tobacco 
Cluster sampling 10  
O’ Cathail et al., 370 Cork city 15-17 M: 38.4, F: 61.6 Tobacco Convenience 8 a 
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Study n Region Age Gender (%) Substance(s) 
surveyed 
Sampling method MINORS 
score 
Notes 
2011 
Office of Tobacco 
Control, 2006 
777 Republic of Ireland 8-24 Unable to 
identify 
Tobacco Stratified random 6  
Palmer et al., 
2008 
462 South-east Ireland 
& Cork city 
14-19 M: 45, F: 55 Alcohol, BZDs, 
Cannabis 
Convenience 10 a 
Share et al., 2004 620 Leitrim 14-15 M: 49.2, F: 50.51 Tobacco Randomised 
control trial 
5 a, c 
Smyth et al., 2011 133 Republic of Ireland 15-16 M:43.6, F: 56.4  Alcohol Simple 
randomisation 
8  
UNICEF, 2011 508 Republic of Ireland 16-20 Unable to 
identify 
Alcohol, Cannabis, 
Tobacco 
Convenience 6 d 
             M = Male, F = Female, DNS = Did not specify, BZDs = benzodiazepines, Notes: a – school(s) survey, b – in-home interviews, c –  
             intervention study, d – online survey 1 – some participants did not answer the question 
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2.3 Results 
A total of 2,562 articles were found in the database search, and 11 were 
found in additional searches. The titles and abstracts for each article were 
reviewed and duplicates were removed. This reduced the number of 
remaining articles to 1,773. The next stage was to examine the title and 
abstracts of the remaining articles and eliminate those which did not match 
the eligibility criteria. 1,702 articles were discarded; 360 were excluded 
because the study was not investigating Irish young people, 1309 were 
excluded because they were not measuring drug prevalence, 10 were 
excluded because they measured prevalence in a different age group, 18 
were excluded because they were not original research i.e. editorials, 
literature reviews etc., and 5 were excluded because they were studies that 
were based on data used from previous studies. After the excluded articles 
were discarded, 71 remained. The full-text articles were then obtained and 
assessed for suitability. Fifty-three articles were excluded; 8 had no Ireland-
specific data, 36 were not substance use prevalence studies, 7 had data 
from studies with age ranges that included ages over 24, 2 had data based 
on previous research, and 1 was not a research article. There were 18 
articles included in the review. A PRISMA flow diagram (Figure 2.1) provides 
a summary of the stages, and the number of studies in  each stage (111). 
The study characteristics for the papers included in the review are 
summarised in Table 2.1. One of the included studies was a randomised 
control trial (RCT) that measured the effect of a smoking prevention initiative 
(118). There were eleven observational studies that had partial or full 
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randomisation in the sampling process (90, 112, 113, 119-126), and one 
study employed cluster 
 
 
Figure 2.1. Adapted from the PRISMA flow diagram 
 
Sampling (127). Convenience sampling was used by three of the studies 
(102, 128, 129), and the method of sample selection could not be identified 
in two studies (130, 131). Half of the studies surveyed the use of a single 
substance while the majority of the remaining studies investigated the use of 
three or more substances. Sixteen studies had tobacco as a substance 
studied, eleven studies investigated alcohol consumption, nine studies 
looked into cannabis use, and six investigated benzodiazepine use. 
 
To facilitate observation of trends over time, the studies are presented 
according to three time periods: Period 1 (2000-2006), Period 2 (2007-2009), 
and Period 3 (2010-2012). As fewer studies were published in the earlier 
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years, Period 1 encompasses a longer timeframe of 7 years. Period 2 and 3 
have equal timeframes of 3 years. These groupings provided approximately 
equal-sized groups, in terms of numbers of publications thereby avoiding 
issues such as diluting the group size to one or two articles.  
 
2.3.1 Tobacco Usage 
There were sixteen studies which collected data on tobacco usage, and a 
summary of the data can be seen in Table 2.2. One study was a RCT (118), 
eleven were observational studies with randomly-selected participants (112, 
113, 119-126), one study used cluster sampling (127), two used convenience 
sampling (102, 128) and two did not describe how participants were selected 
(130, 131). 
.  
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Table 2.2. Summary of smoking prevalence rates 
Study name n Age range 
(yrs) 
Lifetime use of 
tobacco 
First cigarette by 
13 years 
Tobacco use in the 
previous month 
Daily tobacco use 
Currie et al., 2008 4840 11-15 26% (13 y.o.), 50% 
(15 y.o.) 
33% (female), 29% 
(male) 
- 3% (13 y.o.), 15% 
(15 y.o.) 
Curtin, 2004 248 15-16 50% - 31% 19% 
Flanagan et al., 2003 1426 12-19 50.8% 30.2% - 18.2% 
Hibell et al., 2004 2407 15-16 67% 45% 33% - 
Hibell et al., 2009 2221 15-16 52% 32% 23% - 
Hibell et al., 2012 2207 15-16 43% 21% 21% - 
Kabir et al., 2010 2805 13-14 - - 10.6%1 - 
Kelleher et al.,2003 2297 14-18 61.3% 49.7% 30.0% - 
Manning et al., 2002 2580 13-14 - - 19.0%1 - 
McNeill et al., 2011 214 13-15 - - 10.5-13.5% - 
Moran et al., 2000 1070 12-19 - - 39% 22.5% 
Morgan et al., 2008 1048 18-24 - - 29% (18-19 y.o.), 40% (20-
24 y.o.) 
23% (18-19 y.o.), 
31% (20-24 y.o.) 
O’ Cathail et al., 2011 370 15-17 48.4% - 18.1% - 
Office of Tobacco 
Control, 2006 
777 8-24 - - 16%2 (12-17 y.o.), 42%2 
(18-24 y.o.) 
 
Share et al., 2004 620 14-15 57% 38% 21%1 11% 
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Study name n Age range 
(yrs) 
Lifetime use of 
tobacco 
First cigarette by 
13 years 
Tobacco use in the 
previous month 
Daily tobacco use 
UNICEF, 2011 508 16-20 - - 23% - 
Notes: Dash – No data reported, 1 – Answer positively when asked if they are currently smoking, 2 - Figure represents current smokers that 
smoke greater than once a week or more, 3 - y.o = year-olds 
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 2.3.1.1 Lifetime use of tobacco 
This was reported in over half of the studies.  
 
Period 1 (2000-2006): The levels from five studies in Period 1 ranged 
between 50-67% (118-120, 122, 130). The variation in the levels may exist 
because four of the five studies were measuring regional populations. The 
only national study reported a lifetime usage level of 67% (120). The largest 
of the regional studies reported a similar figure at the high end of the range, 
61%, and so the true estimate probably lies in the somewhere in this region 
(122).  
 
Period 2 (2007-2009): Two studies in Period 2 surveyed lifetime use: one of 
the studies measured usage in 13 year-olds and 15 year-olds and reported 
26% and 50% respectively (112), while the second study reported 52% in a 
survey of 15-16 year-olds (113). Both of these studies were on a large scale 
and encompass national populations so their estimates would be close to the 
true figure.  
 
Period 3 (2010-2012): There were two studies from Period 3, and these 
studies estimated lifetime tobacco usage at 48% and 43% respectively. 
There were differences between the two studies however, the former study 
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was conducted in Cork City (128) while the latter was a nation-wide study 
(126). 
 
2.3.1.2 Smoking a cigarette by age 13 years 
The second category examined was smoking a cigarette by age 13 years. It 
has been shown that initiation of substance use prior to 13 years of age is 
associated with chronic substance use (132). There were seven studies that 
collected data on this. 
 
Period 1 (2000-2006): Four studies were published with results which ranged 
from 30-50% (118-120, 122). 
 
Period 2 (2007-2009): Two studies were published which both had similar 
levels of approximately 30% (112, 113). These studies had good study 
designs and used a national sample so the true level is likely to be close to 
this.  
 
Period 3 (2010-2012): A single study published reported a level of 21% 
(126). 
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2.3.1.3 Smoking in the previous month. 
The third category examined was smoking in the previous month. This is 
considered a good indicator of regular use.  
 
Period 1 (2000-2006): The studies from Period 1 ranged from 19-39% (118, 
120, 122, 123, 125, 130, 131). Some of the variation in this can be explained 
thus: the two studies with the lowest percentages, 19% and 21%, were 
phrased in a different manner (118, 123). They measured positive responses 
to a question relating to whether they were currently smoking. This is not a 
clearly defined question and may account for the lower percentage. Two of 
the studies did not clearly indicate how samples were picked (130, 131), and 
so caution is advised when generalising the results from these studies. The 
final two studies gave estimates of smoking in the previous month to be 33% 
and 30% respectively, so the true level is likely to be near this figure (120, 
122). 
  
Period 2 (2007-2009): The level of smoking in the previous month in Period 2 
was measured in two studies, and was estimated to be 23% (113) for one 
and between 29 and 40% for the other (127). The study was a large-scale, 
nationwide survey, and it is likely that the result is indicative of the true figure. 
  
Period 3 (2010-2012): Five studies were found from Period 3; it is difficult to 
make a direct comparison between them due to significant heterogeneity in 
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the studies. Two studies recorded levels of 10.6% and 10.5% for 13-14 year-
olds (121) and 13-15 year-olds (124) respectively, even though the former 
study measured the percentage of young persons currently smoking, and the 
latter measured the percentage of young persons that smoke greater than 
once a week or more. Two studies measured the level in older adolescents, 
15-17 year-olds and 16-20 year-olds and reported levels of 18% (128) and 
23% (102) respectively. Both of these studies however used convenience 
sampling to select their participants. The remaining study from Period 3 
looked at 15-16 year-olds, and showed a level of 21% (126). 
 
2.3.1.4 Daily tobacco use 
The final category examined was daily tobacco use.  
 
Period 1 (2000-2006): The range in data from Period 1 was 11-23% (118, 
119, 130, 131). However, caution should be exercised when interpreting 
results of the studies reporting the two highest levels, 23% (131) and 19% 
(130), as the method of sample selection was not specified in the paper. The 
remaining two studies had good design; however they were both regional 
studies and so may not give a good indication of the national estimate.  
 
Period 2 (2007-2009): There were two studies from Period 2 and both 
studies reported two levels; the first study reported one for 13 year-olds, 3%, 
and one for 15 year-olds, 15% (112). The second study reported on levels of 
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18-19 year-olds, 23%, and 20-24 year-olds, 31% (127). These are nationally 
representative studies and have good design so it is likely that they 
approximate the national level closely. 
 
Period 3 (2010-2012): None of the studies from Period 3 reported levels of 
daily smoking. 
 
2.3.2 Alcohol Usage 
There were eleven studies that looked into alcohol usage and a summary is 
provided in Table 2.3. Randomised sample selection was used in seven of 
the studies (90, 112, 113, 119, 120, 122, 126), convenience sampling was 
used for two (102, 129), cluster sampling in one study (127), and the method 
of sample selection was not described in one of the studies (130). 
  
2.3.2.1 Lifetime use of alcohol 
For lifetime use of alcohol, the figures varied both between and within these 
periods.  
 
Period 1 (2000-2006): There were four studies published in Period 1, and 
their levels ranged from 71-92% (119, 120, 122, 130). Differences in levels in 
these studies can in part be attributed to the age range of the participants. 
The studies with the lowest figure had a participant age ranging from 12-19 
years, while each of the others studies had a
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Table 2.3. Summary of alcohol prevalence rates 
Study name n Age 
range 
(yrs) 
Lifetime use of 
alcohol 
First alcohol consumption 
before 13 years 
Alcohol use in 
the previous 12 
months 
Alcohol use in the 
previous month 
Currie et al., 
2008 
4840 11-15 - 38%1 - - 
Curtin, 2004 248 15-16 82% - - 59% 
Flanagan et al., 
2003 
1426 12-19 71.3% - - - 
Hibell et al., 
2004 
2407 15-16 92% 47% (beer), 45% (wine), 
32% (spirits) 
88% 73% 
Hibell et al., 
2009 
2221 15-16 86% 33% (beer), 31% (wine), 
21% (spirits) 
78% 56% 
Hibell et al., 
2012 
2207 15-16 81% 40% (beer), 18% (wine), 
35% (spirits) 
73% 50% 
Kelleher et 
al.,2003 
2297 14-18 90.2% 50.2% 83.4% 62.4% 
Morgan et al., 
2008 
1048 18-24 84% (18-19 y.o.), 93% 
(20-24 y.o.) 
- - 78.3% (18-19 y.o.), 84.5% 
(20-24y.o.) 
Palmer et al., 
2008 
462 14-19 86.10% - 82.6%2 61.6%3 
Smyth et al., 
2011 
133 15-16 58% - - - 
UNICEF, 2011 508 16-20 77% - - - 
Notes: Dash – No data reported, 1 - only 15 y.o. reported, 2 – those who drank alcohol once a year or more often, 3 – those who drank once a 
month or more often, 3 - y.o = year-olds 
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 minimum age of 14 or 15 years.  One of the  studies reported a lifetime level 
of 82%, but this study was conducted in County Cork with an unknown 
method of sampling, so it is difficult to extrapolate from it (130). Two studies 
demonstrated close agreement at 92% and 90% levels for lifetime usage and 
the true level is likely to be close to this (120, 133).  
 
Period 2 (2007-2009): Only two of the three studies in Period 2 had data 
relating to lifetime alcohol usage and both of those studies reported similar 
results: 86.1% and 86% (113, 129). 
  
Period 3 (2010-2012): There were three studies published in Period 3 and 
they reported 77%, 58% and 81% usage (90, 102, 126). The wide 
discrepancy between these figures may be due to the age of participants; up 
to 20 years in one study (102) and up to 16 years for the latter 2 studies. 
Another reason could be the nature of the studies: one was an internet poll 
and this may be a source of bias in the study (102). This contrasts with the 
third study which was a national study with randomised sampling (126). 
 
2.3.2.2 Consumption of alcohol before 13 years of age 
Period 1 (2000-2006): This examined the percentage of young persons who 
first consumed alcohol before 13 years of age. A limitation with this category 
was that it was reported in only two studies. Unfortunately, one of the studies 
quoted percentages for three types of alcohol (beer, wine, and spirits) which 
50 
 
ranged from 32-47%, so it was not possible to get an overall figure (120). 
The remaining study reported an overall consumption level of 50% (122).  
 
Period 2 (2007-2009): two studies from Period 2 reported on this category. 
One of the studies differentiated between alcohol types, which ranged from 
21-33% (113). The other study, Currie et al., reported a level of 38% (112). 
Both of the studies were well-designed and were probably an accurate 
reflection of the actual population level.  
 
Period 3 (2010-2012): A single study from Period 3 reported levels of first 
consumption prior to 13 years of age at between 18% and 40% for the three 
types of alcohol mentioned above (126). 
 
2.3.2.3 Alcohol use in previous 12 months 
Alcohol use in the previous 12 months was used as a measure of occasional 
use. Five studies (two from Period 1, two from Period 2, and one from Period 
3) included data on 12 month usage (113, 120, 122, 126, 129).  
 
Period 1 (2000-2006): Both studies reported similar values, 88% and 83% 
(120, 122). Both studies were large scale and had good design, so it 
probably reflects an estimate of the population figure.  
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Period 2 (2007-2009): The two studies from Period 2 were in broad 
agreement with each other. Hibell et al. and Palmer et al. reported levels of 
78% and 83% respectively (113),(129). The result from Palmer is a 
percentage of positive responses to the question if they drank once a year or 
more.  
 
Period 3 (2010-2012): The single study from Period 3 reported a level of 73% 
for alcohol use in the previous year (126). 
 
2.3.2.4 Alcohol use in the previous month 
The final category related to alcohol use in the previous month. Only one of 
the most recent studies reported data, but there were data from six older 
papers (three from Period 1, two from Period 2, and one from Period 3) (113, 
120, 122, 126, 127, 129, 130).  
 
Period 1 (2000-2006): The studies from Period 1 reported a range of levels 
from 59-73%. The 59% figure comes from the paper by Curtin, which was a 
small County Cork study and the study design was unknown (130). This 
affects the ability to generalise with its data and gives precedence to the 
results from the other studies which were 73% and 62% (120, 122).  
 
Period 2 (2007-2009): Hibell et al., 2008 had a level of 56% for the alcohol 
use in the previous month (113), while Palmer et al. gave a level of 62% 
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(129). This final figure was the percentage of those that responded positively 
when asked if they drank alcohol once a month or more often.  
 
Period 3 (2010-2012): The study from Period 3 reported a level of 50% in this 
category (126). 
 
2.3.3 Cannabis Usage 
A summary of the studies reviewed that included surveyed cannabis usage is 
displayed in Table 2.4. There were nine studies that reported cannabis use 
amongst adolescents and young adults in Ireland (102, 112, 113, 119, 120, 
122, 126, 127, 129). The studies were mostly randomised school surveys, 
while the remaining two studies were convenience studies (102, 129). All of 
the studies measured lifetime use of cannabis and there was a wide variation 
between levels, 20-80%. The two highest usage levels, 80% and 41%, were 
reported by two studies that used convenience sampling, so the true level 
may differ (102, 129). A pattern was seen in the other studies based on their 
year of publishing. 
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Table 2.4. Summary of cannabis prevalence rates 
Study name n Age range 
(yrs) 
Lifetime use of cannabis Cannabis use in the 
previous 12 months 
Cannabis use in the previous 
month 
Currie et al., 2008 4840 11-15 20%1 17%1 7% (female)1, 11% (male)1 
Flanagan et al., 
2003 
1426 12-19 31.0% - 12.8% 
Hibell et al., 2004 2407 15-16 39% 31% 16% 
Hibell et al., 2009 2221 15-16 20% 15% 9% 
Hibell et al., 2012 2207 15-16 18% 14% 7% 
Kelleher et al.,2003 2297 14-182 28.6% 24.2%% 15.4% 
Morgan et al., 2008 1048 18-24 - 12% (18-19 y.o.), 14% (20-24 
y.o.) 
- 
Palmer et al., 2008 462 14-19 41.1% 32.5% 13.62%3 
UNICEF, 2011 508 16-20 >80% (weed)4, 46% (hash) - - 
Notes: Dash – No data reported, 1 – only 15 y.o. reported, 2 – 13 and 19 y.o. excluded due to lack of data, 3 – cannabis use once a month or 
more frequently, 4 – precise percentage could not be determined 
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2.3.3.1 Lifetime use of cannabis 
Period 1 (2000-2006): Earlier studies from Period 1 showed a usage level of 
between 29 and 39% (119, 120, 122). 
 
Period 2 (2007-2009): There were three studies in this period. Two of the 
studies had a level of 20% (112, 113), and the third study had a level of 
41.1% (129). 
 
Period 3 (2010-2012): There were two studies from Period 3 that reported on 
lifetime cannabis use. The most  recent European School Project on Alcohol 
and Other Drugs (ESPAD) study reported a level of 18% (126), while the 
second report gave separate levels for the dried plant form (weed), >80%, 
and the extracted resin (hash), 46% (102). These levels are largely different 
from levels reported at any time throughout the entire time range, and so 
their use as a representative figure must be cautioned. Overall, the levels are 
suggestive of a decreasing experimentation with cannabis amongst young 
people.  
 
2.3.3.2 Cannabis use in the previous 12 months 
A similar pattern was observed in the reporting of cannabis use in the 
previous 12 months.  
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Period 1 (2000-2006): Higher levels were observed amongst the earlier 
studies, 25-31% (120, 122) than in subsequent periods. 
 
Period 2 (2007-2009): There were four studies in period two and these 
studies showed a decrease compared to earlier studies to 12-17% (112, 113, 
127). The exception to this is the study carried out by Palmer et al., which 
gives a level of 33% for 12 month usage (129). A possible explanation for 
this higher figure may be that the study covers a broader age range (14-19 
years), and the level of use generally increases with age. Owing to problems 
with generalisation of this study, the true level is likely to be closer to Currie 
et al. and Hibell et al. (112, 113). 
 
Period 3 (2010-2012): A single study from Period 3 reported a level of 14% 
(126). 
  
2.3.3.3 Cannabis use in the previous month 
Period 1 (2000-2006): The trends in cannabis use in the previous month 
paralleled those in use in the previous 12 months. The three studies from 
period one showed high levels of use, 13-16% (119, 120, 122). 
 
Period 2 (2007-2009): There were three studies ranged from 7-14% (112, 
113, 129). The highest of the more recent figures, (14%) is from Palmer et 
56 
 
al., which as mentioned already suggests that the true level may be lower 
than this (129). 
 
Period 3 (2010-2012): There was one study in Period 3 that reported this 
data and the level was 7% (126). 
 
2.3.4 Benzodiazepine Usage 
A summary of the studies reporting benzodiazepine usage can be found in 
Table 2.5. Four of the six studies had sample sizes greater than 2,000 and 
participants were randomly selected, so there is a high degree of confidence 
in the figures reported from these studies (113, 120, 126, 127). One study 
reported an overall prevalence level for benzodiazepine usage, and the 
remaining studies categorised usage into prescription use and non-
prescription use. The percentage of subjects who have tried 
benzodiazepines without the advice of a doctor was consistently higher than 
prescription use in each of the studies.  
 
2.3.4.1 Lifetime benzodiazepine use on prescription 
Period 1 (2000-2006): There were similar levels for the prevalence of lifetime 
prescription benzodiazepine use at 9.2% and 10.0% (120, 122). Variation in 
the figure can be attributed in part to the difference in participant age with 
one study carried out by Kelleher et al. ranging from 13-19 years (122) while 
the other had a narrower age range. Another contributing factor to the 
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difference was that the participants in the Kelleher et al. study were recruited 
from three counties in the west of Ireland only, while the other study selected 
participants nationwide. This suggests that the higher end of the range is 
closer to the actual prevalence of non-prescription benzodiazepine use. 
 
Period 2 (2007-2009): There were two studies in this period (113, 127). 
There was a wide discrepancy between the values in these two studies. 
 
Period 3 (2010-2012): There was only one study in the third period, and this 
reported a level of use 9.0% (126). 
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Table 2.5. Summary of benzodiazepine prevalence rates 
Study name n Age range 
(yrs) 
Lifetime use of 
benzodiazepines 
Lifetime use of benzodiazepines 
without prescription 
Lifetime use of 
benzodiazepines on 
prescription 
Hibell et al., 2004 2407 15-16 - 2.0% 10.0% 
Hibell et al., 2009 2221 15-16 - 3.0% 10.0% 
Hibell et al., 2012 2207 15-16 - 3.0% 9.0% 
Kelleher et al., 2003 2297 13-19 - 5.6% 9.2% 
Morgan et al., 
2008 
1048 18-24 - 0% (18-19 y.o.), 1.4% (20-24 y.o.) 1.0% (18-19 y.o.), 1.1 (20-24 y.o.) 
Palmer et al., 2008 492 14-19 10.8% - - 
Notes: Dash – No data reported 
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2.3.4.2 Lifetime benzodiazepine use without prescription 
Period 1 (2000-2006): The levels ranged 2.0% to 5.6%, with the Kelleher et 
al. study reporting a level of 5.6% and the Hibell et al., 2004 study reporting 
2% (120, 122). 
 
Period 2 (2007-2009): There were three benzodiazepine studies that 
measured lifetime non-prescription benzodiazepine use. Two of the studies 
had reported differing levels of usage. One of the studies reported a level of 
3.0% (113), while the other reports between 0 and 1.4% usage (127). One of 
the studies reported both prescription and non-prescription benzodiazepine 
use at 10.8% (129). This level appears to be in agreement with the rest of 
the studies; however the study cohort was not a national sample nor were 
the participants randomly selected. Both of these factors mean that 
generalisation of the results is not possible. 
 
Period 3 (2010-2012): There was a single study in Period 3, and it reported a 
level of 3.0% (126). 
 
2.4 Discussion 
2.4.1 Summary of Evidence 
This review examined available peer-reviewed research and other available 
reports on substance use in Irish young people since the year 2000. The 
review found a variety of studies that ranged from RCTs to online surveys 
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and from small-scale rural studies to national studies. This allowed for a wide 
perspective on substance use. Some overall trends were observed in the 
literature. The clearest pattern that was elucidated was a trend towards a 
decrease in all substance use over time between Period 1, Period 2 and 
Period 3. This decrease in use was consistent between the first period and 
the most recent period. An explanation for this trend is not suggested by the 
majority of authors, though something may be learnt from their observations. 
One author suggests that the fall in tobacco usage levels may be attributed 
in part to tighter government restrictions on the sale, display, and usage of 
tobacco products (124). A likely significant factor to contribute to Ireland’s 
decreasing substance use rates is the creation and publication of Ireland’s 
first National Drug Strategy document in 2000 (134). It was the first time that 
a comprehensive and national approach to substance use was examined. 
There had been a report previous to this, Government Strategy to Prevent 
Drug Misuse 1991 (135), but this had separate strategies for Dublin and the 
rest of the country. The National Drug Strategy paper introduced for the first 
time in Ireland the four pillar system. These pillars are (i) supply, (ii) 
prevention, (iii) treatment, and (iv) research. This allowed resources to be 
allocated to areas where they are needed. It allowed “the bringing together of 
key agencies, in a planned and co-ordinated manner, to develop a range of 
appropriate responses to tackle drug misuse…” (134).  
 
The report resulted in the creation of a National Awareness Campaign which 
used traditional media such as brochures and radio, and newer forms of 
promotion i.e. Facebook, Twitter and Drugs.ie website to increase 
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awareness of the effects and consequences of substance use. The most 
recent National Drug Strategy document (9) builds on the determination to 
lower substance use.  The biggest change in this report is the inclusion of 
alcohol as a drug of abuse. The high level of alcohol use nationally amongst 
adults and young people, and the cost to the public health system warranted 
its inclusion. Another stated reason for its inclusion was “For many, alcohol is 
also seen as a gateway to illicit drug use, particularly for young people, while 
poly -drug use - which very often includes alcohol - is now the norm among 
illicit drug users”. A recommendation in the report aimed at school students 
was the delivery of drug education to primary and post-primary students in 
schools through the Social, Physical, and Health Education (SPHE) 
curriculum.  
 
It would appear that the combination of more harsh sales restrictions and 
increased education and awareness has had its intended effect on drug 
levels. The efforts of those involved should be applauded, and their support 
should be continued to maintain this positive trend. This work should be 
augmented by international good practice such as the WHO’s guidelines on 
reducing harmful alcohol use (136). These recommend implementing various 
strategies should as pricing changes, closely regulating the advertisement of 
alcoholic drinks, and modifying the system of selling alcohol, such as 
reducing the hours of retail sales, and regulating the number and location of 
businesses that can sell alcohol. Further reduction in illicit substance use 
may come from educational interventions as outlined by Faggiano et al. 2005 
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(137) and 2010 (138). By continuing efforts such as these, the burden of 
substance use on young people can be reduced. 
 
As stated above, tobacco and alcohol use followed the trend of decreasing 
use across all measures of use, experimental, occasional, or regular. The fall 
in levels of use are a positive step in the reduction in the burden caused by 
“the single most preventable cause of death in the world today”; cigarettes 
(139), and reducing the level of total alcohol consumption amongst the Irish, 
who rank second highest in the EU and 15th highest in the world (140). 
Sustaining these trends could result in reduced burden on the health-care 
system due to chronic treatment for preventable diseases, and on the justice 
system owing to reduced public order violations. The trend in decreasing 
tobacco use in Ireland mirrors that of Europe. The average lifetime use of 
tobacco for 15/16 year-olds across the 34 countries included in the ESPAD 
study fell from 67% to 60% between 2003 and 2007 (113). The same report 
gave a similar description for tobacco use in the previous month, and daily 
smoking; the former falling from 32% to 28%, while the latter fell from 10% to 
8%. An opposite trend was observed in relation to alcohol use. There was no 
change in the average lifetime use of alcohol from 2003 to 2007 (113), and 
the percentage of 15/16 year-olds who consumed alcohol in the previous 
month fell from 65% to 62% over the same four-year period. When looking 
broadly, it is positive to see a reduction of the levels of both experimental and 
regular use of these widely-available substances when compared to our 
European counterparts (113).  
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 There was a trend, amongst Irish adolescents, of decreased lifetime 
cannabis use, use in the previous 12 months, and use in the previous month 
over the length of the study period (113, 120, 126). The pan-European levels 
indicated by the latter report were similar to the levels of use in Ireland in 
2007 (113). Ireland differs from the European average however as the level 
of Irish use decreased while the European level increased from 12% in 2003 
to 19% in 2007. Most of this increase can be attributed to countries in the 
east of Europe, as the United Kingdom, France, Italy, Germany, Norway, 
Sweden, and Austria also had decreased lifetime cannabis use between 
2003 and 2007. A similar pattern was observed in the category of cannabis 
use in the previous month (113). 
 
Benzodiazepine usage was unchanged across the time periods studied. 
European levels appear to vary from Irish levels according to the most recent 
survey of benzodiazepine usage (126). The estimated average level of illicit 
benzodiazepine use was 6%, compared to 3% in Ireland. The level of 
prescribed use of benzodiazepines in Ireland was 1% higher than the 
European average of 8%. The levels of prescription and non-prescription use 
in Ireland did not appear to have changed significantly throughout the years 
of reference of this review. An explanation that may account for the steady 
level of benzodiazepine use in Ireland is that no campaign on the dangers of 
inappropriate benzodiazepine usage has been active in the country in the 
last ten years, since the launch of the Benzodiazepine: Good Practice 
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Guidelines for Clinicians document in 2002 (53). Such a campaign could 
encourage a young person or their parents to ensure that prescription usage 
is within safe limits, and deter its illicit use. 
 
2.4.2 Limitations 
A limitation to this systematic review is that the conclusions are only as 
accurate as the studies it returns. This is a limitation with every systematic 
review and literature review. To minimise the impact of low quality studies on 
the review, it was decided to quantify the quality of the studies using the 
Methodological Index for NOn-Randomised Studies (MINORS) tool (117). 
 
An important limitation in the studies in this review was the lack of 
consistency in survey design. An example of this is evident in Table 2.2 
under the column “Tobacco use in the previous month”. It is a standard, 
internationally-used question used to estimate regular use of a substance. 
Some studies chose to survey regular use with questions such as “Are you 
currently smoking?” and “Do you smoke one or more cigarettes each week?” 
Each question is attempting to measure the same outcome but because of 
the differences in the actual questions, it makes cross-study comparisons 
inappropriate and difficult. This limitation affected the ability to make 
comparisons between studies surveying tobacco, alcohol, cannabis, and 
benzodiazepine use.  
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There were few papers found in the literature search that surveyed 
benzodiazepine usage. A comprehensive search of scientific databases and 
grey literature could only find six relevant papers. Each of these studies 
measured usage superficially; one or two questions were asked as part of a 
section dealing with illicit substance use. It is difficult to get a clear 
understanding of benzodiazepine usage from these papers. It is important at 
present to look closer for patterns in benzodiazepine use because it was the 
only substance in this review whose usage did not appear to be decreasing. 
This could be the first stage in the development of a targeted educational 
campaign highlighting the dangers of inappropriate benzodiazepine usage. 
 
There is a category of young person that is excluded from most of the 
studies in this review. As can be seen in the ‘Notes’ column in Table 2.1, 
twelve of the seventeen studies chose participants from pupils attending the 
schooling system in Ireland. This method of selection has many advantages; 
it is more efficient to randomly select young persons around the country, and 
it saves time because the students are all in the same place at the same 
time. However, this misses out on early school-leavers, who account for up 
to 14.1% of school-leavers in total(141). This cohort of young persons is a 
significant absence from any study reporting on substance use. International 
studies have shown that early school-leavers are more likely to use both 
legal and illegal substances(142). Excluding this group has the potential to 
underreport the true level of substance use in young persons. 
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2.4.3 Conclusions 
This review has shown that substance use is still occurring in Ireland. Much 
of the research that is being undertaken on this topic in Ireland is of high 
quality and it indicates that the level of use is declining across many 
substances. However, there is still further work that can be done by policy-
makers to ensure that this positive trend will continue.  However, the fall in 
use is not evident with some substances and efforts must be increased to 
inform the public on their risks. Future work should redress the imbalance in 
substance use research that sees the majority of researchers looking at a 
few substances while little work is done on the others. Knowledge derived 
from these papers and reports, and from future work should guide the 
development of targeted drug prevention programs that are directed at the 
sections of population that will benefit the most from them. 
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 Benzodiazepine prescribing guideline 3.
adherence and misuse potential in Irish 
minors 
 
 
 
.
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3.1 Introduction 
3.1.1 Background 
Benzodiazepines are a commonly used substance worldwide. Data from the 
International Narcotics Control Board for 2011 estimate that between 26 and 
26.5 billion defined daily doses (DDD), which is the average dose of a drug 
used in adults (143), were prescribed globally (144). The same study 
reported that European consumption of benzodiazepines, between the years 
2009 and 2011, was the highest in the world at approximately 64 DDD/1,000 
(persons)/day. Oceania, including Australia, had the second highest 
consumption at approximately 53 DDD/1,000/day, while the consumption of 
the remaining regions was below 36 DDD/1,000/day. While the majority of 
benzodiazepines are prescribed by doctors, benzodiazepines are also 
obtained illegally for recreational use. Recreational use amongst young 
people (under 18 years) in Europe has been studied and it is important to 
understand the pattern of recreational use in this group to understand 
potential benzodiazepine misuse in the future. Whilst benzodiazepine misuse 
without prescription amongst European 15-16 year olds decreased from 7% 
in 1999 to 6% 2003, the levels remained stable from 2003-2011 (113, 126, 
145, 146). This pattern is also reflective of  the situation in Ireland as 
demonstrated in a review of studies surveying benzodiazepine misuse 
between 2000 and 2012, which found that levels remained stable at 3% 
(147).  
 
Recreational benzodiazepine misuse as well as prescribed benzodiazepine 
use can have adverse lifelong consequences if used on a long-term basis. 
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The acute effects of benzodiazepine use can include; muscle weakness, 
episodic memory impairment, and paradoxical disinhibition (148). Chronic 
benzodiazepine use is associated with visuospatial and verbal learning 
impairment, depressive symptoms and increased suicide risk (148-151). The 
consequences of benzodiazepine misuse are not restricted solely to the 
person misusing but also affect the community around them. Regular 
benzodiazepine misuse in Ireland has been associated with crime such as 
robbery, vehicle theft, fraud (152) and  violent behaviour (153, 154). The 
consequences of benzodiazepine misuse at society level and the burden on 
the justice system and the health-care system are also worth noting. In 2011 
in Ireland, the Garda Síochána (police force of Ireland) seized approximately 
287,000 benzodiazepine tablets. This corresponded to a 6.4% increase on 
the number of tablets seized in 2010 (155). In 2010, benzodiazepines were 
the second most common substance involved in poisoning deaths. Of the 94 
cases where benzodiazepines were involved, approximately 20% involved 
the consumption of multiple benzodiazepines (156).  
 
Problematic misuse of benzodiazepines was known before this and in 2000 
the Minister for Health and Children in Ireland established the 
Benzodiazepine Committee. The Committee sought to establish good 
practice guidelines to guide prescribers who prescribe benzodiazepines. The 
Committee published their Good Practice Guidelines for Clinicians in August 
2002 (157). The guidelines sought to promote safe benzodiazepine 
prescribing. The guidelines provided recommendations on prescribing 
benzodiazepines for the first time to patients, prescribing for benzodiazepine-
70 
 
dependent patients, prescribing to children and prescribing in nursing homes. 
This study analyses the implementation of these guidelines in young people 
under the age of 18 years. 
 
3.1.2 Aims 
The aims of this study are: 
1. to examine Ireland’s benzodiazepine consumption within a 
European context, 
2. to evaluate the prescribing  of benzodiazepines in under-18’s in 
Ireland relative to guidance issued in the Good Prescribing 
Practice for Clinicians guidelines, 
3. to highlight areas in prescribing where the potential for under-18’s 
to misuse benzodiazepines can occur. 
 
3.2 Methods 
Ethical approval was sought and granted for this study from the Clinical 
Research Committee of the Cork Teaching Hospitals (see Appendix V). Data 
for this study came from Primary Care Reimbursement Service (PCRS); 
these data are collected by the Health Service Executive (HSE) and 
accessed using the Health Intelligence Ireland (HII) database (158). Access 
to the database was granted for information relating to medicines dispensed 
between January 2009 and December 2012. The HSE collects information 
about community-pharmacy-dispensed medicines in Ireland that are 
subsided fully or in part by the Irish government. The database includes 
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information on patient details such as gender, age, and area of residence 
(however this did not include whether the patient lived in an urban or rural 
area). Prescription details available on the database include (i) the World 
Health Organisation’s Anatomical Therapeutic Chemical (WHO-ATC) 
classification, (ii) brand name, (iii) strength, (iv) quantity, (v) reimbursement 
price, (vi) the prescribing physician and (vii) the dispensing pharmacy. As the 
database is based on pharmacy reimbursement claims, there is no 
information regarding clinical diagnosis. The database contained information 
on three reimbursement schemes operating in Ireland (159).  
 
Every Irish citizen is entitled to participate in the Drug Payment Scheme 
(DPS). An individual or family pays a maximum of €144 per month for 
approved medicines. DPS uptake was 35.8% of the Irish population in 2011. 
The General Medical Scheme (GMS) requires patients to pay a small fee for 
each approved medicine up to maximum ceiling. The fee was first introduced 
in October 2010 and between October 2010 and the end of the study period, 
the charge was €0.50 per item up to a maximum of €10 per person. 
Participation in the GMS is restricted to people who have a low income, have 
high medical costs, or are over the age of 65. GMS uptake was 37.0% in 
2011. The Long-Term Illness scheme (LTI) is available to patients who have 
certain chronic illnesses such as epilepsy, diabetes, cystic fibrosis, and 
mental illness in patients less than 16 years. Patients on this scheme are 
entitled to free medicines for the treatment of their chronic condition. The 
HSE must give written approval for any medicine before it may be dispensed 
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under the LTI scheme. Uptake of the LTI scheme in 2011 was 1.3%. The 
remaining 25.9% of the population did not participate in these schemes. 
 
For the purposes of this study, benzodiazepines are defined as any drug that 
has a benzodiazepine structure or acts in a similar pharmacological manner 
to benzodiazepines, i.e. zolpidem, zopiclone and zaleplon. Therefore 
benzodiazepines in this study were defined as drugs with WHO-ATC codes 
in groups N05BA for anxiolytics, and N05CD and N05CF for hypnotics. 
 
In this study, dispensing data are used as a surrogate for consumption data. 
Irish national consumption data could not be calculated directly as some 
(25.9% of population in 2011) are not enrolled in government reimbursement 
schemes. The level of benzodiazepine consumption amongst those who are 
dispensed benzodiazepines privately could not be identified directly and so 
an estimate of private benzodiazepine consumption was calculated based on 
DPS consumption levels. This estimate was chosen because those patients 
receiving private prescriptions are entitled to enrol in the DPS, and so private 
patients and DPS patients are likely to be more similar to each other.  
 
Comparative national benzodiazepine consumption data between 2009 and 
2012 were obtained from publicly-accessible information published by: 
• the Danish Medicines Agency (160),  
• the State Agency of Medicines of Latvia (161),  
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• the French Agency for the Safety of Health Products (162),  
• the Finnish Medicine Agency/Social Insurance Institution (163, 164),  
• the Health-care Insurance Board of the Netherlands(165),  
• the Family Practitioner Service section of Business Services 
Organisation in Northern Ireland (166),  
• the Norwegian Institute of Public Health (167),  
• the Information Services Division of the NHS in Scotland(168),  
• and the Swedish National Board of Health and Welfare (169).  
Data sources for some countries (Finland, Ireland, Scotland and the 
Netherlands) did not include 2012 information and therefore 2009-2011 
information only, is provided. Although data were also available for Spain 
(170), Italy (171), and Portugal (172), it was decided not to include them as 
some of the benzodiazepines e.g. bentazepam, delorazepam, and 
mexazolam respectively, used in these countries, did not have an official 
WHO-ATC designation. 
 
Benzodiazepine prescribing was compared against guidelines published by 
the Department of Health and Children in 2002. Guidance which relates 
specifically to under-18’s are given below (157): 
1) Benzodiazepines should be prescribed only for as long as is 
necessary, aiming for the shortest possible time but no longer than 4 
weeks, 
2) The long-term risks of using benzodiazepines need to be balanced 
against the benefits. If a decision to prescribe maintenance 
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benzodiazepines is made then the following recommendation is 
suggested; 
Issue small quantities at a time (usually not more than one-week), 
3) They are contraindicated for use as hypnotics in children. 
 
3.2.1 Analysis 
Consumption of benzodiazepines in this study was quantified in terms of the 
Defined Daily Dose (DDD). DDD is a term created by the World Health 
Organisation (WHO), and is defined as “the assumed average maintenance 
dose per day for a drug used for its main indication in adults” (173).  This 
definition highlights both the strengths and the weaknesses of the system. Its 
major strength is that it allows researchers to measure the consumption of 
drugs in a similar class, as it accounts for the fact that drugs within a class 
have different potency. This allows for the comparison between drugs in a 
class, age groups, and countries. The disadvantages of DDD are that it is 
defined by (i) the maintenance dose of a drug, (ii) only includes a drug’s main 
indication, and (iii) includes the recommended adult dose. These 
weaknesses can have an impact on measurement of DDD, but these 
weaknesses are inherent in any system for measuring drug consumption. 
The DDD system is the most recognised system used internationally. Irish 
benzodiazepine consumption was calculated as DDD/1000/day as 
recommended by the WHO to allow for comparison with other countries 
(174). It is generally calculated annually for each benzodiazepine as per 
Equation 3.1 (174). 
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Equation 3.1. DDD/1,000/day calculation 
𝐷𝐷𝐷 1,000⁄ 𝑑𝑎𝑦⁄ = ��𝑛𝑑 ∗ 𝑠𝑑
𝐷𝐷𝐷𝑑
�  ∗ � 1000
𝜎 ∗ 365� 
Where nd = number of dosages of the dispensed benzodiazepine,  
sd = strength of the dispensed benzodiazepine dosage,  
DDDd = the defined daily dose of the dispensed benzodiazepine, and  
σ = population of group being measured. 
The sum of consumptions for all benzodiazepines was calculated to give the 
national consumption estimate.  
 
The calculation of receiving greater than four weeks treatment was based on 
a patient receiving greater than 28 DDD in a month. Some patients may not 
have received their prescription at the start of the month, so patients who 
cumulatively received greater than 28 DDD over two consecutive months 
were also included as having receiving greater than four weeks of 
benzodiazepines. 
 
For comparisons the Mann-Whitney U test was performed on non-normally-
distributed continuous/interval data. For categorical data, Pearson’s chi-
square analysis was performed. A significance level of α=0.05 was used for 
any inferential statistics calculated. All statistical analyses were performed 
using Predictive Analytics SoftWare Statistics (PASW; SPSS Inc. Chicago, 
Ill.) version 18.0. 
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Sensitivity analyses were performed on the main results to determine if 
excluding patients who were not taking benzodiazepines for their anxiolytic 
or hypnotic properties would significantly alter the results of the study. The 
PCRS database does not provide a diagnosis of the patient’s illness or an 
indication for which the medicine is being used, so an alternative means of 
doing this was required. It was suspected that benzodiazepines prescribed 
on the LTI scheme would be for the treatment of clinically-diagnosed mental 
illness and/or epilepsy as they are the only indications of benzodiazepines 
covered by the LTI scheme. A separate sensitivity analysis was performed 
for all patients who received benzodiazepines by non-oral routes as these 
benzodiazepines are not likely to be misused. 
 
3.3 Results 
3.3.1 All-age benzodiazepine use in a European context 
Firstly, an overview of benzodiazepine prescribing in Ireland will be placed in 
the context of international patterns of benzodiazepine prescribing. Figure 
3.1 represents benzodiazepine consumption between 2009 and 2012 for 
selected countries where consumption data were publicly available. 
Benzodiazepine consumption in Ireland decreased from 59.3 
DDD/1,000/year in 2009 to 49.8 DDD/1,000/year in 2011. This 16.0% 
decrease was the largest decrease among the countries surveyed. This is in 
contrast to the 16.1% increase in the Netherlands to 11.5 DDD/1,000/year 
over the same period. There were four countries with increased 
consumption, Latvia, Netherlands, Sweden and France, by 2.3, 1.6, 1.0 and 
0.9 DDD/1,000/year respectively. The consumption of the remaining 
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countries, Finland, Norway, Denmark, Northern Ireland, and Scotland, 
decreased by, 7.6, 6.4, 5.1, 2.8, and 1.3 DDD/1,000/year respectively. 
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 Figure 3.1.Benzodiazepine consumption in selected European countries between 2009 and 2012   
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3.3.2 Benzodiazepine use among young people in Ireland 
3.3.2.1 Patient and benzodiazepines consumption data 
There were 14,916 individuals aged less than 18 years who were dispensed 
51,222 items on 46,208 prescriptions over the period from 2009 to 2012 
inclusive. The majority of prescriptions (90.0%) had a single benzodiazepine 
dispensed, while 9.4% had two benzodiazepine items on their prescriptions. 
The remaining 0.6% of prescriptions contained three or four benzodiazepine 
items. Patients who received a single benzodiazepine prescription accounted 
for 63.9% (9,535) of all patients. The median consumption of 
benzodiazepines per patient was 5.3 DDD (IQR = 2.5 - 17.9). Diazepam was 
the benzodiazepine with the highest consumption between 2009 and 2011, 
while in 2012, clobazam had the highest consumption. Table 3.1 displays the 
characteristics of patients who received prescriptions for benzodiazepines 
between 2009 and 2012.  
Table 3.1. Background statistics of patients issued benzodiazepines between 
2009 and 2012 
Measure Year 
 
2009 2010 2011 2012 
Patients 4876 4597 4534 4727 
Male 49.1% 50.3% 50.3% 51.0% 
Age group 
         0-4 years 15.5% 14.8% 16.3% 15.7% 
     5-9 years 18.0% 17.8% 15.5% 17.2% 
     10-14 years 24.8% 23.9% 25.2% 25.0% 
     15-17 years 41.7% 43.5% 43.0% 42.1% 
Scheme     
     GMS 64.1% 67.5% 70.7% 70.0% 
     LTI 9.7% 14.0% 14.0% 16.2% 
     DPS 26.2% 18.5% 15.3% 13.8% 
 
The percentage of male patients was similar during the years 2009-2012 (χ² 
= 3.487, p = 0.359). The percentage of 5-9 year olds decreased in 2011 
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compared with 2009 and 2010 (χ² = 17.851, p = 0.037). No other significant 
differences were found. Likewise, there was an association between scheme 
and the year the patient received benzodiazepines (χ² = 337.109, p < 0.001). 
There was a decrease in the percentage of DPS patients issued 
benzodiazepines in the time period, while the percentage of GMS and LTI 
patients issued benzodiazepines increased. 
 
Total benzodiazepine prescribing increased by 4.7% between 2009 and 
2012 in contrast to hypnotic consumption which decreased 9.2% during the 
same period (Table 3.2). 
 
Table 3.2. Benzodiazepine prescribing between 2009 and 2012 
Measure Year 
 2009 2010 2011 2012 
Total benzodiazepine 
consumption (DDD) 181,264.6 178,607.9 190,316.5 199,689.2 
Total hypnotic consumption 
(DDD) 74,856.8 63,969.5 69,972.0 67,933.7 
 
 
Figure 3.2 shows benzodiazepine prescribing in patients ranging between 
5073.0 DDD (0 years) and 125,930.9 DDD (17 years) over the study period. 
Prescribing increased with age with an increase of 56.4% in prescribing 
between 15 and 16 year olds and an increase of 72.8% between 16 and 17 
year olds. 
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 Figure 3.2. Benzodiazepine prescribing between 2009 and 2012 by age 
 
3.3.2.2 Benzodiazepine guideline 1: “Benzodiazepines should be 
prescribed only for as long as is necessary, aiming for the 
shortest possible time but no longer than 4 weeks” 
Almost 15% of patients were prescribed benzodiazepines for greater than 
four weeks and thus were outside guideline 1; of these, there were a greater 
percentage of males (16.0%) than females (13.4%) (χ² = 19.237, p < 0.001). 
A greater percentage of DPS prescriptions were not compliant with guideline 
1 (16.6%) compared to GMS (14.6%) or LTI (14.2%) prescriptions (χ² = 
10.317, p = 0.006). A greater percentage of those who had been prescribed 
a hypnotic (23.5%) had received over four weeks of benzodiazepines than 
those who had not been prescribed a hypnotic (9.0%) (χ² = 594.035, p < 
0.001) (Table 3.3). 
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3.3.2.3 Benzodiazepine guideline 2: “Issue small quantities at a time 
(usually not more than one-week)”  
Over half (51.4%) of those who were in breach of guideline 1 were issued in 
quantities all greater than one week, contravening benzodiazepine 
prescribing guideline 2, while there were 15 patients (0.7%) whose 
prescribing was completely within guideline 2 (Table 3.4). There was no 
difference in the percentage of males and females who were issued 
benzodiazepines for greater than 7 days (χ² = 2.022, p = 0.568). More than 
half of patients (58.5%) who were issued a hypnotic had received all their 
benzodiazepines in contravention to guideline 2, compared with less than 
half of those not prescribed hypnotics (47.2%) (χ² = 32.546, p < 0.001) 
(Table 3.4). 
  
83 
 
  
Table 3.3. Compliance to benzodiazepine guideline 1 
 ≤ 4 weeks 
(compliant) 
> 4 weeks  
(non-compliant) 
Chi-square analysis 
Patients, n (%) 12723 (85.3%) 2193 (14.7%)  
Gender    
     Male, n (%) 6168 (84.0%) 1175 (16.0%) 
χ² = 19.237, p < 0.001      Female, n (%) 7972 (86.4%) 1253 (13.6%) 
Reimbursement scheme    
     GMS, n (%) 9133 (85.8%) 1512 (14.2%) 
χ² = 10.317, p = 0.006      DPS, n (%) 2376 (83.4%) 473 (16.6%) 
      LTI, n (%) 1214 (85.4%) 208 (14.6%) 
Hypnotic prescription    
    Not prescribed, n (%) 8265 (91.0%) 821 (9.0%) 
χ² = 595.035, p  < 0.001      Prescribed, n (%) 4458 (76.5%) 1372 (23.5%) 
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Table 3.4. Compliance to benzodiazepine guideline 2 
 100% of 
dispensings 
≤ 7 days 
1% - 50% of  
dispensings  > 7 days 
51% - 99% 
of  
dispensings  
> 7 days 
100% of  
dispensings 
> 7 days 
Chi-square analysis 
 (compliant) (---------------------non-compliant---------------------)  
Patients, n (%) 15 (0.7%) 258 (11.8%) 792 (36.1%) 1128 (51.4%)  
Gender      
     Male, n (%) 8 (0.7%) 128 (10.9%) 433 (36.9%) 606 (51.6%) 
χ² = 2.022, p = 0.568      Female, n (%) 7 (0.7%) 130 (12.8%) 359 (35.3%) 522 (51.3%) 
Reimbursement scheme      
     GMS, n (%) 11 (0.7%) 183 (12.1%) 525 (34.7%) 793 (52.5%) 
χ² = 71.598, p < 0.001      DPS, n (%) 1 (0.2%) 45 (9.5%) 146 (30.9%) 281 (59.4%) 
     LTI, n (%) 3 (1.4%) 30 (14.4%) 121 (58.2%) 54 (26.0%) 
Hypnotic prescription      
     Prescribed, n (%) 3 (0.4%) 67 (8.2%) 271 (33.0%) 480 (58.5%) 
χ² = 32.546, p < 0.001      Not prescribed, n (%) 12 (0.9%) 191 (13.9%) 521 (38.0%) 648 (47.2%) 
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3.3.2.4 Benzodiazepine guideline 3: “They are contraindicated for use 
as hypnotics in children” 
Hypnotics were prescribed to 5,829 people (39.1%). The hypnotic with the 
highest level of consumption between 2009 and 2011 was zopiclone, while 
nitrazepam consumption was greatest in 2012, increasing to 22,371 DDD 
from 9,722 DDD in 2009. Hypnotic use by males and females was similar at 
39.7% and 38.5% respectively (χ² = 2.307, p = 0.129). There were 
differences in the schemes of those who received hypnotics, with LTI 
patients (85.6%) receiving more than DPS patients (39.3%), who in turn 
received more than GMS patients (32.8%) (χ² = 1466.721, p < 0.001) (Table 
3.5). Patients who were issued hypnotics consumed greater median amounts 
of benzodiazepines (14.0, IQR = 5.3 - 35.0) than those who did not (3.5, IQR 
= 1.8 - 9.2) (Z = -53.963, p < 0.001). 
Table 3.5. Compliance to benzodiazepine guideline 3 
 Not prescribed 
hypnotic 
(compliant) 
Prescribed 
hypnotic 
(non-compliant) 
Chi-square analysis 
Patients, n (%) 9086 (60.9%) 5829 (39.1%)  
Gender    
     Male, n (%) 4428 (60.3%) 2915 (39.7%) 
χ² = 2.307, p = 0.129      Female, n (%) 4658 (61.5%) 2914 (38.5%) 
Reimbursement 
scheme 
   
     GMS 7151 (67.2%) 3494 (32.8%) 
χ² = 1466.721, p < 0.001      DPS 1730 (60.7%) 1119 (39.3%) 
     LTI 205 (14.4%) 1217 (85.6%) 
 
3.3.2.5 Sensitivity analysis 
Sensitivity analyses were performed to examine the effect of the inclusion of 
those not likely to misuse benzodiazepines; LTI patients and those 
prescribed non-oral-route benzodiazepines. When patients receiving non-
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oral benzodiazepines were removed from the analysis, a small change was 
detected. Where there had been a similar percentage of males (34.4%) and 
females (34.0%) prescribed hypnotics (χ² = 0.254, p = 0.652) in the full 
analysis, a statistically significant difference between males (43.9%) and 
females (41.1%) emerged (χ² = 9.400, p = 0.002).  
 
3.4 Discussion 
This study examined benzodiazepine prescribing in patients of all ages in 
Ireland in the context of benzodiazepine prescribing across a number of 
European countries and also examined benzodiazepine prescribing to 
people under the age of 18 years in Ireland from 2009-2012 in the context of 
the Good Practice Guidelines for Clinicians published in 2002 (157).  
 
Benzodiazepine consumption among the entire population of Ireland was 
compared with nine other countries between 2009 and 2012. Irish 
benzodiazepine consumption had the largest decline in prescribing, 
decreasing 16.0% between 2009 and 2011 and was following the trend of 
decreasing consumption in most of the countries surveyed. The decrease in 
overall consumption should lead to an overall reduction in the supply of 
benzodiazepines to young people who wish to misuse. Access to family 
medications and dealers are some of the main ways that young people are 
supplied with benzodiazepines (175). Dealers themselves often get their 
benzodiazepines from visiting multiple doctors or buying them from people 
who are prescribed them (176). Thus it can be seen how reducing the 
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consumption of the entire population can have a positive effect on the illicit 
supply of benzodiazepines to young people.  
 
There was a decrease in estimated global benzodiazepine consumption 
between 2009 and 2011 from 30 billion DDD to 26.25 billion DDD, 
respectively (144). All of the countries included in this study had levels above 
the average global benzodiazepine consumption for 2011, 10.4 
DDD/1,000/year. This figure was calculated using the above estimated 
benzodiazepine consumption and a population estimate for 2011 (6.974 
billion) from the United Nations Population Fund (177). The Netherlands was 
close to this level but its increases are indicating that the country will not stay 
at the low level in the future. 
 
Approximately one in every seven young people who were prescribed 
benzodiazepines was prescribed them for greater than four weeks. Of those 
who were prescribed benzodiazepines for greater than four weeks, over half 
of them were given more than a week’s supply per dispensing. In terms of 
prescribed hypnotics, there was a difference where the majority of those on 
the LTI scheme who were prescribed benzodiazepines (85.6%) were 
prescribed hypnotics compared with those prescribed hypnotics on GMS 
(32.8%) and DPS (39.3%). In contrast to the decreasing consumption 
nationally, there was a 4.7% increase in consumption among under-18s 
between 2009 and 2012, while hypnotic consumption fell by 9.2%. This 
decrease is welcome as the Good Practice Guidelines contraindicates 
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hypnotic use in under-18s (157). The rise in overall consumption is worrying 
because of the long-term potential side effects of regular benzodiazepine 
use. There was an increase in median benzodiazepine dispensing among 
Norwegian 15-16 year olds between 2006 and 2010, while in Australians 
aged 15-24 years, dispensing decreased by approximately half between 
2003 and 2006 (178, 179). Neither study suggested reasons for their change 
in dispensing. 
 
In the current study, prescribing of the study drugs was similar between 
males and females, but there was a significant difference in prescribing 
based on scheme. GMS and LTI scheme patients’ percentage prescribing 
increased while DPS prescribing decreased to such levels that there were 
less DPS patients than LTI patients in 2012. The greater consumption of the 
study drugs by GMS patients compared to DPS patients may be explained in 
terms of income as evidence from the literature, albeit from adult data, 
suggests that benzodiazepine consumption is generally greater in patients 
with lower income and unemployment (180, 181). The increase in the 
number of LTI patients may be related to the increase in clobazam 
consumption, as clobazam and diazepam are the only benzodiazepines 
licenced in the treatment of epilepsy in Ireland (182). 
 
Approximately one in every seven patients were prescribed benzodiazepines 
for greater than four weeks against the recommendations of the Good 
Practice Guidelines (157). There was a difference with overprescribing in 
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males. This result is unexpected as anxiety, for which benzodiazepines are 
most commonly prescribed, affects women to a greater degree than men 
(183). A possible explanation for this difference is prescribing for epilepsy in 
males, as there is a higher prevalence of epilepsy among males, but this 
would imply a higher percentage of LTI patients receiving greater than four 
weeks which is not reflected in the data (184). Another possibility is that 
more males are misusing benzodiazepines for nonmedical use but this 
finding is not unanimous (185, 186). 
 
The potential for iatrogenic benzodiazepine dependence to develop in a 
short period of time should not be underestimated. One study reported that a 
moderately-high daily dose of diazepam (15mg/70kg/day) in healthy 
volunteers produced observable withdrawal symptoms after seven days of 
treatment (187).  The results of that study also show that even at lower 
doses, dependence may develop after four weeks of treatment. This 
dependence would make patients hesitant to discontinue use of 
benzodiazepines and could lead to chronic benzodiazepine therapy. The 
higher levels of hypnotic prescribing in those prescribed benzodiazepines for 
greater than four weeks (23.5% v. 9.0%) is an issue as benzodiazepines with 
shorter half-lives carry a greater dependence potential (188). 
Benzodiazepine guideline number 2 recommends that those who are 
prescribed benzodiazepines for greater than a month should have their 
prescriptions issued in quantities of not greater than one week. Over half of 
patients (51.4%) were prescribed all their medicines in quantities greater 
than one week while 0.7% had their benzodiazepines prescribed according 
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to the guideline. GMS and DPS scheme patients appeared to have similar 
patterns of prescribing but LTI patients were prescribed their 
benzodiazepines in smaller quantities (Table 3.4). Smaller issue quantities in 
LTI may be common where benzodiazepines such as midazolam and 
diazepam can often be given in small quantities irregularly for the cessation 
of status epilepticus. 
 
Hypnotics were prescribed to 39.1% of patients, in contravention of the 
prescriber’s guidelines. Due to their short half-lives, hypnotics have the 
highest potential for tolerance and dependence (148), and this is part of the 
reason why the guideline states that hypnotics are contraindicated in this 
group. This is also the reason why the two most commonly consumed 
benzodiazepines, zopiclone and nitrazepam, state on their manufacturer’s 
licence that they are ‘contraindicated’ and ‘not recommended’ in children, 
respectively (189, 190). Prescribing levels among males and females were 
similar but LTI patients were prescribed hypnotics at a level more than 
double that of GMS or DPS patient (Table 3.5). A probable reason for this 
high level is that midazolam is classified as a hypnotic (N05CD08), but it is 
also indicated for use in epilepsy. Between 2009 and 2011, midazolam was 
recommended as second-line treatment to diazepam for prolonged or 
repeated seizures in the community by the National Institute for Health and 
Clinical Excellence (NICE) (191) and the updated guidelines in January 2012 
recommended midazolam as the first-line treatment (192). The 
recommendation for the use of midazolam in the updated guidelines is likely 
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to cause an increase in midazolam, and as a consequence hypnotic, 
prescribing in under-18s. 
 
There were two sensitivity analyses performed, one which excluded LTI 
patients and one which excluded patients who received non-oral-route 
benzodiazepines. The first analysis showed no significant change in any of 
the results, while there was one change in the second sensitivity analysis. 
The chi-square analysis of prescription of a hypnotic to boys (43.9%) and 
girls (41.1%) returned a value of χ² = 9.400 with a p = 0.002. The 1.8% 
difference between the sexes may have been statistically significant but prior 
to sensitivity analysis the difference was 1.2%. It was deemed that the 
sensitivity analyses showed no major difference because none of the 
significant results were nullified. The exclusion of those patients who were 
not suspected of misusing benzodiazepines did not meaningfully change 
results so including their data was appropriate. 
 
3.4.1 Limitations 
The main weakness of this study is that the HII database did not provide 
diagnoses for patients so the reseacher was unable to differentiate between 
those taking benzodiazepines for psychologically-based illnesses, with 
potential misuse, and those who were not. Our sensitivity analysis attempted 
to eliminate the effect of patients who are less likely to misuse 
benzodiazepines however; the changes that resulted were not large. Another 
limitation was the lack of data on adherence to the prescribed medicines. It is 
92 
 
not possible to know whether a prescribed medicine has been taken by the 
patient at the time of dispensing or stockpiled, with the unintentional 
possibility of misuse by family members, or has been diverted for commercial 
gain, which can occur (193). Notwithstanding these points, the data were 
derived from a nationwide reimbursement database and so would not be 
subject to errors in patient memory compared with a study based on patient 
recollection of prescribed benzodiazepines. 
 
3.4.2 Conclusion 
Benzodiazepine consumption levels to patients of all ages in Ireland had the 
largest decrease of the nine countries surveyed. This finding is contrasted by 
the increase in consumption by under-18s. Prescribing of benzodiazepines to 
young people is often not in adherence with the benzodiazepine guidelines 
for safe prescribing, with at least 40% of patients prescribed 
benzodiazepines outside of the guidelines. The consequences of this can 
include lifelong benzodiazepine usage and increased burden upon the Irish 
health-care system. It would be prudent to further investigate the reasons for 
not adhering to the guidelines so that inventions may be developed to 
improve adherence in the future. 
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 Use of addiction treatment services by Irish 4.
youth: does place of residence matter? 
 
 
 
The work of this chapter has been accepted for publication: Murphy, K. D., 
Byrne, S., Sahm, L., Lambert, S., & McCarthy, S. (2014). Use of addiction 
treatment services by Irish youth: does place of residence matter? Rural and 
Remote Health, In Press.
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4.1 Introduction 
4.1.1 Background 
Substance use is a global public health issue. Approximately 7.4 million 
people died worldwide in 2004 due to alcohol and tobacco use; this 
accounted for 12.6% of all deaths worldwide according to the World Health 
Organisation (WHO) (96). The same report highlighted substance use as the 
cause of approximately 245,000 deaths and the loss of over 13 million 
disability-adjusted life years (DALYs) (96). The impact of substance use was 
more pronounced in Europe. The WHO European region accounted for 
13.7% of the world’s population in 2004, yet 28.1% of  deaths attributed to 
addictive substances occurred there (96). 
 
Most experimentation with substances of potential misuse begins in 
adolescence (91, 194). Early experimentation (less than 13 years of age) can 
be problematic and can progress to misuse (132, 195). There are long-term 
problems associated with early initiation of substance use, such as greater 
likelihood of multiple substance use (106) and increased incidence of 
psychosocial problems (94, 196). Geographical location is a factor that 
influences substance use. Living in an urban area has traditionally been 
associated with increased substance use while rurality was a protective 
factor (197, 198). This situation is changing as the gap between the patterns 
of substance use in urban and rural setting becomes narrower. Two reviews 
examined urbanisation as a risk factor for substance misuse found no 
conclusive evidence that it led to higher levels of substance misuse in urban 
areas compared with rural areas (199, 200). Another review examined the 
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impact of substance abuse on rural areas found that there was “a 
convergence in substance use patterns between metropolitan and non-
metropolitan areas” (201). These papers suggest that it is too simplistic to 
discuss which area has a higher level of substance misuse.  
 
It is more appropriate to examine individual substance use patterns; one 
review noted that though overall levels were similar, cocaine and cannabis 
levels were higher in urban areas while alcohol, methamphetamine and 
inhalant use levels were higher in rural areas (201). Other international 
studies concur with these findings and conclude that the differences are now 
to be found at the level of the individual substance (202-208). There are 
scarce data relating to urban/rural comparisons of substance use in Ireland. 
In a study of approximately 3,400 young people in Ireland  urban and rural 
alcohol use was examined and a marked difference was observed (209). The 
study found that young people from rural areas reported having their first 
alcoholic drink at an older age and had the lower percentage for having 
drunk alcohol in the last 30 days. This report focussed solely on one 
substance thereby making it impossible to generalise the findings.  
 
There is also literature on the perceptions of parents who reside in rural 
areas that suggests that differences in urban and rural drug use may be 
narrowing (210). In the Cork/Kerry region of Ireland, where this study took 
place, a single study comparing urban and rural substance use levels in the 
general population was published (211). Substance use was compared in 
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Cork city, Cork county, and Kerry. Lifetime use of any substance was highest 
in Cork city (41%), compared to Cork county (31%) and Kerry (29%). The 
study also listed the lifetime use of individual substances. Cork city was 
highest in each substance listed except for over-the-counter codeine, where 
Kerry (4.4%) was greater than Cork city or county, with 3.0% and 1.8% 
respectively. There were no statistical analyses of these differences so no 
definite conclusions can be drawn. A recent review of Irish substance use 
has shown that substance use levels have changed since the report was 
published in 2004, so these patterns may have changed (147). 
 
Two studies were conducted in substance misuse treatment centres in 
Ireland in the past (212, 213). The treatment centres were almost exclusively 
urban populations in Dublin. Both of the studies omitted location from their 
studies, so it was not possible to use these data as a comparator. Another 
limitation to these studies is that they focussed on one or two substances. 
One of the studies examined concurrent alcohol and cocaine use (212) while 
the other performed an in-depth analysis of alcohol consumption (213). It is 
often difficult to include rural substance users in studies such as these, as 
services are less prominent than in urban areas and substance users may 
not be captured by the system. However, the treatment centre in this study  
has attendees from the counties of Cork and Kerry and thus serves a larger 
population from rural areas; therefore this study will attempt to redress this 
issue. The Cork/Kerry area of Ireland has the third highest level of substance 
treatment uptake in the country (103) . The level increased from 74.2 per 
100,000 to 110.1 per 100,000 in period between 2005-2007 and 2008-2010 
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respectively. This increase highlights the need for more information about 
those who are entering these services. The review of the literature 
highlighted gaps in the knowledge of substance use in urban and rural areas 
in the general population which has not been updated in nearly a decade. 
The lack of research into the nature of rural substance use was also 
highlighted by the literature review. There is also a need for research 
regarding those attending treatment centres, and how having urban or rural 
residence can affect the nature and success of treatment. Finally, it is 
important that an emphasis is placed on adolescents in each of these areas, 
as substance misuse can harm adolescents immensely.  
 
4.1.2 Aims 
The aims of this study were to examine the data of young service-users (up 
to 21 years old) attending a substance treatment centre, and compare 
attendees from urban and rural areas, between 2007 and 2011. 
 
4.2 Methods 
4.2.1 Design 
Ethical approval for this research was obtained by the Clinical Research 
Ethics Committee (CREC) of the Cork Teaching Hospitals and University 
College Cork (Appendix VI). Matt Talbot Services (MTS) is substance misuse 
treatment centre for young people under the age of 21 years. It is the only 
Tier 3 substance misuse treatment centre in the Cork/Kerry region that will 
admit young people under the age of 18 years (211). Before 2010, MTS 
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exclusively treated males, but a policy change resulted in the admission of 
females. Young people must provide written informed consent to allow their 
data to be used for research as part of the requirements for admission.  
 
Between 2007 and 2011, 684 young people requested treatment from MTS. 
Of these, 457 (66.8%) of the young people received a place. Seven of these 
service-users were omitted from analysis because they were over the age of 
21 years, and 14 were excluded because there were no data on their 
location of residence. A total of 436 service-users were included for analysis. 
The Health Research Board (HRB) requires all treatment services receiving 
public funding to complete the National Drug Treatment Reporting System 
(NDTRS) form to collect information such as demographic information, 
treatment history, and substance use history (excluding tobacco use). 
Electronic copies of the NDTRS forms submitted by MTS from the years 
2007 to 2011 were obtained from the HRB for the purposes of this study 
(Appendix VII). In the Cork/Kerry region, there is a single city, Cork city, so 
for the purposes of this study, urban service-users were those who resided in 
Cork city, while rural service-users resided outside Cork city. 
 
4.2.2 Analyses 
Descriptive analysis of demographic and recent substance use data was 
performed. The highest level of education was taken directly from the 
National Drug Treatment Reporting System (NDTRS) survey, so some of the 
terms may be unfamiliar to those outside of Ireland. A  brief description of 
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these options given follows: (i) did not complete primary education (age 
approximately less than 12 years), (ii) completed primary education (age 
approximately 12 years), (iii) completed the Junior Certificate (the first 
national examination; age approximately 15 years), (iv) received the Leaving 
Certificate (the final examination of secondary level education; age 
approximately 18 years). International readers may be unfamiliar with the 
term “head shop drugs”. It is the term used in Ireland for novel psychoactive 
compounds not restricted by law such as mephradone. Sale of head shop 
drugs was made illegal on 23rd August 2010. 
 
An independent t-test was performed to measure the difference in age at 
admission and the age of first substance use between urban and rural 
service-users, while the Mann-Whitney U test was used to test for 
significance in the differences between lifetime/previous month/daily use of 
multiple substances. For the remaining categorical data, Pearson’s chi-
square analysis was performed (with Yate’s continuity correction for 2x2 
tables), and where expected values fell below 1 (or 5 for 2x2 tables), Fisher’s 
Exact Test was used. If contingency tables yielded significant differences, 
then a column proportion test with Bonferroni correction was applied to 
identify the items that contributed to the significant value.   A significance 
level of α=0.05 was used for any inferential statistics calculated. All statistical 
analyses were performed using Predictive Analytics SoftWare Statistics 
(PASW; SPSS Inc. Chicago, Ill.) version 18.0. 
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4.3 Results 
There has been a steady increase in the number of individuals who were 
accepted for treatment from 2007-2011. Of the total number of cases 
recorded during this period: 26 were in 2007, 70 in 2008, 90 in 2009, 101 in 
2010, and 163 in 2011. The percentage gap between the urban and rural has 
lessened in the same period, with urban service-users accounting for 73.1% 
in 2007, 35.7% in 2008, 52.3% in 2009, 53.7% in 2010, and 45.3% in 2011. 
The regional breakdown of these service-users was 212 from Cork city, 223 
from Cork County and a single person from Kerry, so further analysis using 
these categories was not performed. 
 
Table 4.1 presents data on urban and rural service-users. There were more 
service-users from rural areas (51.3%) than from urban areas (48.7%). Both 
groups were similar in mean age, urban (16.7 ± 1.39 years) and rural 
service-users (16.8 ± 1.48 years). Males accounted for most users from both 
urban and rural settings. The percentage of service-users that resided with 
their parents was also similar for urban (93.3%) and rural (92.2%).  The 
highest level of education was found to be similar between urban and rural 
service-users. The service-users current work/educational status was 
examined also; significant differences were observed between urban service-
users and rural service-users. More urban service-users were unemployed 
when compared to rural service-users. 
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Table 4.1. Comparison of demographics between urban and rural service-
users 
Measure Urban 
(n=212) 
Rural 
(n=224) 
Significance 
Mean age ± standard 
deviation (years) 
16.69 ± 
1.39 
16.78 ± 
1.48 
t=-0.640, p=0.523 
Gender 
Male (%) 
Female (%) 
 
98.6% 
1.4% 
 
96.8% 
3.2% 
 
p=0.341 
Living situation (%) 
Resides with parents (%) 
Does not reside with 
parents (%) 
 
93.3% 
6.7% 
 
92.2% 
7.8% 
 
χ²=0.067, dF=1, 
p=0.795 
Nationality 
Irish 
Other European 
 
98.2% 
1.8% 
 
98.6% 
1.4% 
 
p=1.000 
Highest level of education (%) 
Primary level incomplete 
Primary level 
Junior Certificate 
Leaving Certificate 
 
1.0% 
29.1% 
62.1% 
7.8% 
 
1.1% 
43.8% 
48.3% 
6.7% 
 
 
p=0.153 
Current status (%) 
In paid employment 
Unemployed 
Adult training course 
Student 
Other 
 
4.1% † 
33.3% † 
22.2% 
37.4% 
2.9% 
 
10.3% ¶ 
22.2% ¶ 
17.0% 
47.4% 
3.1% 
 
 
 
χ²=12.287, dF=4, 
p=0.015* 
 Subscript † and ¶ indicate that the difference in a measure was due to the items 
with the subscript. *p < 0.05 
           
An examination of the source of referrals between urban and rural service-
users showed that the distribution in the source of referrals was similar (p = 
0.158). However, when the drug of referral was examined, there was a 
difference observed between the urban and rural service-users (p < 0.001). 
More benzodiazepine and head shop drug referrals were associated with 
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urban service-users while more alcohol referrals were associated with rural 
service-users. Age of first substance use was also examined. Both groups 
had similar mean ages of first substance use (12.4 years for urban service-
users and 12.7 years for rural service-users) (p = 0.058).  The percentage of 
urban service-users who had ever used three or more substances was 
significantly higher (p = 0.001).  A more detailed examination of their 
substance use histories revealed that usage was greater for urban service-
users for the number of substances used monthly (p = 0.003) and daily use 
(p= 0.004). There was a significant difference between the two groups when 
the first substance used was examined (p < 0.001). A more detailed analysis 
found that first use of inhalants by urban service-users was significantly more 
frequent while alcohol use was more common in rural service-users. See 
Table 4.2 for detailed descriptions. 
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Table 4.2. Comparison of substance use between urban and rural service-
users 
Subscript † and ¶ indicate that the difference in a measure was due to the items 
with the subscript. **p < 0.01, ***p < 0.001 
 
Measure Urban Rural Significance 
Source of referral (%) 
Self 
Family/friends 
Social/Community Services 
Medical services 
Irish legal system 
Education sector 
Employer 
 
7.1% 
30.0% 
20.0% 
1.9% 
37.1% 
2.9% 
1.0% 
 
10.4% 
25.9% 
17.5% 
1.4% 
44.3% 
0.5% 
0.0% 
 
 
 
p=0.158 
Drug of referral (%) 
Opioids 
Cocaine 
Ecstasy 
Benzodiazepines 
Inhalants 
Cannabis 
Alcohol 
Head shop drugs 
 
1.4% 
1.9% 
0.9% 
16.0%† 
0.9% 
54.0% 
22.5%† 
4.2%† 
 
0.4% 
2.2% 
0.4% 
4.0% ¶ 
0.0% 
59.6% 
32.3% ¶ 
0.9% ¶ 
 
 
 
 
 
p < 0.001*** 
Age of 1st substance use (years) 12.4 12.7 t=1.899, p=0.058 
Percentage that have lifetime use 
of at least 3 substances 
73.7% 52.2% Z=-3.203, p=0.001** 
Percentage that have last month 
use of at least 3 substances 
49.3% 31.3% Z=-2.998, p=0.003** 
Percentage using at least 2 
substances daily 
11.3% 4.9% Z=-2.882, p=0.004** 
First drug used (%) 
Cocaine 
Ecstasy 
Benzodiazepines 
Inhalants 
Cannabis 
Alcohol 
Head shop drugs 
 
0.0% 
0.0% 
4.1% 
6.1%† 
81.7% 
7.6%† 
0.5% 
 
0.5% 
0.5% 
1.5% 
0.5% ¶ 
80.9% 
16.1%¶ 
0.0% 
 
 
 
 
p < 0.001*** 
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4.4 Discussion 
4.4.1 Summary 
For both urban and rural service-users, the typical service-user was an Irish 
male aged between 16 and 17, who resided with his parents. Service-user 
characteristics were analysed to examine for differences between urban and 
rural service-users. In terms of employment, there were a greater percentage 
of rural service-users who were employed, while there were a significantly 
greater percentage of urban service-users who were unemployed. There 
were differences in the drug of referral between urban and rural service-
users, particularly for alcohol and benzodiazepines. A greater proportion of 
urban service-users had tried multiple substances in their lifetime and 
continued to use more substances regularly. A significant difference in the 
first substance used by service-users was also highlighted. More urban 
service-users’ first substance was inhalants while their rural counterparts 
tried alcohol first. This differs from a study found on Irish alcohol use (209), 
which saw that alcohol use was greater in urban adolescents. Greater rural 
use of alcohol was detected elsewhere, such as Scotland (214) and the 
United States (201).  
 
The results also showed that benzodiazepine referrals were greater in urban 
areas. A possible explanation for this is the trend of greater levels of 
prescribing in urban areas (215, 216) could result in more opportunities to 
access benzodiazepines. Early initiation of substance use has been linked 
with developing a substance use disorder or dependence (217), mental 
health problems (218), educational under-achievement (219), suicidal 
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ideation (220), and suicide attempts (221). A report from the Substance 
Abuse and Mental Health Services Administration (SAMHSA) compared 
urban and rural attendees of treatment centres in the United States of 
America in 2012 (222). The report concluded that rural admissions were 
more likely to be in full-time employment, and report alcohol as their main 
substance of abuse, while urban admissions were more likely to not be in the 
labour force, and report cocaine or heroin as their main substance of abuse. 
These results correspond with the findings in this study. It was not possible 
to compare results from the current study with research in Ireland or the 
United Kingdom, as there is a lack of research examining associations 
between attendees’ residence and treatment centre attendance.  
 
4.4.2 Limitations 
A limitation to this study is that there were a limited number of characteristics 
to analyse, and so confounding factors may be present, such as parental 
substance use (223), romantic partner use (224), physical abuse at a young 
age (225), level of exercise (226), and sexual preference (227). Another 
limitation on this study is that tobacco was not included as a substance of 
abuse. Tobacco and alcohol are often the first substances that 
preadolescents and adolescents will use (228); excluding tobacco may raise 
the age of first substance use. It should be noted when interpreting this 
result.   
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A further limitation is that service-users of a treatment centre were examined, 
so differences in substance use are not generalisable to the Irish population. 
Service-users form a sub-section of the population that misuses substances. 
However the substance use of these young people may suggest the patterns 
of substance use in their peer group and their locality. This could be a 
reasonable explanation as MTS is the only Tier 3 centre for under-18’s in the 
region, thus limiting the choice of centre. This means that a particular group 
of urban or rural substance users are not self-selecting, and therefore this 
bias is not introduced into the study. 
 
4.4.3 Conclusions 
Urban and rural service-users showed differences in their patterns of use. 
Policy in Ireland needs to take these differences into account. Policies are 
often formulated with urban service-users in mind and this can result in 
suboptimal preventative and treatment strategies for rural service-users. This 
is the first study in Ireland to compare service-users from an urban and rural 
setting and further work needs to be done to fully describe the differences 
between service-users, so that effective strategies to prevent and reduce 
substance use nationwide can be implemented. 
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 Benzodiazepine use amongst young 5.
attendees of an Irish substance treatment 
centre 
 
 
 
The work of this chapter has been accepted for publication: Murphy, K. D., 
McCarthy, S., Byrne, S., Lambert, S., & Sahm, L. (2014). Benzodiazepine 
use amongst young attendees of an Irish substance treatment centre. 
Journal of Addiction Medicine, In Press 
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5.1 Introduction 
5.1.1 Background 
Treatment for substance misuse is a global issue. In 2010, there were 
between 3.1 and 7.2 million people who received treatment for substance 
dependence (229). This is similar to the estimate of treatment uptake in 
2005, which was around 3.7 million people (230). It can be seen that there 
was little change in these numbers between these two periods. In Europe 
however, a different trend is observed as there has been a consistent rise in 
the number of people accessing drug treatment. In 2005 there were 
approximately 326,000 people attending drug treatment centres, but by 2010 
this had increased by 45% (231, 232).  This increase has also been mirrored 
in first-time users of the treatment centres which showed that the numbers 
increased 38% to approximately 177,700 (231, 233).  Ireland has not been 
left untouched by this trend, with an approximate 35% increase in the 
number of cases handled by treatment centres in Ireland between 2005 and 
2010 (103). In the same period of time, there was a 59% increase in the 
number of new persons entering into treatment. In 2010, 9.3% of cases 
(equivalent to 707 people) related to those aged less than 18 years of age, 
which was a 75% increase in the number of adolescents in treatment in 
2005. 
 
 Whilst international treatment service utilisation figures are not available 
nonetheless in Europe, there was a 94% increase in the number of under-
25s accessing treatment between 2005 and 2010 (234). Lifetime drug use 
amongst 15-34 years olds in Ireland has increased between 2002 and 2011 
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by approximately 10% from 25.9% to 35.7% (101). The most commonly used 
drugs in the year previous (2010/2011) in this age group were alcohol 
(86.3%), tobacco (37.3%), opiates other than heroin [such as codeine, 
oxycodone and morphine] (28.3%), cannabis (10.3%), synthetic 
psychoactive substances (6.7%), and sedatives/tranquilisers (4.8%). The 
sedative/tranquiliser category of drugs was the only category in which a rise 
was observed since the previous survey done in 2006/2007. In a recent 
review of substance use amongst young people, benzodiazepines were the 
only substance reviewed whose prevalence did not decrease over its 10-year 
review period (147). These two studies highlight that benzodiazepine misuse 
is not following the trend of decreasing use as other substances are. 
 
Progress has been made in reducing of the numbers of young people using 
benzodiazepines. Between 1995 and 2011, the percentage of 15/16 year 
olds that had used benzodiazepines without a prescription decreased from 
7% (145) to 3% (126), although this is greater than 2003 levels of 2% (120). 
This is in contrast to the percentage of young people who are prescribed 
benzodiazepines in Ireland which has decreased from 11% in 1999 (146) to 
9% in 2011 (126). Combining these, it can be estimated that approximately 
1-in-10 Irish 15/16 year olds use benzodiazepines. Another method of 
measuring benzodiazepine usage amongst young people in Ireland is to 
examine the number of young people entering treatment services in Ireland. 
Between 2003 and 2008, there was a minimum of a 5-fold increase in the 
number of young people aged less than 18 years who received treatment for 
benzodiazepine use (235). 
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Benzodiazepines at therapeutic levels can have serious short-term side-
effects, and chronic use can result in long-term consequences. Acute use of 
benzodiazepines can impair the perception of impaired risk, which can lead 
to high-risk sexual behaviour and reckless driving (28, 236). 
Benzodiazepines can also lead to paradoxical reactions and can result in 
restlessness, agitation, anxiety and aggressive behaviour (237). There is 
evidence that these reactions are more likely to occur to those at either 
extremes of age, that is, at younger or older ages (238), and that combining 
with alcohol can increase the occurrence of violent behaviour (154). 
Cognitive impairment is a well-documented side-effect of benzodiazepine 
use (239-241), both short-term and long-term. There is evidence that these 
effects can remain even after treatment with benzodiazepines has ceased 
(25, 242), although this is not without dispute (26). Although not directly 
related to benzodiazepines, it is also interesting to note in a National Office 
of Suicide Prevention report that benzodiazepines were the second leading 
method of self-harming in Ireland, after alcohol, in 2011, resulting in 3611 
hospitalisations (243). The significance of benzodiazepines in self-harm is 
such that the report views restricting access to benzodiazepines as a priority. 
 
5.1.2 Aims 
The aim of this paper is to characterise service-users who attend Matt Talbot 
Services (MTS) in the south of Ireland.  
Objective: 
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 To describe the demographic characteristics of those service-users 
attending MTS, and their current and past substance use, and to explore the 
use of benzodiazepines amongst this group. 
5.2 Methods 
5.2.1 Design 
Ethical Approval for this research was gained from the Clinical Research 
Ethics Committee of the Cork Teaching Hospitals (Appendix VI). The study 
used data collected from service-users who entered treatment with MTS 
between 2005 and August 2011. Applicants were initially interviewed by staff 
to identify those who would benefit from treatment. Those who passed the 
initial screening were accepted for treatment, while those not accepted were 
referred to alternatively-tiered services that could provide more appropriate 
treatment. A description of the 4-tier structure of mental health services is 
available elsewhere (244). A total of 198 patient files were used in the study. 
Assessment was aided by the use of assessment forms. One of the forms 
included a section on the physical and behavioural impact of substance use 
(Appendix VIII). This was made up of 16 common behavioural symptoms and 
12 physical signs of substance misuse. Service-users were asked to indicate 
if they had experienced any of these because of their substance misuse. 
 
5.2.2 Analyses 
Descriptive analysis of demographic data was done to provide a background 
of the service-user population type. Further descriptive analysis was 
performed on data relating to recent substance use, and examined by age 
and year of access to treatment. Regular benzodiazepine use was defined 
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as benzodiazepine use in the previous month. This is a common measure of 
current use in the substance misuse field (101, 245). For the comparison of 
regular benzodiazepine users and non-regular benzodiazepine users, an 
independent t-test was performed on normally-distributed data, while the 
Mann-Whitney U test was performed on non-normally-distributed 
continuous/interval data. For nominal data, Pearson’s chi-square analysis 
was performed (with Yate’s continuity correction for 2x2 tables), and where 
expected values fell below 1 (or 5 for 2x2 tables), Fisher’s Exact Test was 
used instead. A significance level of α=0.05 was used for any inferential 
statistics calculated. All statistical analyses were performed using Predictive 
Analytics SoftWare Statistics (PASW; SPSS Inc. Chicago, Ill.) version 18.0. 
 
5.3 Results 
5.3.1 Demographic data 
There were 198 service-users included in this study. Because of the number 
of incomplete forms, the sample numbers will vary between statistics; sample 
numbers are provided for each statistic reported. 
 
97.9% (n=185) of service-users were male. The age of service-users that 
had details (n=163) ranged from 13-21 and their mean age was 16.4 years 
with a standard deviation (SD) of 1.3 years. Referral to the service has 
increased from two in 2005 up to 49 in 2010, with 29 service-users accessing 
treatment up to August 2011, as can be seen in Figure 5.1. 
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Figure 5.1. Number of service-user forms filled out by year 
 
Table 5.1. Breakdown of referrals of service users by source of referral 
Referral source % of total referrals (n) 
Juvenile Liaison Officer  34.5 (39) 
Family 18.6 (21) 
Social Worker 16.8 (19) 
Probation officer 14.2 (16) 
Other 5.3 (6) 
Self 3.5 (4) 
Youth Centre 3.5 (4) 
School 2.7 (3) 
Other Treatment Centre 0.9 (1) 
 
A breakdown of referral sources can be seen in Table 5.1. Juvenile Liaison 
officers (JLOs) were responsible for the most referrals (24.5%), while family 
members were the second largest group of referrals at 18.6%. Combining 
the referrals from JLOs and Probation officers, it can be seen that the 
Department of Justice is responsible for nearly half of all referrals (48.7%), 
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whereas referrals from Department of Social Protection workers (social 
workers and youth centres) accounted for only 20.3% of total referrals. 
 
Of the service-users who answered (n=184), 98.9% had ever consumed an 
alcoholic drink (Table 5.2). The median age of first consumption was 13 
years (IQR=12-14.75). Cannabis and tobacco followed closely with lifetime 
use at 93.9% and 92.7% respectively. Cocaine and benzodiazepines were 
the only remaining substances that had lifetime use levels over 50% (54.3% 
and 51.0% respectively). 
 
Table 5.2. Service-users who have ever used a substance 
Substance % ever used (n) 
Alcohol 98.9 (182) 
Cannabis 93.9 (170) 
Tobacco 92.7 (153) 
Cocaine 54.3 (88) 
Benzodiazepines 51.0 (80) 
Ecstasy 49.4 (80) 
Petrol 34.2 (53) 
Amphetamines 28.8 (44) 
Head shop 51.4 (37) 
Mushrooms 18.5 (28) 
Lysergic acid (LSD) 11.8 (18) 
Opiates 3.4 (5) 
Heroin 50.0 (1) 
 
5.3.2 Benzodiazepine use 
Benzodiazepines had ever been used by 80/157 of the service-users. Of 
these, 43 (55.8%) service-users used benzodiazepines in the previous 
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month, a measure of regular use (3 service-users did not answer the 
question). Daily use was recorded by 9 service-users, 19 service-users used 
benzodiazepines 2-6 times a week, and use of once a week or less was 
recorded for 15 service-users. The average age of first benzodiazepine use 
was 14.9 ± 1.4 years. Characteristics of service-users entering treatment and 
their substance use history, as it relates to benzodiazepines, are examined in 
Table 5.3. 
 
Table 5.3. Comparison of service-user characteristics of regular and non-
regular benzodiazepine users 
Measure Regular 
users 
Non-
regular 
users 
Significance 
Mean age ± S.D. (years) 16.6 ± 1.0 16.7 ±1.2 t=0.585, p=0.561 
Gender 
     Male (%) 
     Female (%) 
 
97.5 
  2.5 
 
100.0 
  0.0 
 
p=1.000 
Source of referral 
     Juvenile Liaison Officer (%) 
     Probation and Welfare 
Officer (%) 
     Social Worker (%) 
     Other (%) 
     Family (%) 
     Youth Centre (%) 
     Self (%) 
 
30.0 
15.0 
 
10.0 
 10.0 
25.0 
10.0 
  0.0 
 
28.6 
21.4 
 
21.4 
  0.0 
14.3 
  7.1 
  7.1 
 
 
 
p=0.776 
Median substances ever used 
Median substances used in 
the previous month 
Mean age of first 
benzodiazepine use 
  7 
 3 
 
14.8 
  7 
  1 
 
15.2 
Z=-1.750, p=0.080 
Z=-5.096, p<0.001 
 
t=-1.105, p=0.269 
                  Bold highlight signifies significance ≤ 0.05 
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A comparative examination of regular and non-regular users showed no 
significant difference in the age of first benzodiazepine use, as can be seen 
in Table 5.4. Regular users of benzodiazepines were regular users of 
significantly more substances (3, IQR=2-3) when compared with non-regular 
benzodiazepine users (1, IQR=1-2).  
 
Regular benzodiazepine users showed more behavioural signs (12, IQR=10-
14) than non-regular users (9, IQR=7-12). Similarly, the physical signs were 
significantly different between regular (8, IQR=6-11) and non-regular (5, 
IQR=3-10) users. Both behavioural and physical signs were examined for 
differences between regular and non-regular users. Reporting of paranoia 
(p=0.018), loss of interest in sports and hobbies (p=0.039) and attention-
seeking behaviour (p=0.022) were behaviours that differed significantly for 
regular and non-regular users. Pale/white skin (p=0.031) and vomiting 
(p=0.031) were the physical signs that were significantly different in both 
groups (See Table 5.4). 
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Table 5.4. Comparison of physical and behavioural symptoms experienced by benzodiazepine users 
Measure Regular 
users 
Non-regular 
users 
Significance Total, % 
(n) 
Median behavioural symptoms 12   9 Z=-2.434, p=0.015  
Behavioural symptoms 
     Alcohol or prescription drugs going missing or dwindling in the house 
     Changing friends and moving away from old friends 
     Dramatic attention-seeking behaviour 
     Extreme apathy 
     Hyperactivity 
     Impulsive behaviour 
     Increased irritability 
     Increased time spent alone in room/withdrawn behaviour 
     Loss of interest in sports and hobbies 
     Low mood 
     Money/objects missing from home that could be easily converted into 
cash 
     Paranoia 
     Relationships with peers/siblings/parents affected 
     Suicidal ideation 
     Suicide attempts 
 
 
69.4% 
79.5% 
81.3% 
80.6% 
83.8% 
94.7% 
89.7% 
88.9% 
97.3% 
87.2% 
66.7% 
 
94.9% 
94.4% 
35.1% 
22.9% 
 
55.2% 
72.4% 
50.0% 
60.7% 
76.7% 
83.3% 
74.2% 
69.0% 
80.0% 
73.3% 
55.2% 
 
74.2% 
80.8% 
31.0% 
20.7% 
 
χ²=0.859, p=0.354 
χ²=0.153, p=0.696 
χ²=5.232, p=0.022 
χ²=1.960, p=0.161 
χ²=0.178, p=0.673 
p=0.227 
χ²=1.947, p=0.163 
χ²=2.837, p=0.092 
p=0.039 
χ²=1.317, p=0.251 
χ²=0.477, p=0.490 
 
p=0.018 
p=0.119 
χ²=0.008, p=0.930 
χ²=0.000, p=1.000 
 
47.7 (73) 
68.9 (111) 
65.2 (101) 
60.0 (87) 
67.7 (109) 
79.6 (129) 
78.9 (131) 
63.3 (100) 
76.8 (129) 
70.4 (114) 
48.4 (74) 
 
72.0 (116) 
79.7 (122) 
28.0 (44) 
15.7 (24) 
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Measure Regular 
users 
Non-regular 
users 
Significance Total, % 
(n) 
     Temper outbursts 92.3% 80.0% p=0.163 79.8 (134) 
Median physical signs 8 6 Z=-1.969, p=0.049  
Physical signs 
     Blackouts 
     Bloodshot eyes that appear glassy or vague 
     Change in appetite 
     Change in weight 
     Deterioration in appearance 
     Excessive sleeping 
     Insomnia 
     Loss of fine motor co-ordination e.g. holding a glass 
     Short-term memory loss 
     Vomiting or flushed complexion 
     White or pale face 
 
83.8% 
85.7% 
86.1% 
81.6% 
74.3% 
59.5% 
79.5% 
75.0% 
91.7% 
71.4% 
86.8% 
 
83.3% 
71.4% 
67.9% 
60.0% 
48.3% 
55.6% 
60.7% 
60.7% 
93.1% 
40.7% 
60.7% 
 
p=1.000 
χ²=1.164, p=0.281 
χ²=2.096, p=0.148 
χ²=2.880, p=0.090 
χ²=3.535, p=0.060 
χ²=0.003, p=0.955 
χ²=1.979, p=0.160 
χ²=0.905, p=0.341 
p=1.000 
χ²=4.702, p=0.030 
χ²=4.654, p=0.031 
 
71.4 (115) 
61.3 (93) 
61.3 (95) 
62.0 (103) 
54.8 (86) 
49.0 (77) 
59.9 (97) 
46.5 (72) 
69.2 (108) 
44.1 (67) 
65.9 (108) 
Bold highlight signifies significance ≤ 0.05 
  
119 
 
 
 
5.4 Discussion 
5.4.1 Summary 
This study examined the substance use history of a cohort of service-users 
attending an outpatient substance misuse treatment centre. An examination 
of these service-users’ backgrounds was also conducted. The majority of 
those attending the service were male and the mean age was 16.4 years. 
The biggest source of referrals from this cohort was from Juvenile Liaison 
Officers, which accounted for approximately a third of all referrals. Over 90% 
of attendees reported lifetime use of alcohol, cannabis, and tobacco. 
 
Over half of the attendees reported lifetime use of benzodiazepines, while 
over a quarter of attendees used benzodiazepines more than once a month, 
and the mean age of first benzodiazepine use was 14.9 years. A comparison 
of regular benzodiazepine users and non-regular benzodiazepine users 
showed that regular users experienced more behavioural symptoms. 
Paranoia, attention-seeking behaviour, and loss of interest in sports were 
shown to occur more in regular benzodiazepine users. Regular users also 
reported more physical symptoms, with pallor and vomiting being 
significantly more common in regular users.  
 
There was a large discrepancy between the number of males and females 
that attended the treatment centre. The majority of service-users in treatment 
centres are generally male, and this can be seen in many other studies 
(246). The overwhelming majority of attendees were male in this study 
120 
 
 
 
(97.9%), and this is partially due to the aforementioned bias. However 
another cause must be factored in which is the mission statement of MTS 
was to help males that had substance dependence issues. Unofficially, they 
would accept females in crisis situations, so this kept the number of female 
clients lower than would be expected. This policy was changed in 2010 to 
accept both males and females. Regular admission of females should bring 
the gender ratio back in line with the studies shown above. 
 
Delusions such as paranoia can be known to occur with benzodiazepine use 
and this effect is classed in a category known as paradoxical reactions (247). 
The Summary of Product Characteristics (SPC) for Valium states that 
delusions occur in response to using benzodiazepines predominantly in the 
elderly and in children (247). Attention-seeking behaviour is often a symptom 
of borderline personality disorder (248) and histrionic disorder (249), and 
both of these disorders have been associated with benzodiazepine 
dependence, possibly because those the two disorders mentioned above are 
prone to depression and anxiety (250). The loss of interest in sport may be 
related to effects of benzodiazepines. It is a common effect of regular 
substance use; it is listed as one of the criteria for substance dependence in 
the Tenth Revision of the International Statistical Classification of Diseases 
and Related Health Problems (16). Specifically for benzodiazepines taken at 
clinical doses can lead to fatigue, drowsiness, decreased alertness, and 
depression (247). All of these side effects can lead to decreased motivation 
which can result in decreased time spent on sports and hobbies. 
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Skin pallor in benzodiazepine use is related to benzodiazepine withdrawal 
and can last weeks after withdrawal (251). There does not appear to be a 
link between benzodiazepine use and vomiting according to SPCs. There 
was a weak link in the literature that described benzodiazepines as a 
potential anti-emetic (252). This suggests that vomiting may be a 
benzodiazepine withdrawal symptom, and there are cases reports that would 
support this hypothesis (253), as well as evidence from primate research 
(254), and reviews (255). 
 
Looking more generally at negative behavioural and physical symptoms, 
regular benzodiazepine users experienced more behavioural and physical 
effects than non-regular users. This is to be expected as regular users will 
have more problems than others, however it is surprising that regular users 
experienced a wider spectrum of symptoms. In the case of physical 
symptoms, the difference is greater than 50%. It would be difficult to explain 
this discrepancy alone by increased benzodiazepine use; that would more 
likely lead to increased occurrence of similar symptoms. One possible factor 
that could influence this result was the difference between the numbers of 
regular medicines used by both groups of benzodiazepine users. 
Polysubstance use could account for a portion of the extra symptoms 
experienced by regular benzodiazepine users. 
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5.4.2 Limitations 
This study was cross-sectional in design. The ability to generalise these data 
to other substance misuse centres should be done cautiously. This is a 
retrospective study so the researchers had no control over the design of the 
forms used by the staff at the MTS.  This would have been advantageous as 
it would have been possible to customise the form so that more thorough 
data could have been derived from it. Including further information on 
psychosocial and physical symptoms could provide a clearer picture of the 
experiences of these service-users. More information about the service-
users’ family history may help give researchers a better perspective on how 
their substance misuse fits in their lives. 
 
This study surveyed adolescent service-users attending a substance misuse 
treatment centre. This is a specialised population that is not comparable to 
the general population. The level of drug use will be substantially higher 
among this population that among the population of adolescents in Ireland. 
 
5.4.3 Conclusions 
This study presents data on the use of benzodiazepines among Irish 
adolescents attending a drug treatment centre. It is important that awareness 
about the level and severity of adolescent use of benzodiazepines is 
disseminated throughout the community, in particular among health-care 
professionals. Benzodiazepines are powerful prescription medications used 
for a wide range of indications, including anxiety, insomnia, and epilepsy. 
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Half of those who had taken benzodiazepines in this study became regular 
users. Recreational use of benzodiazepines can have acute and chronic 
effects, especially in a formative stage of life such as adolescence. Paranoia, 
attention-seeking behaviour, loss of interest in sports, pallor could indicate 
regular benzodiazepine use. Regular benzodiazepine users often are 
polysubstance users and raising awareness of polysubstance use amongst 
this group is important. The effects of benzodiazepine misuse affect the 
individual, their family, and society as whole through hospitalisation, 
substance treatment and crime. Identifying regular benzodiazepine users can 
help reduce the burden of benzodiazepines. 
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 “You Don’t Feel” – The Experience Of Youth 6.
Benzodiazepine Misuse 
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6.1 Introduction 
6.1.1 Background 
The most recent worldwide benzodiazepine usage estimate was that 
approximately 8.4 people per 1000 were consuming benzodiazepines daily in 
2009 (256). Within this worldwide context, Europe had the highest level of 
benzodiazepine consumption for both anxiolytic benzodiazepines and 
sedative/hypnotic benzodiazepines between 2007 and 2009, according to a 
report by the International Narcotic Control Board (257). Anxiolytics in 
Europe were consumed by approximately 42 people per 1000, which 
contrasts with consumption levels of approximately 25 people per 1000 in the 
Americas and approximately 5 people per 1000 in Africa. 
 
The increase in benzodiazepine consumption in Europe has been mirrored 
by an increase in the number of individuals seeking treatment for 
benzodiazepine misuse. Between 2004 and 2011, there were a 2.5 times 
increase in the number of users seeking outpatient treatment for 
benzodiazepine misuse (258). During the same time period, there was an 
increase in the percentage of cases where benzodiazepines were the 
primary substance of abuse from 1.8% to 3.0%. This highlights that problem 
benzodiazepine use has become a greater burden on the addiction services 
system in Europe. Similarly, Ireland has seen a sharp increase in the number 
of benzodiazepine users seeking treatment; there was an almost threefold 
increase in numbers between 2004 and 2010 (103, 259). The percentage of 
cases where benzodiazepines were the main substance of abuse increased 
in the same time period from 2.6% to 4.4%. The increase in demand was 
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largely due to an increase in the number of younger users seeking treatment. 
The median age of first use (by new users of benzodiazepines) has fallen 
from 20 years (2003-2008) to 18 years (2005-2010) (103, 235). 
 
This trend of earlier admission for treatment of benzodiazepine misuse 
corresponded to the trend for increased use by young people. The 
percentage of 15-16 year-olds in Ireland who had experimented with 
benzodiazepines without a prescription between 2003 and 2011 increased 
from 2% to 3% (120, 126). There has been little research into the motivations 
behind this trend. Three studies in this area are: (a) an American study that 
looked into alprazolam consumption in 15-18 year-olds who were attending a 
treatment facility (260), (b) an Irish study that examined substance use in 15-
19 year-olds (261), and (c) another Irish study that conducted interviews and 
focus groups with a wide variety of members of the local community about 
benzodiazepine use (262). These studies have strengths and weaknesses in 
relation to this topic. The first study was well conducted and gave a good 
description of adolescent benzodiazepine use; however it focussed on a 
single benzodiazepine, alprazolam, and might not fully reflect different 
experiences of different benzodiazepine types. The second study gives a 
thick description of substance use, however it did not focus on any individual 
substance and so it would difficult to determine if particular findings are 
relevant to benzodiazepines. The third study was extensive; it involved 
interviews and focus groups with health-care professionals, people who had 
been prescribed benzodiazepines, polysubstance misusers, and, “Young 
people who are likely to include benzodiazepines in their drug repertoire”  
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which is of relevance to our study (262). This indicated that the young people 
interviewed might not have first-hand experience with benzodiazepines. 
These studies are important as they point to the issues that might affect 
young people who consume benzodiazepines. 
 
6.1.2 Aims 
This study aims to give a thick description (as described by Lincoln and 
Guba as “…a sufficient base to permit a person contemplating application in 
another receiving setting to make the needed comparisons of similarity” 
(263) of the experiences of young people who have used benzodiazepines 
without being prescribed them. This will be done by conducting semi-
structured interviews with young people who consumed benzodiazepines as 
adolescents. 
 
6.2 Method 
6.2.1 Approach 
 The reseacher sought and obtained ethical approval from the Clinical 
Research Ethics Committee (CREC) of the Cork Teaching Hospitals 
(Appendix IX). Semi-structured interviews were chosen as the data collection 
method of choice as it allowed data collection to be focussed on topics 
surrounding benzodiazepine misuse in young people, whilst allowing 
freedom to explore new topics that emerged from interviews. The qualitative 
descriptive approach as described by Sandelowski was used (264, 265). 
This approach is favoured where prior qualitative research is scarce and  
128 
 
 
 
established theories are absent, as “there is no pre-selection of variables to 
study, no manipulation of variables, and no a priori commitment to any one 
theoretical view of the target phenomenon” (264). This allowed the results of 
this study to be determined entirely by the data. Quality assurance was 
achieved by following the recommendations of authors in this subject area 
(266, 267). These authors recommend that credibility and dependability can 
be maintained at a high quality by having a clear audit trail, where a record is 
kept of decisions made at every stage of the research process. The authors 
of this study wanted to maintain the highest standard of reporting, so the 
reseacher wrote the report as suggested by the Consolidated Criteria for 
Reporting Qualitative Studies (COREQ) guidelines (268). The guidelines 
were compiled from 22 existing checklists for qualitative reporting. 
 
6.2.2 Sampling 
A purposive sampling strategy was chosen as it allowed us to focus on 
obtaining data from data-rich sources. The reseacher asked substance 
misuse treatment centre and community drugs workers in Cork city, Ireland, 
to act as gatekeepers for the recruitment of young people. The inclusion 
criteria used in the selection of participants was that the interviewees used 
benzodiazepines when they were younger than 21 years of age. Candidates 
were excluded if they were vulnerable subjects or had an intellectually 
disability, as assessed by their gatekeeper. Participants were told by their 
counsellor/drugs worker that a pharmacy PhD student (the primary 
researcher and interviewer, the researcher) from the local university was 
interested in knowing more about their benzodiazepine use and were invited 
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to participate in the study. If the participant agreed to be interviewed, then 
they met with the interviewer who explained the purpose of the study and to 
establish rapport with the interviewee; the interviewer told of his personal 
motivation for studying this topic, which was the researcher’s regular contact 
with benzodiazepine-dependent patients in community pharmacy. The 
reseacher then gave the participant an information sheet with frequently 
asked questions about the interview process and contact details in the event 
that the participant wished to contact the researcher afterwards. Participants 
were asked to sign a consent form if they agreed to do an interview, and 
were asked to tick a box if they allowed quotes from the interview to be used 
in an anonymous manner in the study’s report (Appendix X). Of the 14 
people who were asked, 13 people agreed to participate and one person 
declined to be interviewed because they did not wish to talk about their 
benzodiazepine use. 
 
6.2.3 Interview 
 In line with COREQ guidelines, for the purposes of reflexivity a description of 
the interviewer is provided. The reseacher was the interviewer, and is a male 
qualified pharmacist who is in the 3rd year of his Doctoral studies. The 
interviewer had no formal qualitative interviewing experience, but had 
received training in interview techniques and in qualitative research methods. 
Single semi-structured interviews were conducted in the treatment 
centre/community centre that the interviewees were attending, as this would 
be a safe, familiar environment that would encourage free speech. 
Interviewees had the option of conducting the interviews in the presence of 
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their counsellor/drugs worker. This option was chosen by three of the 
interviewees. The interviewees composed of a mix of men and women, over 
the age of 18 years from Cork city in Ireland. The reseacher asked 
interviewees questions from a topic guide that was produced from the topic 
guide of previous research into recreational benzodiazepine use (260). 
Additional topics, such as family history of benzodiazepine use and 
benzodiazepine in their social environment were included to get a more 
comprehensive view of benzodiazepine use. The reseacher and PhD 
supervisors reviewed the topics and changes were made based on their 
comments. The topic guide was then shown to an attendee of the treatment 
centre and changes were made to ensure that the language used in the 
interview was suitable and could be understood easily. All interviews were 
recorded by a dictaphone (Sony ICD-P620), and interviews lasted between 6 
minutes and 41 minutes (median = 16 minutes). Notes were written as 
appropriate after the interviews had concluded.  
 
6.2.4 Analysis 
The researcher decided to use the method suggested by Francis et al. to 
determine when informational redundancy had been reached (269). The 
authors suggest that a minimum of 10 interviews be conducted and that the 
stopping criterion for interviews is when there are three consecutive 
interviews without any new themes. Another study suggests that the vast 
majority of themes emerge from the first 12 interviews (270). Sandelowski 
states that informational redundancy is attained when a researcher has 
“seen and heard the same thing over and over again” (271). The reseacher 
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transcribed the recordings and after transcription was completed, the 
transcript was checked against the original recording to ensure fidelity and 
also to familiarise the researcher with the sense of the interview. NVivo® 
software was used in the coding phase of analysis.  
 
Inductive content analysis was chosen as the method of analysis because it 
allows the data to guide the results and is more appropriate in situations 
where previous studies in the area are lacking (272). Content analysis was 
performed as suggested by Berg (273). The basic unit of analysis used in 
coding the data was themes. These first level codes were then organised 
into higher level categories, and the categories were then organised into 
themes, which were more abstract. In this process, codes were constantly 
re-examined to ensure their appropriateness to the higher level categories 
and themes. If a code was not appropriate, then it was reassigned to a more 
appropriate category/theme or if there were none appropriate, then the code 
was given a separate category/theme. To ensure the high credibility of the 
research, peer-debriefing was performed. The reseacher performed the initial 
coding and one fo the PhD supervisors independently coded four randomly 
selected transcripts. Both researchers met and minor discrepancies were 
discussed to reach consensus. Additionally, negative case analysis was 
incorporated into the reporting of the study as suggested by Creswell as “real 
life is composed of different perspectives that do not always coalesce, 
discussing contrary information adds to the credibility of the account” (274).  
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6.3 Results 
6.3.1 Benzodiazepine terminology 
Table 6.1 is a description of the commonly used street names for 
benzodiazepines mentioned in the interviews. It shows the wide variety of 
benzodiazepines that were used by the interviewees. They are presented 
here to aid comprehension of quotes used in the findings. 
 
Table 6.1. Street names for benzodiazepines 
Street name Brand Name Strength Generic Name Clinical 
Indication 
D10's Anxicalm 10mg Diazepam Anxiolytic 
D5's Anxicalm 5mg Diazepam Anxiolytic 
D2's Anxicalm 2mg Diazepam Anxiolytic 
Duck eggs Tenox 10mg/20mg Temazepam Hypnotic 
Purple hearts Rohypnol 1mg Flunitrazepam Hypnotic 
Roche 1.5's Lexotan 1.5mg Bromazepam Anxiolytic 
Roche 10's Valium 10mg Diazepam Anxiolytic 
Roche 2's Rivotril 2mg Clonazepam Anxiolytic 
Roche 5's Valium 5mg Diazepam Anxiolytic 
Sleepers General name for hypnotics Hypnotic 
Smarties General name for benzodiazepines Anxiolytic/Hypnotic 
Sweets General name for benzodiazepines Anxiolytic/Hypnotic 
Upjohn 10's Halcion 0.125mg Triazolam Hypnotic 
Upjohn 17's Halcion 0.25mg Triazolam Hypnotic 
Upjohn 29's Xanax 0.25mg Alprazolam Anxiolytic 
Upjohn 55's Xanax 0.5mg Alprazolam Anxiolytic 
Upjohn 90's Xanax 1mg Alprazolam Anxiolytic 
Zimo’s Zimovane 7.5mg Zopiclone Hypnotic 
Zok's Zopitan 7.5mg Zopiclone Hypnotic 
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6.3.2 Coding Tree 
The coding tree of themes developed from the interviews can be seen in 
Table 6.2. There were six main themes uncovered from the interviews, with a 
total of 14 categories within the themes. The themes are presented in 
chronological order as the interviewee would experience them, to aid reader 
comprehension. 
Table 6.2. Themes and categories discussed in interviews 
Themes Categories 
1. 1st benzodiazepine misuse a) Prior knowledge of 
benzodiazepines 
b) Circumstances of first misuse 
2. Motivation to take 
benzodiazepines 
a) Barrier against the world 
b) Social group using them 
3. Taking benzodiazepines a) Benzodiazepine sources 
b) Positives of benzodiazepine 
misuse 
c) Negatives of benzodiazepine 
misuse 
d) Compulsive nature of 
benzodiazepines 
4. Consequences of 
benzodiazepine misuse 
a) Effects on personal life 
b) Effects on family life 
5. Associated substance use a) Alcohol and benzodiazepines 
b) Cannabis and benzodiazepines 
c) Associated substance misuse 
6. Withdrawal effects a) Short-term withdrawal effects 
b) Long-term withdrawal effects 
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6.3.3 1st benzodiazepine misuse. 
6.3.3.1 Prior knowledge of benzodiazepines 
The young people interviewed had mixed knowledge of benzodiazepines 
prior to taking them for the first time. There were three interviewees who had 
indicated that they had knowledge of benzodiazepines and six that said that 
they had no knowledge. Knowledge of benzodiazepines mostly came from 
seeing others in their peer group taking them. The interviewees learned 
about the acute effects of benzodiazepines from seeing the behaviour of 
their friends, “I knew what to expect cos I’ve seen people out of their heads, 
I‘ve been in company of people out of their heads, and I didn’t take them.” 
(YP10) 
 
Some of those who did not indicate any knowledge of benzodiazepines said 
that they had expectations based on hearsay or friends’ descriptions. These 
expectations were often false,  
“It was when I started taking yokes around the same time, you know, and 
I saw them, I saw them as any kind of drug, you know, and I was like I’ll 
take them, might as well, you know.” (YP8),  
“And I'd never actually heard of them, never heard of them before and it 
was just like, the first was actually a friend of mine brought them up and 
goes, these are like a party drug, everybody takes them.“ (YP12)  
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As can be seen above, each of the interviewees knew, or thought they knew, 
what to expect when they took benzodiazepines. A negative case for this 
category was from Interviewee 11, who took a benzodiazepine tablet that 
they had found on the street, without any expectation of what its effects 
would be,  
“You’d rarely see tablets on the ground like, and I just said, what are 
these. I just said, I don’t know like. It was kind of stupid too, I was 13 
years old ... It could’ve been anything to me. I just went away and took it 
like, just being stupid. And then my brother told me what it was after 
kicking in like.” (YP11). 
 
6.3.3.2 Circumstances of first misuse  
The majority of young people interviewed described that their first experience 
of benzodiazepines was as part of a group. These young people said that 
they were curious about their effects or that they took them because they 
were available. The availability of benzodiazepines as a reason for taking 
them seemed to be linked to a culture of trying substances in the young 
person’s peer group. Taking other substances in the past appears to have 
lowered their internal resistance to taking benzodiazepines. They perceived it 
as being one more substance to try. Some of the interviewees also 
mentioned that they were intoxicated at the time of their first benzodiazepine 
use, “just to see what it was like ...“  (YP1),  
“I was already after taking other different drugs right, so I was after 
stepping into that kind, that kind of network or whatever, so then 
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someone pulled out these, these smarties, and I just took them for the 
sake of ... “ (YP3) 
 “... one of my buddies robbed them off his, his Mam or Dad or 
something, do you know. I was after drinking a naggin* and 4 cans, I 
swallowed 10 of them, and just couldn't remember the night”. (YP13) 
             *Naggin = 200ml measurement of spirits commonly sold in Ireland 
 
There were two interviewees who defied this pattern, and the quote from 
interviewee 11 in the section above applies to this section also,  
“I found a stash of them in my Mum’s room of them and it said Upjohn on 
them, you know, on the pouch for them anyway, so I took a rake of them 
anyway.” (YP8). 
 
6.3.4 Motivation to take benzodiazepines 
6.3.4.1 Barrier against the world 
A common description of their reason for taking benzodiazepines involves 
two words, feeling and caring. The interviewees wished to avoid these two 
emotions, “You don’t feel, it’s the best way to describe it. You don’t feel 
anything at all…” (YP2), 
 “... they give you, do you know they make you really stoned, when 
you first start out on them, you’re stoned, and when you’re stoned, 
you just don’t really care what goes on around you, do you know?“ 
(YP3) 
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Conflict in the young person’s personal life was noted as a common reason 
for taking benzodiazepines. It helped the young person to cope with the 
negative emotions, “I think that’s one of the reasons as well why I take them, 
cos they get rid of every single problem you have.” (YP10), “I started taking 
them when my Mam and Dad broke up. I started taking them and I was 
taking them f**king everyday” (YP13). 
 
6.3.4.2 Social group using them 
The majority of young people interviewed have a peer group that was 
supportive of benzodiazepine misuse and of substance misuse in general. 
The young people acknowledged that substance taking was expected in 
group settings, “... then I started hanging around with this other fella, this 
other friend of mine, and I started to take them ferocious amounts of them.” 
(YP3), “We did them together. We all did it together.” (YP8), “... the whole lot 
of us did, it was about, it was, would’ve been between 10 and 15 of us I’d say 
like. It would’ve been a big gang ...” (YP9). A small number of young people 
indicated that their friends were not taking benzodiazepines or were actively 
trying to dissuade them from taking benzodiazepines. Their friends’ attempts 
at dissuasion did not succeed, “... before when I used take them now, none 
of my friends were taking benzos ...” (YP1), 
“... my proper friends would have said it to me like. Friends I grew up 
my whole life with were saying like what the f**k you doing, that's not 
you at all like do you know. You're just being stupid like.” (YP13) 
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6.3.5 Taking benzodiazepines 
6.3.5.1 Benzodiazepine sources 
Multiple sources were mentioned for obtaining benzodiazepines, and the 
most common ones were general practitioners (GPs), dealers, friends, and 
family. GPs were mentioned as a source by ten interviewees. They spoke 
about attempting to get them directly from the GP and others acknowledged 
that it can be indirectly obtained “off people that get prescriptions of it that 
would be selling it.” (YP5). For some, getting benzodiazepines from a doctor 
would not be sufficient for their consumption, and they would need to be 
“hitting three or four doctors in a week” (YP6). Most of the interviewees 
described methods they had used, or methods they had heard others use. 
One interviewee declined to discuss the subject. The usual methods involved 
feigning an illness to elicit sympathy from the GP and get a prescription, 
 “Most people would say they’re after coming out of prison and they 
were taking heroin in prison. And that they’re f**ked now. They’re 
paranoid, owe a load of money, and they just used get it like.” (YP9) 
“To be honest like they'd go in, and be faking crying and s**t like that, 
telling haven't been sleeping in weeks and s**t like that, and can't 
relax and stuff, you know. And even at that like, the doctor could still 
say no like.” (YP7) 
“Back pain, that was the big one. Back pain. They knew full well you 
can't, like prove proper back pain like. They can test for whether it's 
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muscles or spine. But they can't really prove there's something wrong 
with your back like.” (YP12) 
 
A variation of the feigning illness strategy was to initially reject treatment with 
benzodiazepines to allay any suspicions of misuse that the doctor might 
have, 
“For months he’d say he couldn’t sleep anyway and getting 
headaches and all that kind of craic*. The doctor was offering him this 
and that but he kept refusing it, refusing it and then eventually by the 
end of it he said it was getting too much and he started taking it. So by 
the end of it, the doctor was giving him a large amount of them like.” 
(YP6) 
*and all that kind of craic = and other similar symptoms 
 
The reactions of the GPs to these attempts varied. The young people 
interviewed were able to get benzodiazepine prescriptions themselves or 
knew of people who were able to get prescriptions. Some refused to supply a 
prescription for benzodiazepines because of knowledge of past use or 
suspicions of misuse, “I tried going to the doctors but they said no because 
of my history of substance abuse, you know.” (YP8), 
“Now my doctor is, he's kind of younger and he kind of got it, here's 
some paracetamol like and out the door… He was no fool like, I tried it 
once or twice to go in and try them off him.” (YP12) 
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One interviewee noted that there was a doctor that knowingly prescribed 
benzodiazepines for non-medical purposes for personal reward,  
“I’ve often heard of a doctor now boy that you give him a bottle of 
whiskey and he’ll prescribe you anything, €50 now and he’ll prescribe 
you what you want ...” (YP9) 
 
It was perceived that after getting the initial prescription, “they hand them out 
to you like the new time” (YP7), and being stopped was unlikely. 
Dealers were another source of benzodiazepines. The interviewees thought 
that dealers get access to benzodiazepines because they “go to the chemist 
and don’t take them” (YP4) or “they get prescribed them” (YP11). One 
interviewee thought that dealers were responsible for most of the supply of 
benzodiazepines to users. 
“... if it was a normal fella, then it would say from dealers, but the fellas 
who seem to be copping on are going, they’re hitting three or four 
doctors in a week, getting them off like their parents, finding them 
round the place.” (YP6) 
 
The description provided by interviewees about the availability of 
benzodiazepines was mixed. Some spoke of how easy it was to get 
benzodiazepines, whereas some spoke about how demand for them was 
never satisfied,  
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“Like just 1 year that it was everywhere. And you could get them every 
street corner, every time you turned the corner you'd see someone 
who had them.” (YP12) 
“... people are putting up the price because they can do it. They can 
sell them for this price. That’s exactly why, they’re so addictive as well 
that people put up the price and you are going to buy them. Because 
then you’re addicted to them, when you’re told there’s sweets there, 
they’re gone out the door. No matter who sends them, no matter, no 
matter what, if there’s sweets there, you will always have a buyer.” 
(YP10)  
“... they'd be coming in hundreds and thousands as well, they wouldn't 
come in no packaging now or nothing. They'd just be f**king there in a 
bag or something like but, you can get them f**king piss easy like.” 
(YP13) 
 
There appeared to be discrepancies between the cost of benzodiazepines in 
different areas and for different benzodiazepines. Consequentially there are 
differing opinions about benzodiazepine prices, “Sometimes I find I’ve been 
able to get them for 50c a tablet. That’s brilliant like.” (YP6), 
“They’re expensive to buy on the street, if, like that’s one of them. Do 
you know, you could pay top price there now for f**king, you’d pay 
€1.50 for a D10, you’d pay €3 for a Purple Heart, maybe €3.50.“ 
(YP10) 
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There seems to be consensus that although the price might vary, it is 
cheaper than cannabis, which has similar effects,  
“... the fellas we hang around with, they were mad on the grass like. 
They liked it like but it was always the grass like. They only went with 
them because they were cheaper.” (YP6) 
“You go away and spend €50 on a 50-bag, a 50-bag could be gone in 
2 hours, and do you know, the stone is gone after 4 or 5 hours like, do 
you know what I mean. But it's like paying a tenner or €15 you're 
stoned for the rest of the day like. So that's why people'd be taking 
them I'd say like.” (YP13) 
 
A strategy that one of the interviewees used to reduce the price further was 
to buy benzodiazepines in bulk, which allowed them to get a discount off the 
price per tablet, 
Yeah, they were dear enough like, but like I would have been buying 
them in bulk like, you know, that kind of way. And like f**king, see 
f**king, you'd end up ordering a load because you end up taking the 
bulk of them, like. It'd be about €1.20 like, and that's what you'd be 
paying if you're buying, you know, if you're buying 5 of them or 
something like. (YP7) 
 
Friends were another source of benzodiazepines. The difference between 
friends and dealers was that they were a member of the interviewee’s peer 
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group and so would usually be present when they were consumed. This 
resulted in one of the friends acquiring benzodiazepines and that person 
would “end up sharing stuff with everyone” (YP2). For some of these 
interviewees, their friends would have obtained the benzodiazepines by 
stealing them from their parents, “And my friend eh…one of his parents was, 
eh, on lots of Xanax but she never used to take them because she didn’t like 
to take medication.” (YP8), “... one of my buddies robbed them off his, his 
Mam or Dad or something, do you know. He got a box of 30 ...“ (YP13). 
Friends who had access to larger quantities of benzodiazepines usually 
obtained them from other sources, “And then as I said there was places 
being robbed, there was literally about, I remember there was like 20,000 
Upjohn 17’s like, between all of us like ...” (YP9). 
 
There was an impression amongst the interviewees that taking 
benzodiazepines from family members occurred, “Em, they get like Xanax 
and stuff off their families. They wouldn’t really like get D10s and stuff off 
them. That’s what I think anyway.” (YP5),  
“There's old people there that have months and months scripts 
packed in a f**king Dunnes* bag, thousands of sweets like…Just go 
around and take f**king 500 of them. Sure Nan's not going to notice 
that like. She'd have a bin bag full of them like.” (YP7) 
*Dunnes = Supermarket chain in Ireland 
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Generally, the benzodiazepines would be taken without the parents’ 
knowledge. There was an exception; a single interviewee said that some 
parents give benzodiazepines to help their child’s sleep, “A lot of people like, 
their parents give them sleeping tablets and stuff ...” (YP5). Other sources 
mentioned were the internet and stealing. The impression is that 
benzodiazepines from the internet were not genuine benzodiazepines, “I 
tried the internet but I said that that’s probably risky like, the Xanax might be 
just some kind of dope junk ripoff ...” (YP8), “They’re fake, there’s no, they 
buy them for nothing on the internet. F**King €1.50 a pop and they’re fake 
sweets.” (YP10). 
 
There was one reference to theft of large quantities of benzodiazepines from 
a place “that makes the tablets” (YP9).The interviewee did not know anything 
about how or where this was being done, but there was “about 20,000” (YP9) 
tablets stolen from there.  
 
6.3.5.2 Positives of benzodiazepine misuse  
A common description of the effects of benzodiazepines is that it makes 
them stoned. Some use different words to describe the same effect: buzz, 
bang or chilled. There was usually no further description of being stoned, 
except that it involved a sense of intense relaxation, “It was a good buzz 
like.” (YP1), “If I wasn’t smoking or drinking, just take sweets to get a bang 
off it.” (YP4), “It kind of like being stoned really. Really relaxed, really calm.” 
(YP8),  
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“I used to take them, handfuls of them and I’d get whatever kind of 
buzz I’d get off them. Different kind of buzz I used to get years ago. A 
handful I used to get stoned out of my head, but as time went on, 
handfuls of them wasn’t doing much.” (YP3) 
 
Another commonly described positive effect of benzodiazepines is the 
increase in self-confidence it gives the users,  
“I don't know, it's hard to explain like, but you feel very good on them 
when you're taking them, do you know, you feel very good about 
yourself, and you feel like you could talk to anyone.” (YP13) 
  
In some cases, the increase in confidence can lead to excessive levels of 
confidence. It can lead to a sense of separateness from things around them. 
This separateness could be emotional, where the user does not feel a 
connection to any other person, or it can be physical where a user is immune 
to physical pain, “... you don’t really feel on them. Like I’ve punched walls, 
I’ve punched in windows and not felt it.” (YP2), “You think you’re invincible, 
you don’t care about anyone or anything.” (YP3), “You’re untouchable, you 
can do what you want when you want.” (YP9), “It's just like, I was the king of 
the world like, I was made of steel.” (YP12). 
 
6.3.5.3 Negatives of benzodiazepine misuse 
There were numerous negative effects that the users associated with 
benzodiazepine. The most prominently discussed negative effect was 
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blacking out/memory loss because of benzodiazepine use, “I’ve woke up on 
days, em, I’ve had people call me going just, yeah did you realise you were 
doing this last night, and I’m like going em what day’s today.” (YP2), “... you 
could stab a fella and you don’t know it the next day. You could wake and as 
I said your head is clear, you don’t know what you’re after doing.” (YP10), 
“... everyone would be passing out at random times. Just no sleeping 
pattern whatsoever. And people passing out for like 14 hours straight, 
and not waking up at all and stuff.” (YP5)  
“They were just telling me the next day what was going on, but I can't 
even remember. I don’t know, I can remember falling into a bonfire, 
you know what I mean <laughing>.” (YP13) 
 
Even though memory loss was acknowledged as a negative effect, more 
than one young person claimed to enjoy this negative aspect, “... I think I like 
that side though, the whole messy side to it, you know.” (YP8),  
“I just thought it was funny really I couldn’t remember or nothing, just 
the way I was walking around doing s**t all day like and I couldn’t 
remember a thing. I just thought it was funny like.” (YP9) 
 
The second most commonly talked about negative effect was lack of motor 
co-ordination. This came in two general forms. These forms were physical 
co-ordination and speech difficulties. The interviewees described their 
inability to keep upright after taking benzodiazepines, even in circumstances 
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that involved significant risk to themselves, “You’re sloppy and you’re 
stumbling.” (YP3), “... nearly every time they took it their legs feel like jelly 
that they’d get fierce dizzy afterwards and stuff.” (YP6), “Apparently I was 
roll, I fell down the stairs when I was trying to leave the house and I was 
getting sick everywhere, so he kicked me out of the house.” (YP8), “... I 
couldn't stand, I fell, I was falling, I fell into the bonfire 2 or 3 times ...” 
(YP13). Slurred speech was seen as a signature of benzodiazepine use. It 
can be described as rambling or incoherent, and slow and slurred, “I live 
across the road from a fella and he's chronically on them like, and he'd come 
out like, his speech would be always slow.” (YP7), “You’re, you’re slurring 
words, whereas when you’re drunk, you, can get them out, when you’re 
stoned, <imitation of slurring of speech>, do you know.” (YP10),  
“... if I take a few of them I just get, I just be walking around the place, 
I could talk different. I’d be like <imitation of slurred speech>, and then 
my face looks different ...” (YP11) 
 
Some interviewees spoke about how benzodiazepines would have the 
opposite effect to what has been described previously. The benzodiazepines 
can make a person more agitated, and prone to reacting in a more extreme 
manner. The young people associated this behaviour with the mix of alcohol 
and benzodiazepines, “There’s, there’s a lot of bad things about smarties. 
You know, they could, you could go in home and start breaking up your 
house.” (YP10), 
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“If he was drinking, he would have whacked around the gaff with a golf 
club, or something, might have whacked him around the gaff with his 
fists. He'd only give him a beating like. But a big f**king kitchen blade 
like, the kitchen blade was bigger than a bottle of coke like. It was the 
drug, the sweets you know, f**king, you know.” (YP7) 
 
Other less frequently commented on negatives associated with 
benzodiazepines were weight loss, takes away motivation, clouded-thinking 
and being indoors for long periods of time. 
 
6.3.5.4 Compulsive nature of use 
 Nearly every person interviewed spoke about the compulsion to take more 
benzodiazepines. Benzodiazepine consumption would begin with small 
quantities and would build up to larger quantities,  
“Em, when I first started taking them, then I'd only take a few of them, like 
but, they got very addictive, you know. And I ended then taking kind of 30 or 
40 a day like you know.” (YP7).  
 
In many cases, the limit on benzodiazepine use was imposed on the user 
because of their inability to purchase more or the scarcity of supply in the 
area, “They’d be kind of, they’d want them every day, they mightn’t get them 
every day, but they’d want them, they would never refuse them.” (YP3), 
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“But like, due to his past like, if they give him a month's script [prescription] 
like, month'd be f**king gone in one-go like. And they come back in thinking 
it's next month, the next day.” (YP7) 
 
The compulsion to take benzodiazepines would overpower the interviewees’ 
self-control, leading one interviewee to take medication, “... don’t even know 
if there was a stone off them, you just take them in desperation I swear.“ 
(YP9), 
“And like you try, you'd say you going to buy 100, you say, I'll keep 
these 50 for myself and I'll give these 50 to sell, at double the price. 
That is not going to happen like. As soon as you take one, then 
another one, then another one, another one, they're very addictive 
like.” (YP12) 
 
In other cases the emotional drive to take them appeared to be absent, and 
interviewees described taking them as a habit, “It was more habit than 
anything else when I was taking them, because I was so used taking them. I 
was taking them every day ...” (YP13). 
 
6.3.6 Consequences of benzodiazepine misuse 
6.3.6.1 Effects on personal life  
Benzodiazepines had effects on interviewees’ education and hobbies. The 
motivation to learn disappeared and the amnesiac effect caused 
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interviewees to forget lessons, “I gave up completely, I prefer to stay at home 
now and get stoned.” (YP9), “Like when I was in school, I can’t even kind of 
remember it. But in work, yeah with machines and all that definitely. You’re 
just not, everything is pure slow.” (YP11), “I'd just, I didn't know what was on 
the board like. I was after doing it yesterday but I still don't remember what 
was on the board ...“ (YP12), 
“I went to school, I just, depended on smoking joints at lunch, and 
looking at books was never on, never the case where, I’m looking at 
the book and I’m saying, I don’t give a f**k about this, I just want to, I 
just want to smoke my joint and I want to take my sweets.” (YP10) 
 
Benzodiazepines also affected the ability of interviewees to concentrate 
while in school or at work, which led to accidents or near-misses, 
“... I was doing an apprenticeship in a mechanics, and I remember I 
went up, I fell into the engine of a car that was running, the timing belt 
was flying and all the cam belts were flying. My boss caught me and 
just pulled me up ...” (YP7)  
“You’re just not even thinking like properly like. I often nearly took off 
my finger there, and there’s people in my class who took out eyes, 
with chisels getting stabbed in the eye. Another fella nearly took off his 
finger there over them.” (YP11) 
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Benzodiazepines had an effect on interviewees’ after-school hobbies. 
Students who played sports spent less time playing sports, 
“Played every match, Friday, Saturday, and Sunday. Training twice a 
day like, the weed kind of took the drive and the sweets just f**king 
blew it out of the park. Just dropped it into touch, I couldn't run as far 
as the bus stop now these days, or put a squad car behind me 
anyway and I might.” (YP7) 
 
A negative case for this came from an interviewee who said that 
benzodiazepine use had not affected their personal life, but this interviewee 
used benzodiazepines “once or twice a month.” (YP8), 
“It didn’t have much because I only used them at the weekend, I really 
didn’t use them during the week. But impact during school, nothing 
really. I wasn’t really addicted properly to them, I wasn’t taking them 
as often as I could. I just enjoy taking them every once in a while. I’d 
take a lot when I took them.” (YP8) 
 
6.3.6.2 Effects on family life  
The interviewees tried to hide their benzodiazepine use from their parents. 
Alcohol would often be a cover for their use, “... I might drink when I’m taking 
them which is even worse again. That would be my excuse, that would be 
my way for my Dad not to catch me.” (YP10), “They had a hint like but I 
never got caught, never got caught like. When I got caught, they thought I 
was drinking.” (YP11). For one interviewee, hiding their benzodiazepines 
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around the house did not work out as intended as after taking some, they 
forgot that they were trying to hide their use. 
“Oh yeah, 100% trying to hide it from my family yeah. Now and again 
it would come to the, like after that month when I started doing like 
hiding in the kitchen, sure after I took the 1st four or five of them 
hiding, I was too, in a way, spaced out and I didn't even realise, I was 
like going into the front room and doing this and drinking and they 
were like saying it to me the next morning, you were doing stuff right 
in front of us.” (YP12) 
 
Benzodiazepine-taking often created conflict in the family. This could be as a 
result of the effects of the benzodiazepines themselves or from the parents’ 
attempts to reduce their children’s use, 
“My Mum was really mad. My parents are split up so my Dad doesn’t 
really know too much like, but my Mum was really upset because she 
couldn’t get any more of them for a month. She was pretty upset with 
that. And she was saying it was a bit stupid to be taking them for no 
reason like.” (YP8) 
“Just being kicked out of home. Just getting arrested out of my house 
all the time. My Mam would ring the Guards on me and s**t like that. 
Stupid things now boy, I suppose it wasn’t stupid, but on my part it 
was stupid, and I didn’t want to do them.” (YP9) 
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“I was telling people made me cups of tea, and then when they made 
me a cup of tea, I didn't want it, and why did you make me a cup of 
tea. I can do it myself. I was just creating war for myself like.” (YP12) 
 
6.3.7 Associated substance misuse 
6.3.7.1 Alcohol and benzodiazepines 
 Alcohol and benzodiazepines were commonly taken together by 
interviewees. Some of the interviewees called the combination a “charge 
sheet” (YP11) because mixing the two substances led to aggression. They 
thought that benzodiazepines would not cause such behaviour by itself, “... 
when you drink with them, it’s different, you go mad. They’re dangerous.” 
(YP4),  
“... once you mix sweets with drink as well like, it just goes, you might 
as well just walk into the Bridewell* like and just tell them to put you in 
a cell like.” (YP7)  
             *Bridewell = Garda station in Cork  
“Like I've yet to come across someone anyway who can f**king drink 
and take, take a load of sweets and go drinking. Because it's just a 
recipe for disaster like.” (YP13) 
 
The main effect associated with combining the two substances was memory 
loss. This deterred many from taking both substances together, or the young 
people to take lower doses of the substances, “I wouldn't go drinking when I 
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was taking them because that's just, a bad combination because you're 
going to black out like.” (YP13), 
“Ah yeah, charge sheets boy, that's all they are. You'd have one the 
length of your f**king arm boy in a week and you won't f**king know 
what you're after doing.” (YP7) 
 
6.3.7.2 Cannabis and benzodiazepines  
Many interviewees compared cannabis and benzodiazepines. They had 
some similarities but they also had differences. Both substances gave the 
user a stoned feeling, but benzodiazepines gave the interviewees a “bigger, 
better stone” (YP10), “It kind of like being stoned really. Really relaxed, really 
calm. You could punch yourself in the arm and you wouldn’t feel it, you 
know.” (YP8), “... it’s probably just like smoking weed, they are really.” 
(YP11),  
“It's, it's a bit like weed, you're chilled out, you’re a bit tuned out. But 
it's like a lot stronger version of that like, what you'd smoke a gram of 
weed for, you get in 1 tablet.” (YP12) 
 
Even though benzodiazepines had a greater effect, some of the interviewees 
preferred cannabis, whereas others preferred to take them together. The 
interviewees did not explain their preferences,  
“... with the fellas we hang around with, they were mad on the grass 
like. They liked it like but it was always the grass like. They only went 
with them because they were cheaper.” (YP6) 
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“... if you’re smoking weed like, you’d always want be craving the tablets for 
that extra stone.” (YP9), “If I can’t get smarties then I’m getting f**king weed.” 
(YP10), “They go hand-in-hand like do you know. If you're chilling out having 
a few sweets, you may as well have a few smokes like.” (YP13) 
 
Even though the interviewees said both made them stoned, there appeared 
to be other differences between them. Benzodiazepine had additional 
physical and psychological effects compared with cannabis, “It’s similar like 
to grass or hash, but a lot of my friends say that their legs feel like jelly and 
all that kind of craic.” (YP6), 
“... you could go away and smoke f**king 20 joints a week and you'd 
still have, mentally, or whatever, you'd still have the, what way of 
saying it, the, still have the head about you to not do something like 
you know, whereas if you took f**king 20 sweets like, you walk out 
there and like f**king do anything, you won't know what you're doing… 
“(YP7) 
 
6.3.7.3 Associated substance misuse 
Three of the interviewees talked about using benzodiazepines to minimise 
the effects of withdrawal symptoms of other substances. The substance most 
commonly mentioned in this regard was cocaine, “... I take it to come down 
off like, uppers to bring me down easy. I’m relaxed so I won’t have a 
comedown really as such.” (YP5),  
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“... when we were coming down off something, do you know, you’re in 
pain and your stomach’s in s**t you know and you want to take 
something to get away.” (YP8) 
 
Some of the interviewees also took unknown substances in the hope of 
obtaining benzodiazepine-like effects,  
“I took tablets that I knew I shouldn’t have been taking. Weird things. 
Aww god, don’t even know if there was a stone off them, you just take 
them in desperation I swear.“ (YP9) 
“So I started liking them and started taking them. Found the rest of her 
medication. I found Lexapros, you know, the antidepressants, I was 
taking them but jeez, they had no real effect. They made me feel like 
crap really, you know.” (YP8) 
 
6.3.8 Withdrawal effects 
6.3.8.1 Short-term withdrawal effects  
Short-term withdrawal effects were those that happened within the first few 
days of not using benzodiazepines. It was acknowledged as being “rotten” 
(YP3). Specific symptoms experienced by interviewees while dealing with 
withdrawal were irritability, sweating, sleep disturbances, perceptual 
changes, and craving, “you’d be just craving them and craving them at the 
start.” (YP1), “The sleeping patterns, coming off them, you’ve some weird 
dreams. Very weird dreams. Disturbing dreams, disturbing like. You wouldn’t 
wish on your worst enemy.” (YP2), “If I was coming down then I’d be very 
f**king like agitated, just be snapping at my Mam and fighting ...” (YP9), 
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“Ah f**k it, you’re a wreck, because anytime I come off them it feels 
like…do you know that little tap <taps chair to imitate sound>, 
everything’s a lot louder, in your face.” (YP2)  
“I'd wake up and I would be in absolutely pools of sweat. And this is 
soaking the blankets, as if someone wet the bed, but it's sweat, and 
it's all over you and you really need to get into the shower.” (YP12) 
 
6.3.8.2 Long-term withdrawal effects 
Long-term effects were those that interviewees experienced after the acute 
withdrawal symptoms had dissipated. There were three interviewees who 
described their experiences of chronic withdrawal symptoms. Cognitive 
impairment was the main effect described in the interviews, “You know it 
takes you a while to pick back up after taking a load of them. You’d be a bit 
slow for weeks as well.” (YP5), 
“I dropped the remote, and I picked up the remote. And the batteries 
were in my hands. And I was sitting there with the batteries in one 
hand and the remote in the other hand. And I completely could not 
figure out, I was looking at the plus and the minus, and the plus and 
the minus on the remote and I couldn't completely figure out why, how 
did they come out. And there was people, my Mam was actually sitting 
there talking to me, going <interviewee's name repeated three times>, 
and it was like, I was tuned out. I just, and I, she said when my Mam 
told me about this, I sat there for like 20 minutes. Just sitting there 
158 
 
 
 
going <silence>, completely scared, that how, this should not 
happen.” (YP12) 
 
Craving never disappeared completely in the abstinence period after 
withdrawal, “You still get cravings now but I know now that even if I took 
them now, in a minute I’d be looking for more and tomorrow it’s more and 
more.” (YP9). 
 
6.4 Discussion 
This study investigated the experiences of young benzodiazepine users in a 
treatment centre in the south of Ireland. Interviewees talked about a wide 
variety of experiences concerning benzodiazepine use. In general it can be 
seen there were push and pull factors that encouraged benzodiazepine use 
by the interviewees. These have been described as factors in other studies 
(260, 262). The push factor involved the stress of daily life. The interviewees 
turned to benzodiazepines as a means of escape from these pressures. The 
main pull factor that interviewees experienced was peer influence. Peer 
influence was also mentioned in one of the above studies (260), and in other 
studies (261, 275, 276). Interviewees described how everyone in the group 
took them, and that benzodiazepines were taken in a group setting. Not 
taking benzodiazepines in a situation like this could lead to being different 
from the rest of the group. This might cause stress to the young person and 
as shown above, the interviewees want to avoid stresses in their lives. This 
suggests that the provision of alternative means of stress-reduction or the 
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improvement of coping skills could be helpful to benzodiazepine users. There 
is some support for this approach in the literature (277, 278). 
 
 Another possible means of reducing or preventing the use of 
benzodiazepines by an adolescent, based on the findings of this study, 
would be to encourage and facilitate new friendships with non-users. For the 
majority of interviewees, the description of the benzodiazepine use appears 
to be in accordance with social cognitive theory as outlined by Bandura (279, 
280). Social cognitive theory as it applies to adolescent substance use posits 
that the decision to experiment with a substance is influenced by several 
factors. The main factors are the imitation of substance use behaviour by 
role models/peers, positive reinforcement by role models/peers, positive 
expectation of social and physical consequences of the substance use, and 
use self-efficacy. The first two of these factors was highlighted in the 
interviews when the first exposure to benzodiazepines was described at peer 
gatherings. This follows another study in Ireland which reported that “first 
drug experiences took place in the company of friends and were rarely, if 
ever, embarked upon alone” (261).  
 
The positive reinforcement was offered when the interviewees were offered 
and recommended benzodiazepines. Use by peers in group settings built up 
positive expectations. The interviewees were told of the positive effects by 
the friends, that they were a “party drug”. This expectation was further 
enhanced by the fact that taking this substance allowed the interviewee to be 
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part of the social group, and diminishing the potential for social exclusion. 
The final main factor, use self-efficacy, is the “ability to successfully obtain 
and use substances” (279). Use self-efficacy is can be high for 
benzodiazepines because they are readily available and are in tablet form, 
which means that they do not need to be mixed or prepared to be consumed 
as heroin and cannabis commonly must be. 
 
The interviews suggested that levels of benzodiazepine use can vary with 
the levels of benzodiazepine supply in their area. This suggestion is 
reinforced by two studies that reported that the interviewees thought that to 
discontinue benzodiazepines, a person would have to leave the area (262), 
whereas another study reported that environmental accessibility was quoted 
as a barrier to abstaining from benzodiazepines (260). From this suggestion, 
the harm to users could be reduced if their ability to procure benzodiazepines 
was reduced. One of the main sources of benzodiazepine prescriptions 
appears to be GPs. Although they might not usually supply the user, the 
proximal sources appear to obtain their benzodiazepines from GPs. The 
main proximal sources documented in this study were dealers, friends, and 
family members.  
 
Dealers and friends of users targeted GPs by feigning illness to procure 
benzodiazepines. Various methods of deceiving GPs are described in the 
results section. There were a variety of situations described and it would be 
difficult for GPs to discern between genuine and feigned cases. Methods of 
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procuring benzodiazepines such as these are described in the literature, 
such as feigning back pain (281), being unable to sleep (262), requiring 
symptom control for opiate dependence (282), and “gaining sympathy” from 
GPs (282). These strategies could be used on individual GPs, but they can 
also be used on multiple GPs in an area. This is often known as “doctor-
shopping” and appears to be a common strategy (262, 281, 282). Another 
issue that was mentioned in relation to GPs was the ease with which repeat 
prescriptions were written. There was the impression that the initial 
prescription was the main hurdle and that once the first prescription was 
written, then they “hand out” repeat prescriptions. This perception of the ease 
of getting repeat prescriptions mirrored the view in another study conducted 
in Ireland (262).  
 
This prescribing behaviour contravenes guidelines published in 2002 by the 
Department of Health and Children (157). The report states that 
“benzodiazepines should be prescribed only for as long as necessary, aiming 
for the shortest possible time but no longer than 4 weeks.” The report also 
recommended that for patients receiving long-term prescriptions, they should 
“issue small quantities at a time (usually not more than one week)”, and that 
prescribers should “review regularly (usually monthly)”. The interviewees 
suggest that this practice is not being performed by some GPs. Adherence to 
these guidelines published in 2002 by all medical professionals would be 
important to reduce the amount of benzodiazepines prescribed.  
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The guidelines would also be useful for decreasing benzodiazepine 
prescribing for misusers, but they would also be beneficial for reducing 
unnecessary benzodiazepine prescribing in therapeutically-indicated cases. 
The interviewees in this study commented on how they acquired 
benzodiazepines from their family, mostly unknown to the family members. 
Parents giving their children benzodiazepines to help them sleep has been 
reported in other studies but was not discussed in this study (260, 262). It is 
evident from the interviews that this occurs because family members hoard 
their benzodiazepines. Regular reviews of benzodiazepine therapy and 
prescriptions of small quantities, as recommended by the guidelines should 
reduce stockpiling behaviour. Educating the public on the risks of stockpiling 
medicines and sharing medicines in general could reduce the acquisition of 
benzodiazepine by these means. It could also reduce the potentially harmful 
effects of experimentation with other medications at home, as described in 
the Associated substance misuse category, for example anti-depressants. 
 
Another area where public education would have beneficial effects is by 
increasing awareness of the effects of benzodiazepines. The interviews 
highlighted that many young people who take benzodiazepines for the first 
time were not aware of their effects. This was also highlighted in another 
study (262). In fact, some were told that they were “party drugs”, which would 
have misled them about their depressive effects. Such an educational 
campaign could publicise the negative effects as described by the 
interviewees. Memory loss, bodily clumsiness, speech difficulties, weight 
changes, and decreased motivation could all show the unattractive side of 
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benzodiazepine misuse. The longer-term consequences of benzodiazepine 
misuse can have life-long effects.  
 
The interviewees described how benzodiazepine misuse resulted in 
decreased motivation. In the sample quotes above, interviewees described 
how their school performance deteriorated as a result and that preferred “to 
stay at home and get stoned”. This is not to suggest that benzodiazepine use 
was the only reason for reduced school performance, however it can have a 
noticeable impact. This could result in a lower level of educational 
achievement, and there are many negative results from this. Level of 
education is positively related to physical health (283, 284), mental health 
(285, 286), and employment (287), and social support (288). Benzodiazepine 
use was one the factors that led some interviewees to stop their extra-
curricular hobbies and sports. 
 
The public could also be made aware of the compulsive nature of 
benzodiazepine misuse; how it can lead to use of larger quantities and loss 
of control of behaviour. This is mirrored in other studies that benzodiazepines 
cause the users to behave out of character (262). Some of the effects 
described as positive by interviewees could be described in an educational 
initiative as they are acute, short-term effects but they can have 
consequences over the longer term. Interviewees described how they 
“punched in windows” and did not feel it. Such immunity to pain finishes 
when the substance leaves their body. The user will feel the pain and injury 
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that results from their actions in the following days. The consequences can 
be social as well as physical and emotional. Nearly all of the young people 
interviewed lived in the family home, so changes in behaviour were noticed 
by their parents. This resulted in conflict in the household between the young 
person and their parents. In one case, the conflict reached a level where the 
young person’s mother needed the assistance of An Garda Síochána to 
remove the young person from their house. This action could be explained 
by the parent fearing their own safety in her house, and was likely done out 
of necessity rather than by choice. This shows that the damaging effects of 
benzodiazepines spread beyond the user and, in the case of death by 
overdose, to the community.  
 
The severity of damage to the individual and the community was increased 
when alcohol was consumed with benzodiazepines. The use of both 
substances together was reported in other studies (260, 262). The tendency 
to increased aggressive behaviour was so well known amongst the 
interviewees in this study that their combination was known as a charge 
sheet. This paradoxical reaction to benzodiazepines is well-documented and 
is thought to occur to 1% of benzodiazepine users (247). The likelihood of a 
paradoxical reaction is increased for those at the extremes of age, and when 
alcohol is consumed with it (247). Another substance that was commonly 
associated with benzodiazepines was cannabis. Many interviewees 
commented that both substances have many of the same effects, and that 
both substances help them feel stoned. The consensus amongst the 
interviewees was that benzodiazepines were stronger than cannabis. Even 
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though they had different potencies, some users preferred the weaker 
cannabis to benzodiazepines. This suggests that though similar, either 
cannabis can have other favourable effects, or that benzodiazepines can 
have other unfavourable effects. There is physiological evidence for the 
comparison of cannabis and benzodiazepines (289, 290).  
 
Some interviewees mentioned benzodiazepine use in conjunction with other 
substances. Benzodiazepines were taken to minimise the withdrawal effects 
of stimulant substances that they took. This was mirrored in another study 
where it was reported that benzodiazepines were “used to come down off 
stimulants, particularly ecstasy and cocaine” (262). These reports have a 
physiological basis, as it has been shown in animal models that anxiety 
induced by cocaine withdrawal can be alleviated by a benzodiazepine (291). 
For the withdrawal effects of benzodiazepines, the interviewees did not 
report taking anything, and so they experienced the full withdrawal effects. 
Many interviewees spoke about the short-term withdrawal effects that 
occurred in the days after taking benzodiazepines. The withdrawal effects 
experienced by interviewees could be divided into psychological effects such 
as irritability, and perceptual changes, and cravings, and physical effects 
such as sweating and sleep disturbances. Some of these symptoms, such as 
sweating and sleep disturbances were similarly reported in another 
qualitative study and in a review of benzodiazepine withdrawal symptoms 
(262, 292). Nearly all of these disturbances subsided after an extended 
period with the exception of craving, which continued months after 
benzodiazepine use had stopped. One of the interviewees described 
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experience of cognitive impairment that continued for months after 
benzodiazepine abstinence. Though not a common occurrence, prolonged 
benzodiazepine withdrawal syndrome does occur, and might persist greater 
than six months after withdrawal (242, 293). It is important to give support to 
those who desire to withdraw from benzodiazepines. Support can come in 
many forms from pharmacological to psychological supports. 
Pharmacological substitution using flumenazil, carbamazepine, and 
valproate can reduce the severity of withdrawal symptoms from 
benzodiazepines (294). An example of a psychological support that can be 
effective for benzodiazepine withdrawal is cognitive behavioural therapy 
(CBT) (294). The beneficial effects of CBT continued for up to a year after 
therapy. 
 
6.4.1 Limitations 
This research allows an insight into the experiences of young people who 
consume benzodiazepines; however there were limitations to the study. The 
data collected were semi-structured interview data collected from a 
purposively sampled population. Generalisation of this data is not possible, 
however the authors have attempted to maximise the transferability of this 
research by using thick description in the findings. It could be seen in the 
discussion, that much of what was reported in the findings were corroborated 
by independent qualitative and quantitative studies. A topic guide was used 
to maximise the coverage of the interviews. An inductive approach was used 
in analysis, and while the topic guide was not used in framing the analysis, it 
is a limitation of the study that the topic guide would influence the analysis. 
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The ‘Barrier against the world’ and ‘Cannabis and benzodiazepines’ 
categories arose entirely from the interviewees, and shows that the inductive 
approach revealed categories that were not part of the topic guide. 
 
6.4.2 Conclusions 
Benzodiazepine use by young people is a complex, multi-faceted 
experience. This study captured descriptions of this experience that could aid 
understanding of the experience. Benzodiazepines are used by young 
people coping with the pressures of life, and its use is encouraged and 
normalised by those around them. This short-term remedy has long-term 
consequences of which they are unaware. Education about benzodiazepines 
and their risks to young people, to families, and to the public can raise 
awareness and might reduce benzodiazepine misuse. Improvement in 
services to support young people who want to withdraw from 
benzodiazepines is vital. 
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  “They’re too good” - Health-care worker 7.
views on youth benzodiazepine misuse 
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7.1 Introduction 
Benzodiazepine misuse by young people is growing problem. In Europe, the 
misuse of benzodiazepines by 15-16 year olds has increased by 50% to an 
estimated 6% between 2003 and 2011 (120, 126). In the USA, the level of 
benzodiazepine misuse amongst 10th graders (15-16 years old) was  
comparable at 6.3% in 2012 (295). The level of benzodiazepine misuse 
amongst this age group in Ireland in 2011 was 3%, and a recent systematic 
review revealed that this has not changed in the past 10 years (147). 
 
Benzodiazepines are dependence-forming medicines which produce 
withdrawal symptoms if stopped suddenly (54). Even at therapeutic doses, 
tolerance to their effects can require escalating doses to achieve a 
comparable effect (296). Other features of dependence include a compulsion 
to take the benzodiazepines and continuing use despite harmful 
consequences (16). The acute effects of benzodiazepine use can include 
muscle weakness, episodic memory impairment, and paradoxical 
disinhibition (148). Chronic benzodiazepine use is associated with 
visuospatial and verbal learning impairment, depressive symptoms and 
increased suicide risk (148-151). These effects can be long-lasting especially 
if substance misuse occurs in adolescence as major development of the 
frontal cortex occurs at this time (297). Substance misuse can interfere with 
the normal development of this area which is responsible for impulse control 
and motivation. A study found adolescent decision-making processes differ 
from adult processes as they encourage risky behaviour (298), and this study 
suggested that although adolescents are aware of the risks, perception of the 
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benefits were stronger determinants of whether they would engage in this 
behaviour. 
 
As the perceptions, knowledge and views of those taking benzodiazepines 
may be influenced by their substance misuse and their age, we sought the 
observations of those involved in their care. The aim of this study was to 
describe the experiences of youth counsellors (YC) and general practitioners 
(GPs) in their work with young people who have taken benzodiazepines. 
These health-care workers would have experience with numerous 
benzodiazepine-misusing young people and so could provide additional 
insight into commonalities in benzodiazepine misuse 
 
7.2 Method 
7.2.1 Approach 
Ethical approval for the study was sought and obtained from the Clinical 
Research Ethics Committee (CREC) of the Cork Teaching Hospitals. Data 
were gathered for the study using semi-structured interviews to allow for the 
full exploration of themes. Qualitative description was chosen as the 
methodology for this study (264, 265). Qualitative description assumes no 
prior qualitative research or theories, as “there is no pre-selection of 
variables to study, no manipulation of variables, and no a priori commitment 
to any one theoretical view of the target phenomenon” (264). The results of 
this study would originate wholly from the data. The authors of this study 
wanted to maintain the highest standard of reporting, so this was achieved 
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by following the Consolidated Criteria for Reporting Qualitative Studies 
(COREQ) guidelines (268). 
 
7.2.2 Sampling 
Purposive sampling was used as it allowed researchers to collect data from a 
wide variety of appropriate sources. The area of recruitment for YCs and 
GPs was chosen as counties Cork and Kerry in the Republic of Ireland, as 
YCs from these counties are under the control of the South-Western Drugs 
Task Force, and it would allow for wider recruitment potential.  Recruitment 
letters were sent via the Health Service Executive to every GP working in the 
counties of Cork and Kerry. Extra GP participants were recruited to address 
gaps in demographics of GPs not represented in the framework. The 
inclusion criteria were that the GPs had to be actively working in general 
practice, and that they are practicing in Cork or Kerry. Recruitment letters 
were sent to YCs in Cork and Kerry. Their email addresses were obtained 
from Cork City Partnership Directory (299).  The inclusion criteria for YCs 
were that they worked with young people aged between 13 and 21 years 
who had a history of benzodiazepine misuse and worked in Cork or Kerry.  
 
7.2.3 Interview 
In line with COREQ guidelines, for the purposes of reflexivity a description of 
the interviewer is provided. The interviewer for these interviews is the author 
of this thesis. The interviewer had previous interviewing experience and had 
received training in interview techniques and in qualitative research methods. 
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Single semi-structured interviews were conducted in a location of the 
interviewee’s choosing, as this would be a safe, familiar environment that 
would encourage free speech. The interviewees comprised of both males 
and females over the age of 18 years and worked in either Cork or Kerry. 
The purpose of the study was explained and rapport was established with 
the interviewee; the interviewer told of his personal motivation for studying 
this topic; the researcher’s regular contact with benzodiazepine-dependent 
patients in community pharmacy. Participants were then given an information 
sheet with frequently asked questions about the interview process and 
contact details in the event that the participant wished to contact the 
researcher afterwards. 
 
Participants were asked to sign a consent form if they agreed to do an 
interview, and were asked to tick a box if they allowed quotes from the 
interview to be used in an anonymous fashion in the study’s report. Of the 17 
people who replied to the recruitment letter, all agreed to do the interview, 
though one participant declined to allow extracts from their interview to be 
quoted. Interviewees were asked questions from the topic guide that was 
produced from the topic guide of a previous study conducted by the 
researchers, which looked at youth benzodiazepine misuse (Appendix XI). 
The topics were modified and reviewed by the researcher and his 
supervisors to ensure that the language used in the interview was suitable 
and could be understood easily. All interviews were recorded by a 
dictaphone (Sony ICD-P620). Notes were written as appropriate after the 
interviews had concluded. 
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7.2.4 Analysis 
The method suggested by Francis et al. was employed to determine when 
informational redundancy had been reached (269). The authors suggest that 
a minimum of 10 interviews be conducted and that the criterion for interviews 
to stop is when there are three consecutive interviews without any new 
themes. Sandelowski states that “…informational redundancy is attained 
when a researcher has seen and heard the same thing over and over again” 
(271). Due to the nature of the study with two sets of health-care workers, 
the authors decided to use a more conservative baseline. It was decided to 
use 14 interviews initially instead of 10 as either group could have varying 
viewpoints. 
 
The recordings were transcribed by the researcher, the transcript was 
checked against the original recording to familiarise the researcher with the 
sense of the interview. Nvivo® Version 10 software was used in the coding 
phase of analysis by the researcher. Inductive content analysis was chosen 
as the method of analysis because it allows the data to guide the results and 
is more appropriate in situations where previous studies in the area are 
lacking (272). The basic unit of analysis used in coding the data was the 
individual theme. These first level codes were then organised into higher 
level categories, and the categories were then organised into themes, which 
were more abstract. In this process, codes were constantly re-examined to 
ensure their appropriateness to the higher level categories and themes. To 
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ensure the high credibility of the research, peer-debriefing was performed. 
Initial coding by the researcher and independent coding of three randomly 
selected transcripts was performed by a supervisor. Both researchers met 
and minor discrepancies were discussed to reach consensus. Negative case 
analysis was incorporated.  
 
7.3 Results 
The 17 participants comprised of seven GPs and 10 YCs; nine of the 
respondents were male. Seven of the participants were aged less than 40 
years. Eleven participants were involved in the care of benzodiazepine 
misusers from urban areas, two participants were involved the care of 
misusers from rural areas and four participants were involved in the care of 
misusers from both urban and rural areas. Interviews lasted between 11 
minutes and 74 minutes (median = 31 minutes). 
 
7.3.1 Coding Tree 
The themes and categories which arose from the data are displayed in Table 
7.1. 
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Table 7.1. Themes and categories discussed in interviews 
1. Factors affecting likelihood of 
benzodiazepine misuse 
a) Family and benzodiazepine 
misuse 
b) Friends and benzodiazepine 
misuse 
c) Triggers for misuse 
d) Culture of acceptable use 
2. Benzodiazepine misusers a) Past and present 
b) User differences 
3. Benzodiazepine effects on personal 
life 
a) Effects on school/work 
b) The Gardaí* and 
benzodiazepines 
4. GP prescribing of benzodiazepines a) GPs as a source of 
benzodiazepines 
b) Decision to prescribe 
benzodiazepines 
c) Doctor-patient relationship 
5. Measures to reduce benzodiazepine 
misuse 
a) Limiting sources of 
benzodiazepines 
b) Education 
c) Alternative therapies 
*Gardaí are the national police force of Ireland 
 
7.3.2 Factors affecting likelihood of benzodiazepine misuse 
7.3.2.1 Family and benzodiazepine misuse 
A suggestion which was common to many of the interviews was that 
adolescent benzodiazepine misusers come from unstable families, 
“It'd be fairly chaotic at home maybe as well. They wouldn't be kind of 
the usual boring morning and night routines you know. The boring 
things keep the kids on the straight and narrow.” (YC07) 
 
Families with dysfunctional relationships and “where the family structure has 
broke [sic] down” (YC06), have an increased likelihood of misuse occurring. 
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This can be explained by parents not guiding their child’s development and 
“…a lack of intervention earlier on when they're smoking weed at 14” (YC04). 
This relative lack of parental involvement would increase the “likelihood that 
the substance use will get more and more…serious” (YC04). Parental 
substance misuse would be a complicating factor in this for two reasons. The 
first was that their own substance misuse can shape their attitude to the 
issue and can lead to a parent not seeking treatment for their child, 
“…where there's a lot of drug use in the family as it is, then it's 
minimised. It's not really seen as a big deal as such because it’s like 
drug use is, that's what's familiar and that's what's normal. So it's not 
seen as anything out of the ordinary. It's what people do…” (YC04) 
 
The second issue that can arise is that children can subconsciously see their 
parents’ substance-misusing behaviour and internalise it as a normal 
behaviour. Seeing it as normal in the home can become self-reinforcing 
when they are outside the home, 
“…you'll have Mum using them prescribed by her GP for anxiety and 
that's perfectly ok in their attitude. And I think that's what’s passed on 
to the kids. Sure I'm anxious, so I'll use what Mum is using.” (YC05) 
 
“...you hear the same names, the same family names turning up over 
and over again, you realise it's a very small subset of the population, I 
think, who are actually doing this. And again I know when they go out 
on the street, they are looking for the person like themselves and 
177 
 
 
 
therefore they group together. And it becomes normal in that group.” 
(GP04) 
 
This behaviour is not indicative of all parents of children misusing 
benzodiazepines; parents can also have “a heart attack” (YC09) when they 
find out. Families at this extreme may also suffer due to benzodiazepine 
misuse and they attempt to hide it because “…there’s shame and they don’t 
want Mary next door to know” or because they aren’t “…sure what to do, or 
they think that’ll just pass, that it’s just a phase” (YC06). 
 
7.3.2.2 Friends and benzodiazepine misuse 
Friends were seen as “hugely influential” (YC03) in a young person’s 
benzodiazepine use. The strongest influence was “peer group…more so 
than family” (YC01). It was thought that this was because “…they’re taking 
their guidelines from peers now. Not necessary [sic] from family anymore” 
(YC07). It was commonly perceived that for “…anyone with a problem, all of 
their friends would be using drugs…” (YC09), and “…usually their friends are 
taking benzos as well” (YC08).  
Young benzodiazepine misusers may have sets of friends who use and 
friends who do not use. It was perceived that the young person would identify 
more with one of the groups, “so if they’re gravitating towards their group of 
friends who are using then it’s going to be more difficult” (YC04). It can place 
a strain on the young person’s friendships with those that who do not use so 
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that “the person gives up from nagging them or else they kind of pull away 
from them because they don’t want to hear it” (YC06). 
 
7.3.2.3 Triggers for misuse 
There can also be acute triggers of benzodiazepine use for young people. 
There was an acceptance that “…everyone’s triggers are different…I 
wouldn’t say there’s one common reason…” (YC09), and that triggers 
“…could be anything” (YC01). Other participants observed broad triggers of 
misuse, “anything that happens out of the normal will probably require most 
usage to manage it” (YC06). Triggers were generally seen as events that 
had “the potential to cause…hurt and pain…” (YC04). Examples of situations 
that may trigger benzodiazepine misuse are “when something happens at 
home” (YC07) and “breakup with a girlfriend” (YC04). Benzodiazepine can 
also be triggered by “…an event coming up…it’s this idea of I kind of have to 
build myself up” (YC06). 
 
Alternatively triggers of benzodiazepine misuse can be unrelated to the 
young person’s state of mind. An increased availability of benzodiazepines 
on the street will lead to increased use, “…if there’s a glut of tablets onto the 
street…they’ll keep using them” (YC05). Being intoxicated with alcohol can 
increase the susceptibility of benzodiazepine misusers to take 
benzodiazepines, “…they’ve been off them a while, but often if they go out 
drinking and if they are offered the benzos, they’re more inclined to say yes if 
they have been drinking” (YC08). One participant gave details of the 
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unpredictability of use, “it can be as simple as it’s a group of young lads and 
just to…get out of it for a couple of days… (YC02). 
 
7.3.2.4 Culture of acceptable use 
The culture of the local community can contribute to its young people using 
benzodiazepines when “we…come from a society that has become very 
drug-orientated” (GP04) and when it is acceptable for neighbours to be, 
“pooling all their tablets and putting them in a basin in the middle of 
the table. And literally that you would take a handful of tablets, and 
you would probably having a beer or wine or something” (YC06) 
 
In some communities there is an “expectation of a pill to cure everything” 
(GP05). There is the often an assumption that tablets will solve the problem, 
“The 13 year old wasn't sleeping. So he was up all night. And the 
mother was saying, I'll bring him down to the doctor to get some 
sleepers for him…the problem with him was like, she was leaving him 
up all night on the Xbox…“ (YC09) 
 
There is no hesitation in these communities because “…there’s no illegality 
about it, it’s an ok drug to be on” (YC03) and “the doctor’s prescribing these, 
so it must be ok” (YC02). All of these factors can combine to give a sense to 
normality to benzodiazepine use, especially where alternative messages 
about benzodiazepines are not picked up by young people. 
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7.3.3 Benzodiazepine misusers 
7.3.3.1 Past and present  
The participants often spoke about differences in relation to misuse at 
present and those that they had experience with in the past. A commonly 
mentioned difference was that “…GPs are becoming more aware and they’re 
not giving them to young people” (YC08). This was because “there wasn’t 
the same awareness of habituation” (GP04) and “that the thinking 30 or 40 
years ago was somebody’s depressed, give them some benzos” (GP03). 
This is not the case now, as “there’s been a bit of tightening up in GPs…” 
(YC01) and “…we have finally gotten to the point where the psychiatry 
services aren’t prescribing benzodiazepines” (GP01). 
 
Another change from the past was that more young people “…are no longer 
saying oh I’m satisfied having a drink and taking a weed” (YC07), and “if I 
was to look back 5 years ago…they would have come in relation to their 
alcohol and maybe use of cannabis…now benzos are involved” (YC08). 
Others disagreed with this saying, “the only thing I would have seen 
was…the price would have gone up…that’s the only thing I would have seen” 
(YC03). 
 
7.3.3.2 Benzodiazepine misusers 
Participants spoke about the differences between benzodiazepine users at 
present. The areas where differences were observed were in gender, 
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educational/social background, and in age. There was a consensus that “the 
problem is just as big with young girls and women as what it is with, men” 
(YC01). The difference between the sexes was in terms of outcome, 
“there was use with girls and they’d slip the net a little bit. You know 
they didn't tend to get into as much trouble as boys. Em, because 
maybe there was a bit of drinking at home you know, and their friend 
would come in and they'd drink” (YC07) 
 
This has the consequence that “fellas are…directed to services 
because…they’re in trouble more” (YC01). Another area where differences 
were apparent to the participants was in terms of social class. Participants 
thought that young people from “…more disadvantaged backgrounds…” 
(GP07) were more likely to misuse. This view is reinforced by other 
participants commenting on third level students that “…it does not appear to 
be a recreational drug of use in…the student population” (GP05). However 
this was not universally acknowledged with some commenting that 
benzodiazepine users come from “…all walks of life…we’ve had some right 
sort of posh kids as much as we’ve had lower socioeconomic groups coming 
in here using benzos” (YC05). 
 
It was suggested that benzodiazepine misuse is,  
“…across the board. That is also scary in itself, in the fact that there’s 
no one particular group that is concentrating on benzodiazepine use. 
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Cos usually with drugs, you could nearly categorise them into, you 
know you’ve got your party drugs, and you’ve got your alcohol and 
cannabis for the younger ones…it’s really across the board” (YC02) 
 
The age of the user plays a significant part in the pattern of benzodiazepine 
misuse. Those in early adolescence who take benzodiazepines would be 
“…getting them on the street…” (YC08) or “…that they’re stealing Mum’s 
tablets or Nan’s tablets…” (YC06). Another feature of benzodiazepine use at 
a younger age is that they are “…taking a pill here or a pill there…they’re not 
saying they’re taking them regular” (YC07) and “they’re using 
them…because they’re being handed out” (YC06). Because of this 
behaviour, benzodiazepine use is “much more in group than it is individually 
in a home setting…usually in a party out at night” (YC06). Benzodiazepines 
are not the only substance misused by this group, “with the younger ones 
more so, it’s benzos, cannabis, you know, alcohol” (YC02) and “you’re not 
looking at one usage, rarely in my experience is one substance on its own. 
Particularly in the younger age group” (YC06). 
 
Those in late adolescence would have a different attitude to 
benzodiazepines. It is at this stage “when they get to be kind of 18, up to 20, 
25, that they’re recognising that the tablets, that they actually need them to 
cope” (YC07). They have moved from taking benzodiazepines sporadically 
with friends and, 
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“It becomes a little more sophisticated as they get older…they actually 
then have a system. So they take so many maybe to get them up in 
the morning. Then there's, there’s a program to the day around usage. 
So then there might be something to get you up, something to what I 
call lose time. So they want to remove x number of hours in the day, 
and then a certain amount again to sedate you to put you to sleep. 
Because without it, they won't sleep…” (YC06) 
 
Heavy episodic (binge) benzodiazepine use would not disappear as the 
misuser got older but it would be less extreme, for example a person could 
be “taking 3 or 4 a day, and then some days if they felt they wanted more 
they’d take more” (YC08). They would not get their benzodiazepines on the 
street, “…definitely the 18 to 25 year old, seem to get prescriptions from 
doctors, easy enough…they would have told me that they were going to 
different doctors” (YC07). For those starting at a very young age, often a 
level of tolerance can build up such that benzodiazepine users “move on to 
the heroin when they’re 19 or 20. The benzos stop working for them then” 
(YC05). Even then benzodiazepines can be  
“a managing tool…so if you are using heroin and there’s a 
drought…or there’s a problem with supply, or they have no money. 
They would mostly move to benzodiazepines” (YC06) 
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7.3.4 Benzodiazepine effects on personal life 
7.3.4.1 Effects on school/work 
Awareness of the deleterious effects of benzodiazepines on school or work 
varied between participants. The GPs gave a common type of response 
when asked about their awareness of effects on school or work, “not that I’m 
aware of” (GP01). Some GPs were not able to give an answer because they 
“…don’t hear them commenting on adverse effects cos we actually don’t 
prescribe that much” (GP05). One GP offered an explanation for why they do 
not hear about effects on schooling, “they wouldn’t have that insight. If it was, 
that wouldn’t be their worry” (GP03). YCs had differing views from GPs, they 
believed that poor school/work performance was “probably a combination of 
factors, but benzos would probably be one of the more predominant factors” 
(YC04). Young benzodiazepine misusers “might be going to school, but few 
would have jobs…missing days, not getting up. In bed all day type of thing” 
(YC09). If they do attend school/work, “…they’re kind of not…mentally 
present…meaningful work through school or their work would be very difficult 
to achieve…” (YC02). This can eventually lead to getting “…pretty much 
expelled or they would leave themselves…most of my guys are on the dole 
now…” (YC02). Others would have doubts about “…whether there’s other 
psychosocial issues going on previous to their use that would have them out 
of school anyway” (YC05). 
 
7.3.4.2 The Gardaí and benzodiazepines 
GPs and YCs were mostly in agreement that “…anybody I’ve had put on my 
list, who are on benzodiazepine have big legal issues. All of them, or more or 
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less all of them” (GP04). Some participants thought that young people’s 
interactions with the Gardaí were due to “…using illegal drugs rather than 
prescribed drugs” (GP02). Others suspected that compared with 
benzodiazepines alone, mixing alcohol with benzodiazepines made users 
“…more visible, sometimes very equal in lifestyle and everything but just in 
more trouble with the law” (YC03). Some thought that “where they might get 
involved with the Guards, not through their behaviours while stoned, but from 
either stealing or...dealing” (YC05) or from “stealing usually…not a lot of 
violence now” (GP02). In contrast to these views, one participant believed 
that involvement with the Gardaí was as common among non-drug users, 
“…that’s the area we’re in. That wouldn’t set them out in the 
practice…involvement with the Guards…probation officers, and social 
workers and all that. That doesn’t set them apart from drug users” 
(GP03) 
 
7.3.5 GP prescribing of benzodiazepines 
7.3.5.1 GPs as a source of benzodiazepines 
GPs can be a common source of benzodiazepines for misusers. As shown 
above, those in early adolescence tend not to get benzodiazepines from 
GPs. The older adolescent misusers would be “…comparing notes, who's the 
best doctor to go…just tell him…you're feeling depressed or feeling suicidal, 
you can't sleep. Just tell him that and he'll…write you the script” (YC09). The 
success of this strategy “…depends on the GP. There’s certain GPs in the 
area that won’t give them out” (YC08), conversely “…there were very large 
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prescriptions available because we had an issue with a practitioner…” 
(YC06). 
 
Benzodiazepines prescribed are sometimes not enough and patients can 
“…supplement whatever the doctor will give them with extras” (YC02). 
Another strategy used to increase the number of benzodiazepines prescribed 
is to have “3 or 4 doctors…what we find here is that you'll have a gang, say 4 
or 5 people like. They'll all have scripts” (YC09). 
 
7.3.5.2 Decision to prescribe benzodiazepines 
GPs appeared to have conflicting views on prescribing benzodiazepines. 
Some admit that “…they’re very effective” (GP03) and “they work” (GP04).  
While holding this positive view, GPs simultaneously “…wish they didn’t exist 
on the market…in many ways, they’re too good” (GP01), and “because 
they’re so effective, they’ve become very popular” (GP04). GP participants 
spoke of benzodiazepines being useful for “…severe short-term 
anxiety…measured in matters of hours to days…” (GP02). The temporary 
nature of their use was reiterated by other GPs who thought of their use 
“…where somebody needs fast-acting medications such as a panic attack or 
a specific phobia maybe of flights…” (GP07), and they “…would not give 
more than 4 to 5 days [supply]” (GP05). Some participants would offer 
“…beta-blockade as a way of symptomatic relief of physical signs of 
anxiety…” (GP05) first line. Other uses of prescribed benzodiazepine would 
be as a “…muscle relaxants in situations…like whiplash and torticollis, where 
187 
 
 
 
they have acute muscle spasm…” (YC07), “…in the treatment of epileptic 
seizures” (GP02), “…and for hypnotic treatment…” (GP05). 
 
The views of GPs about prescribing benzodiazepines to under 18s ranged 
from “…I don’t think I could justify giving a minor a benzodiazepine…” 
(GP04) to “…I would almost never prescribe to an under-18…I would take 
psychiatric advice” (GP01) to “If I was going to prescribe…it would really be 
with extreme caution…starting off with the lowest dose possible” (GP03). All 
of the GPs who offered an opinion did not like prescribing benzodiazepines 
in under 18s. GPs were also cautious in prescribing benzodiazepines where 
“…there’s a history of addiction there” (GP03) or even outside of the 
individual where there was a “…history of benzodiazepine use in the family” 
(GP01). 
 
Some GPs accepted that patients were using benzodiazepines prescribed by 
GPs but had to focus more on “…damage limitation” (GP04). They would 
continue to prescribe benzodiazepines in some circumstances where 
“…patients who initiate benzodiazepines, do so from outside the practice” 
(GP02), but the approach to potentially new patients was, 
“…just don’t let the new generation get hung up on them like the older 
generation did…cos it’s much easier to not do it in the first place, than 
to try and stop once it’s started already” (GP07) 
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7.3.5.3 Doctor-patient relationship 
GPs noted several ways that they could recognise new patients who were 
misusing benzodiazepines. The main pattern was that patients would tell the 
GP that they had received benzodiazepines previously and that they want to 
get them now, for example some would say “…they got it elsewhere and it’s 
the only thing that works…they always get it from their previous doctor…” 
(GP05). Variations on this theme can be that the patient had misused 
benzodiazepines in prison “and they’ve just been released and they need a 
supply otherwise they’re going to withdraw” (GP01) or that “…they’ve been 
up the country but normally they’ll say they’ve been in the UK” (GP03). Some 
patients would be offered “…other treatments like psychological 
treatments…beta-blockers they’d usually say neither of those work for them” 
(GP05). Some patients try an alternative strategy of threatening self-
destructive behaviour unless the GP prescribes them benzodiazepines. 
Examples of such threats are that “…if I didn’t give him “Valium”™ that he 
would be forced to go on booze and other illegal drugs. That would be at my 
door” (GP07) or “I’ll go out of here and I’ll have a seizure and it’ll be on your 
head doctor” (GP03).  
 
In contrast to deceitful attempts to get prescribed benzodiazepines, some 
patients will be “…straight up and say that they’ve got an addiction problem 
and…they want to enter into a program to wean off them” (GP01). These 
interactions with patients appear to influence GPs opinions, “…I think what 
they do is they find the soft touches. The soft touches being single-handed 
practitioners, often people with problems themselves…” (GP04). Some 
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practitioners believe that the behaviour described above is typical, “they’re 
normally deceitful…they are very rarely actually looking for help. They’re just 
looking for prescriptions” (GP01), and that “…they don’t really want to come 
clean” (GP07). Other GPs have a more positive opinion of “…people who’d 
have genuine serious social problems…it’s hard to blame them for wanting 
something to blot it out” (GP04) and seek “…concordance, or a shared 
understanding of what…the patient’s problem is” (GP02). One GP expressed 
the view that “it’s not for me to blame them. It’s for me to show them that 
there’s possibly another way of living your life” (GP04). 
 
GPs were united in their reticence to prescribe and generally did not want to 
give patients the impression that “…by multiple re-presenting that they will be 
able to get a meaningful sustained…prescription of any benzos” (GP05). 
Adherence to this belief could affect relationships with their patients, “…who 
have left the practice because I just won’t prescribe” (GP02). GPs deter 
benzodiazepine prescribing in a variety of ways from warning of side-effects 
like “…this will make you sleepy…” (GP07) to “…repeat prescriptions with 
benzodiazepines must be reviewed every 3 months” (GP04). One GP’s 
differing approach to deterring prescribing was that  
“…if you’re going to deny something that they feel is the only thing 
that’s going to work, it’s important to have another reasonable 
evidence-based alternative…psychological treatments…more 
appropriate pharmacological approaches like the SSRIs…” (GP05) 
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Even though a GP may try to dissuade a young person, often using the 
strategies mentioned above, patients may still try to manipulate GPs 
resulting in an inner conflict between their desire to help and “…knowing that 
you shouldn’t really be prescribing in a person in their 20s, long-term 
Valium… (GP07). This can occur because “…in the real world of general 
practice the pressure on a general practitioner to prescribe is almost always 
driven…by the lack of alternative support therapies” (GP05). GPs can also 
feel pressure from long-term benzodiazepine patients who, “…if the subject 
is raised…about possibly discontinuing their benzodiazepines, get quite 
agitated” (GP02). When a GP takes over from an existing practice and 
decides to change benzodiazepine prescribing practices, there can be 
resistance from the patients who think “…my other doctor gave me these and 
there was no problem and they were great and what are you talking about 
now” (GP07). This means that new GPs can often continue 
“…the prescription because, new doctor, new face, new system. 
Patients already have their back up about that. I didn’t initially want it 
to be new treatment as well. You have to win their trust.” (GP03) 
 
Some GPs accepted that they cannot get all of their patients to discontinue 
benzodiazepines and accept that they will have patients on benzodiazepines, 
“…we're beating ourselves up trying to achieve this ideal…one of the 
things of maturing is to understand what you can't change...it would be 
easiest thing in the world for me to write to the PCRS* and say I want 
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the following 20 people taken off my list...all I'd be doing is transferring 
the patients to some other poor bugger.” (GP04) 
*Primary Care Reimbursement Service (PCRS) is responsible for the 
administration of government-subsidised medical aid in Ireland  
 
7.3.6 Measures to reduce benzodiazepine misuse 
Faced with the problems described in the previous themes, participants gave 
suggestions about how benzodiazepine misuse could be reduced. 
 
7.3.6.1 Limiting sources of benzodiazepines 
Participants had a variety of ideas about how to “…make the availability of 
benzodiazepines…much harder” (GP02). Suggestions for changing GP 
practice ranged from “…training through postgraduate bodies to ensure that 
they have the confidence to em, say no…” (GP05) to “…enforcement is the 
way to go…I think there should be a traffic light system out there…” (GP04). 
Other suggestions were in the area of “…regulation of benzos….it’s not a 
controlled substance” (YC05). Some were advocating severe regulation of 
benzodiazepines “…where we could not prescribe for longer than a 
month…where people are told that they would get perhaps say six weeks 
supply of benzodiazepines in their lifetime…” (GP02), and one participant 
supported banning them outright. Another participant thought that strategies 
to reduce prescribing to young benzodiazepine misusers will have problems 
as “…swapping of drugs amongst all age groups has always gone on and 
will probably continue to go on“ (GP05). 
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7.3.6.2 Education 
Education was another suggestion that was popular among participants to 
reduce benzodiazepine misuse. Participants thought that educating doctors 
“…how to speak to patients, how to relay the information is very clear how 
addictive these substances can be…” (YC02) and about “…guidelines as to 
the maximum duration, maximum dosage… (GP05). Some GPs saw “…the 
big challenge is to educate the patient…how we can use them effectively” 
(GP03). GPs should be “informing of side-effects. Informing of the possibility 
of addiction. Most people are afraid of getting addicted to things…” (GP07). 
Another participant thought that Patient Information Leaflets were too 
confusing, 
“…datasheets need to be…simplistic not legalistic…this is designed 
for short term use only, if you are using it long-term please ask your 
doctor why…this is a habit-forming drug…this drug will…work less 
every time you use it. Why not talk to your pharmacist or your doctor 
about it” (GP04) 
 
Finally, increased public awareness by “…running campaigns about the 
dangers of benzodiazepine use or excessive benzo use” (YC02) was 
identified as important. 
 
7.3.6.3 Alternative therapies 
There was a view among some participants that “…prescribing them for long 
periods of time…doesn’t get to the root of the problem” (YC05) and that 
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“...when we look at addiction we need to look beyond the physical and get 
into the psychological” (GP04). This view was common among both health-
care workers, that GPs are “…under pressure and prescribe. I think if there 
was a therapist within each practice, it might prevent the…high level of 
prescribing of benzos” (YC03). 
 
7.4 Discussion 
This study explored the views of the health-care workers who would be in 
frequent contact with young benzodiazepine misusers.  Participants 
discussed their views on a range of topics from the factors which can make a 
young person more prone to substance misuse to measures which could 
help to reduce youth substance misuse. To the authors’ knowledge, this is 
the first qualitative study to use the views of trained health-care workers, 
GPs and YCs, to describe the patterns of behaviour of young people who 
misuse benzodiazepines. One of the main findings of interest was that 
participants perceived that benzodiazepine prescribing had reduced greatly 
compared to levels in the past. Both groups also agreed that extra controls 
should be placed on the prescription of benzodiazepines of all age groups, 
not just young people. Most participants felt that many of the factors that 
influenced young people’s misuse were outside of the young people’s 
control. Family structure, parental attitude to substance misuse, and 
acceptability of substance use within the local community were identified as 
having an influence on young people.  
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The large influence of family on a young person’s benzodiazepine misuse 
was indicated by participants in this study. Parental substance misuse or 
attitude to misuse, and absence of proper parental supervision can lead to 
positive expectancies and the opportunities to misuse benzodiazepines 
respectively. Study of adolescent benzodiazepine misuse found an inverse 
association between misuse and parental bond (300, 301). This association 
is not unique to benzodiazepine misuse, as there were studies showing that 
maternal neglect is associated with the development of substance use 
disorders (SUDS) (302, 303). An Irish study in 2010 found that use of alcohol 
and cannabis was “linked with an increase in consumption of various kinds of 
substances by young people” (304). This finding has been supported by 
other studies (305, 306). The influence of the community’s perceived 
acceptance of benzodiazepine was highlighted by participants as influencing 
the misuse of benzodiazepines.  Although  no studies relating to this were 
retrieved from the literature, studies relating to alcohol misuse highlighted 
that perceived community disapproval of underage drinking was inversely 
associated with youth alcohol misuse (307, 308). These findings highlight 
that the community in which a young person grows up in has an enormous 
influence on a young person’s substance misuse progression. 
 
Participants held views that GPs were now more aware of benzodiazepine 
prescribing than in the past and that benzodiazepine prescribing decreased 
in recent years. There corroborates with evidence from Chapter 3, which 
showed all-age benzodiazepine prescribing decreased by 16% between 
2009 and 2011 (section 3.3.1). Another difference highlighted between the 
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past and the present was that young people are experimenting with 
benzodiazepines at a younger age. The European School Project on Alcohol 
and Other Drugs (ESPAD) study investigated the percentage of 15-16 year-
olds who had ever misused benzodiazepines at any time between 1995 and 
2011, and found that the level decreased from 9% to 3% (126, 145). The 
same studies found that the percentage of those who first used 
benzodiazepines under the age of 13 years decreased from 2% to 1%. 
These studies suggest that early misuse of benzodiazepines appears to be 
decreasing, contrary to the opinion of participants. Analysis of the referrals to 
substance misuse treatment centres in Ireland however shows that the 
median age of benzodiazepine misuse initiation among new cases has been 
decreasing. The median fell from 20 years between 2003 and 2008, to 18 
between 2005 and 2010 (103, 235). This indicates that while fewer young 
people may have been misusing benzodiazepines, those who were misusing 
them were beginning at a younger age. 
 
Participants opined that there was no gender preponderance regarding 
substance misuse, a finding which is corroborated by the 2011 ESPAD 
survey indicating a 3% prevalence of misuse in male and females (126). The 
participants noted that males accessed more treatment than females. 
Between 2005 and 2010, the majority (60.8%) of new cases of 
benzodiazepine misuse treatment were males, in line with the findings of this 
study (103). Study participants suggested that benzodiazepine misusers 
originate from disadvantaged backgrounds and obtained lower levels of 
education and this is supported in the literature (309, 310). 
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One of the themes which arose from the interviews was the effect of 
benzodiazepines. One of the categories within this theme was the effect that 
benzodiazepines have on school and work. There is clear evidence in the 
literature that benzodiazepines can affect cognitive performance in long-term 
users (25, 239), and there is some evidence that prescription misuse is 
linked with dropping out of school (311). Some participants also spoke about 
young people staying in bed all day, and this could be due to the hangover 
effect of long-acting benzodiazepines (312). Overall the views expressed by 
the participants are in agreement with findings in the scientific literature. 
Another consequence of benzodiazepine misuse was interaction with the 
legal system. It has been noted that taking benzodiazepines can result in 
violent behaviour (313, 314). It is posited that violence from an anxiolytic is 
due to irritability caused by withdrawal effects or due to taking unusually high 
doses. This is in contrast to the views of some of the participants that the 
benzodiazepine use did not lead to violent crime but to theft or drug dealing. 
A search of the literature returned a single study that reported an association 
between regular benzodiazepine use and acquisitive crime in Ireland (152). 
The participants also noted that mixing benzodiazepines with alcohol can 
result in more violent behaviour. This has been called a paradoxical reaction 
to benzodiazepines (238). It has been reported in several studies that mixing 
alcohol and a benzodiazepine will lead to increased aggression (154, 315). 
These studies support the views of the participants. 
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The study included GPs decision-making regarding prescribing 
benzodiazepines to young people under 18 years. The overall view of 
benzodiazepines was quite negative although participants conceded that 
there were circumstances in which benzodiazepines are effective and 
appropriate. They felt that only short-term prescribing of benzodiazepines 
was acceptable. Guidelines for benzodiazepine prescribing recommend that 
benzodiazepines be prescribed for the shortest period possible but no longer 
than four weeks (157, 316, 317). 
 
Participants reported that young people misused prescriptions from GPs. 
Participants reported that there was a view among misusers that it was 
easier to obtain prescriptions from some GPs than others. Some participants 
mentioned that benzodiazepine misusers would attempt to get 
benzodiazepine prescriptions from multiple GPs as another means of 
increasing their supply of benzodiazepines. The idea of “doctor shopping”, 
the simultaneous use of several physicians by a patient, is a topic that 
appears in the literature (318). In one study doctor shopping allowed for the 
greatest number of benzodiazepines to be obtained (193). The same study 
also mentioned obtaining benzodiazepines from a single doctor and from 
“script doctors”, physicians who sell prescriptions illegally. No reference to 
such behaviour was discussed in these interviews, but it may be a feature of 
benzodiazepine acquisition in Ireland. 
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The nature of the GP-patient consultation was discussed by both sets of 
participants. Their opinions about the strategies used by young substance 
misusers differed. YCs described how misusers would feign the appropriate 
mental illnesses to acquire benzodiazepines. GPs spoke about misusers 
telling them of moving from elsewhere and wishing to continue their 
prescription with this GP. Another approach used by misusers was to 
threaten greater self-destructive behaviour if they did not get 
benzodiazepines. From studies of GP-patient consultations, some of these 
approaches are common among the general population. The most frequent 
reason for a benzodiazepine request among all patients in one study was the 
“initiation and continuation of treatment for anxiety, depression, or side 
effects” (319). The approaches suggested by participants of the current study 
are in line with approaches used by the general population, although 
threatening self-destructive behaviour was not observed in the literature.  
 
GPs were generally suspicious of young people looking for benzodiazepines. 
Some GPs opined that young misusers did not come for help but for 
prescriptions to continue their benzodiazepine habit. A recent study found 
that GPs labelled drug addicts as undeserving patients  (320). The same 
study did note that in some cases, a GP’s empathy for the suffering of some 
patients may lead the GP to prescribe to a patient with substance issues. 
These exceptions were noted in some participants who felt conflicted 
between helping patients who are in need of help and feeling guilty about 
prescribing benzodiazepines to a young person where there is a chance that 
they might be risking a lifetime of benzodiazepine use. Another source of 
199 
 
 
 
conflict amongst the GPs was starting in a new practice or when doing GP 
locum work. Their training put pressure on them to change the chronic 
benzodiazepine prescribing pattern that the patient was used to. There is an 
awareness of the conflict between old and new prescribing practices, and 
between older and more recently trained doctors in the literature (320).  
Some GPs resigned themselves to the fact that some patients will not ever 
come off benzodiazepine but just saw it as something they had to live with. 
 
The participants did make suggestions to reduce the misuse of 
benzodiazepines. One of the suggestions was to limit the prescribing of 
benzodiazepines by GPs. Limiting the prescribing programs such as the 
triplicate prescription program in New York State show that benzodiazepine 
prescribing can be reduced (321, 322). Another form of limitation was 
pursued in the Netherlands where in 2009, the government excluded 
benzodiazepines from their reimbursement list when used as an anxiolytic, 
hypnotic or sedative. This policy change resulted in a dramatic decrease in 
the number of long-term and short-term prescriptions issued (323, 324). 
Changes to benzodiazepine-prescribing laws and reimbursement policies 
must be carefully examined as there can often be unintended consequences, 
such as substitution to other potentially unsuitable medicines (325). 
 
Education was another area that participants thought was important. Both 
patient and public education could play a role in reducing the demand for 
benzodiazepines. A simple educational strategy described in the literature 
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was to send benzodiazepine patients letters that advised gradual reduction in 
benzodiazepines. This strategy was most successful in short-term users, 
however it had a poor success rate among long-term users (326). A higher 
level of success was obtained when the letter sent to each patient was 
customised with details of the patient and their benzodiazepine history (327). 
There have also been educational strategies aimed at GPs with conflicting 
results. Some studies reporting a lasting improvement while other studies 
describing no change (328, 329). A recent Cochrane review of educational 
visits to change health-care professional care reported that education can 
make small but potentially important changes to practice (330). Further 
exploration of professional education in relation to benzodiazepine 
prescribing is warranted. The other form of education suggested by 
participants was public health campaigns. Scientific literature in the area of 
public campaigns to modify health behaviours suggests that they can have a 
small-to-moderate impact (331). Research indicates that public health 
campaigns to modify addictive behaviours are more effective when run as 
preventative campaigns before the behaviour begins compared with 
cessation campaigns (331). Thus, a campaign directed at young people who 
have never used benzodiazepines may be more effective than those that 
take them regularly.  
 
The third suggestion that participants recommended was to offer 
benzodiazepine patients and potential patients non-pharmacological 
alternatives to benzodiazepines. Some participants used CBT as an example 
of an evidence-based alternative. CBT has been shown to be effective for 
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anxiety and depressive disorders in children and adolescents (332, 333). A 
meta-analysis of randomised control trials showed that CBT was an effective 
treatment for adult anxiety disorders (334). The other indication for which 
benzodiazepines are commonly prescribed, insomnia, can also be treated 
effectively by CBT (335, 336). Indeed, the results of two randomised direct 
comparison trials between CBT and nonbenzodiazepines with controls 
indicated that CBT was superior in treating chronic insomnia and should be 
recommended as first-line therapy (337, 338). Although there is a small body 
of evidence supporting this, more research is needed before it can replace 
hypnotics, however it does highlight the potential power of CBT in the 
treatment of these serious conditions. A practical consideration that may 
stifle the introduction of CBT as a means of treatment is the relative expense 
of counselling therapies in comparison to benzodiazepines. 
 
7.4.1 Limitations 
This study gives an insight into the experiences of YCs and GPs dealing with 
adolescent benzodiazepine misusers. A limitation of this study was that the 
population was purposively-sampled population, and whilst the study cannot 
be generalised to the larger population, the authors have attempted to 
maximise the transferability of this research by using thick description in the 
findings. The discussion section of this paper relates the findings of this 
study to existing literature. Another possible limitation could be due to the 
fact that the interviewer was a pharmacist, GPs may have felt pressure to 
give a socially desirable response when asked about their attitude to 
prescribing to young people. It would be difficult to verify this without 
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examining their prescribing data, however as some of the GPs mentioned in 
their interviews that they had prescribed to under 18s, the effect of this bias 
is thought to be limited.  
 
7.4.2 Conclusion 
Young people may have poor insight into their substance misuse so working 
with health care workers who encounter them on a regular basis serves to 
give further understanding into their behaviour. Many of the factors which 
can influence whether they will misuse are outside of their control. Measures 
which seek to reduce youth benzodiazepine misuse should be multi-faceted. 
Restrictions on benzodiazepine prescriptions can reduce the supply of 
benzodiazepine to patients and to the communities for whom the patients 
can be dealers. Measures to reduce misuse should also reduce the desire to 
misuse. Educating patients and the public about the long-term effects of 
benzodiazepines can reduce their attractiveness. The provision of 
psychologically-based therapies such as CBT can simultaneously provide 
GPs with an evidence-based alternative for patients afflicted with mental 
illness, and reduce both the burden of the cost of medicines and on the 
substance misuse treatment services. Due to the cost of such therapies, 
further research should be conducted on their economic feasibility.  
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 Thesis Discussion 8.
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8.1 Discussion 
Substance misuse has been a documented problem in Ireland for over 150 
years. Until the late 1960s, alcohol misuse was perceived as the sole 
problem by the Irish government (6). It was not until the rising opiate misuse 
problems in the 1980s that the government seriously invested in substance 
prevention and treatment (7). This lead to the decentralisation of treatment 
and the creation of the methadone scheme and regional drugs task forces 
(6). The rise in cases of misuse of prescribed medicines led to increasingly 
stricter regulations from the 1990s onwards, whilst the increasing availability 
of unregulated novel psychoactive compounds in the late 2000s resulted in 
the ban on these substances and the premises where they were sold (head 
shops) (339). The history of substance misuse in Ireland came full circle with 
the release of the National Substance Misuse Strategy in 2012 (10). This 
report made reduction in alcohol misuse a priority. Similar to goals of the 
earliest alcohol misuse prevention campaigns, the National Substance 
Misuse Strategy aims to reduce not only alcohol dependence, but alcohol 
misuse amongst the general population. 
 
Substance misuse amongst young people was the focus of a systematic 
review conducted (Chapter 2); youth and adolescence tend to be the times 
when substance misuse most frequently starts (5) and so it is important to 
appraise the evidence available. Including studies from the period 2000-2012 
allowed a retrospective analysis of whether misuse of the four most-used 
substances: alcohol, tobacco, cannabis, and benzodiazepines (126) was 
increasing or decreasing. The studies included in the review had varying 
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quality, as highlighted by their Methodological Index for Non-randomised 
Studies (MINORS) score (see Table 2.1). The results of the review 
concluded that alcohol has still the highest level of misuse, followed by 
tobacco, cannabis and benzodiazepines. This corresponds to European data 
which also cites the same four substances in 2011, with alcohol lifetime 
misuse at 87%, tobacco at 54%, cannabis at 17%, and benzodiazepines at 
6% (126). A novel finding from the systematic review was that substance 
misuse levels, in general, were decreasing over the period studied (see 
section 2.4), however; lifetime benzodiazepine misuse levels were stable 
over the same period. The ESPAD studies published in 2000 or 2004 did not 
give average European levels of substance misuse, however data collected 
in 2007 did show that alcohol, tobacco and cannabis misuse decreased by 
2% between the 2007 and 2011 study (113).  
 
Benzodiazepine misuse did not change across the various time points. 
Differences were observed when data on European substance misuse was 
compared to data from the USA. The Monitoring the Future survey (MTF) 
was similar to the ESPAD survey, but it surveyed students of 8th, 10th and 
12th grade in the USA (340).  Comparisons between data from the 10th grade 
students (approximately 15 years old) are most applicable to the ESPAD 
survey. Alcohol was still the substance with the highest lifetime misuse, but 
at 56% it is at least 30% lower than European counterparts. Cannabis 
misuse at 34.5% made it the second-most-misused substance at a level 
double of Europe’s. Tobacco and benzodiazepine misuse was at 30% and 
7%, respectively. Comparing misuse levels in 2007 and 2011, cannabis was 
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the only substance which did not show a decline. Differences between 
European and American cannabis misuse levels could be due to the more 
relaxed attitude towards cannabis in the USA (341). Examples of this relaxed 
attitude can be seen in the use of medical cannabis in 18 states, and the 
decriminalisation of cannabis for recreational use in the states of Washington 
and Colorado (342). The disparity in alcohol misuse levels may be due to the 
differing minimum drinking ages in the USA (21 years) and Europe (16-20 
years depending on country) (343). Benzodiazepine misuse levels were 
similar in both areas, but misuse has fallen in the USA while European levels 
were static (340). Future work should focus on the reasons for the decline in 
the USA and how European countries reduce their levels. 
 
Since benzodiazepines can only legally be obtained on foot of a prescription, 
an investigation into benzodiazepine prescribing in young people was 
performed to examine if excessive prescribing could be a contributing factor 
to their availability. Chapter 3 examined benzodiazepine prescribing in 
Ireland using pharmacy claims data. National prescribing data was presented 
firstly to put the youth prescribing in context. Ireland had the largest decrease 
(16%) in benzodiazepine prescribing between 2009 and 2011, as shown in 
section 3.3.1, although it was still the fourth highest level of those countries 
surveyed. The decrease is welcome but further reductions must continue if 
Ireland’s prescribing level is to match the global average of 10.4 
DDD/1,000/day in 2011 as calculated in section 3.4. This average however is 
likely to increase as developing countries get better access to clinical 
diagnoses (344). The low level of prescribing in some countries may be due 
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to underdiagnosis, and increasing diagnosis may result in increased 
prescribing. The decrease in Irish prescribing levels could lead to a reduction 
in the supply of benzodiazepines to young people via family and/or dealers. 
These can be the sources of benzodiazepines when misusers are at a young 
age (175, 176). The decreasing overall prescribing is counteracted by the 
≈5% increase in benzodiazepine prescribing to those aged under-18. This 
may be due to increased prevalence of mental health disorders in young 
people (345), and increased misuse of these benzodiazepines. 
 
Adherence to the national Good Practice Guidelines for Clinicians varied. 
Approximately 40% of patients had been prescribed hypnotics, while 
approximately 15% of those had been prescribed benzodiazepines for a 
period of more than four weeks, either of which would constitute non-
compliance to Guidelines (157). Adherence to these guidelines in particular 
is important because hypnotics can cause rebound insomnia which may be 
mistaken as a return of the original complaint and may result in the patient 
continuing to take the medication (346). Withdrawal effects can develop 
within a short period (3-14 days) of taking benzodiazepines, which is the 
reason that the benzodiazepine manufacturers’ licences limit use to four 
weeks (190, 247). Such can be the speed of tolerance development that one 
review recommended tapering the dose of benzodiazepines for children who 
have received benzodiazepines for more than 5-7 days (347). The 
development of tolerance to the effects of benzodiazepines can, in some 
circumstances, lead to ‘topping up’, as described in Chapter 7; a 
phenomenon whereby young patients can supplement benzodiazepines 
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prescribed from their doctor with benzodiazepines bought on the street 
(section 7.3.5.1). This may not occur after a single month’s benzodiazepine 
use, but the longer duration of use will increase the likelihood of it occurring. 
Apart from iatrogenic dependence to benzodiazepines, the results of Chapter 
7 in this study shows that it is possible for intentional misusers to feign illness 
to supplement and/or feed their addiction (section 7.3.5.1). The findings in 
Chapters 6 and 7 showed that young misusers seek prescribers who will 
prescribe them benzodiazepines. Reducing the number of patients who 
receive prescriptions for greater than four weeks could help reduce the 
availability of benzodiazepines to misusers. 
 
Chapters 4 and 5 examined substance misuse amongst young people 
attending a substance misuse treatment centre in Cork city, Ireland. Firstly, 
an examination of the differences between attendees from urban and rural 
areas was examined (Tables 4.1 and 4.2). Secondly, a comparison of regular 
and non-regular benzodiazepine misusers with respect to substance-related 
symptoms recorded at admission was conducted (Tables 5.3 and 5.4). The 
results of these studies showed that the percentage of benzodiazepine and 
head shop referrals was higher in urban attendees (P < 0.001). 
Benzodiazepine referrals may be  higher due to the higher levels of 
prescribing in urban areas (215). Another Irish study supported this finding in 
relation to urban preference for head shops (348). The similar levels of 
lifetime use in the majority of substances showed further evidence for the 
convergence of urban and rural substance misuse as described in other 
studies (210, 349). If this convergence continues then it could result in similar 
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admission levels for benzodiazepine misuse for both urban and rural 
misusers. Another interesting result was that urban misusers used more 
substances on a regular basis than rural misusers (Table 4.2). This may 
appear contradictory however as regular substance misuse can be 
influenced by other factors such as income; evidence suggests that urban 
dwellers are at a disadvantage i.e. urban areas have a higher level of poverty 
in comparison to rural areas of Ireland (155). 
 
Chapter 5 illustrates that regular benzodiazepine misusers tend to misuse 
higher numbers of substances on a regular basis compared with those 
classified as non-regular misusers. This was to be expected, however the 
results show that regular benzodiazepine misusers misused two more 
substances than non-regular misusers (Table 4.2). An explanation for the 
higher level of regular misuse may be evident from the findings of the 
interviews in Chapter 7 i.e. the participants spoke about two types of 
benzodiazepines misusers; those who were at an early stage in their misuse 
and those who were more advanced. The former were described as taking 
benzodiazepines sporadically whereas the advanced misusers had settled 
into a pattern of daily benzodiazepine misuse (section 7.3.3.2). It was also 
described by participants of the interview study how some of those at the 
advanced stage will have a high level of tolerance which may lead to the 
progression to other substances such as heroin.  
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Other interesting results from Chapter 5 include the behavioural signs and 
physical symptoms that were experienced by regular misusers compared 
with non-regular misusers (Table 5.4). Loss of interest in sports was one 
such sign, and participants (Chapter 6) spoke about their decreased 
motivation and how their school performance was adversely affected. One 
participant commented that the only thing he wished to do was to stay at 
home and use drugs (section 6.3.6.1). For misusers experiencing this level of 
decreased motivation, involvement in sport or other hobbies can be non-
existent. Paranoia was also a feature of regular benzodiazepine misuse and 
according to interviews (Chapter 6) perceptual changes were listed as 
withdrawal effects experienced by misusers. Paranoia is also a paradoxical 
side effect of benzodiazepines (247).  
 
Chapter 6 focused on young people who had misused benzodiazepines and 
their experiences of misuse while in Chapter 7 YCs and GPs were 
interviewed to give their perspective as trained health-care workers. 
Common themes emerged from both studies, however the individual studies 
provided unique insights into youth benzodiazepine misuse. There were 
shared opinions about the awareness of benzodiazepine’s effects. In 
Chapter 6 participants stated that younger doctors were more aware of 
misuse and would offer alternatives (section 6.3.5.1) while in Chapter 7, 
some participants noted that GPs had become more aware of the potential 
for benzodiazepine misuse (section 7.3.3.1). Reasons given for this included 
the feeling that older doctors were not aware of the habituation effects of 
benzodiazepines or that prescribing of benzodiazepines had started in the 
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treatment of depression (section 7.3.3.1). This gave evidence that newly-
trained GPs were taught about the misuse potential of benzodiazepines 
while it was not known at the time of the predecessors’ education.  
 
In relation to misuse of prescribed benzodiazepines, both YCs and young 
people mentioned that feigning illness was a common strategy used to 
procure a prescription for benzodiazepines (sections 6.3.5.1 and 7.3.5.1). 
The GPs did not mention this strategy. They instead spoke about stories 
from the patient about recently relocating, and wanting to renew their 
prescription (section 7.3.5.3). This suggests that GPs may not be aware of 
some of the strategies used by young benzodiazepine misusers. All 
participants discussed the adverse effects of benzodiazepines on the young 
person’s schooling and education (sections 6.3.6.1 and 7.3.4.1). Participants 
spoke about how benzodiazepine misuse led to deterioration in school 
attendance, and if in school, the inability to concentrate. This correlates with 
evidence on the long-term consequences of benzodiazepine misuse on brain 
development and on the lower level of educational attainment by those who 
misuse benzodiazepines (219). Although some misusers may successfully 
withdraw from benzodiazepines, the many disadvantages associated with a 
low level of education such as; (i) poorer health, (ii) higher likelihood of 
unemployment and (iii) poorer social support, remain (286-288).  
 
Chapter 6 participants spoke about the use of benzodiazepines to minimise 
the severity of the withdrawal effects from stimulants such as cocaine 
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(section 6.3.7.3). The fact that regular benzodiazepine misuse can occur in 
conjunction with regular cocaine misuse could provide another explanation 
for the higher number of regularly misused substances amongst regular 
benzodiazepine misusers noted in Chapter 4. A contribution to the 
understanding of benzodiazepine misuse that came from Chapter 7 was the 
effect that both the family and the community had on the individual’s 
benzodiazepine misuse (section 7.3.2). Parents can influence their children 
subconsciously by implicitly promoting substance misuse by (i) misusing 
substances in front of their children or (ii) by their attitude to misuse as 
described in Chapter 7. Outside of the family, participants thought that the 
community’s perceived attitude to substance misuse could also either 
promote or dissuade substance misuse. The young people interviewed in 
Chapter 6 did not mention these as influencing factors but it is possible that 
their experiences of life outside of their home or outside of their community 
may be restricted. In their immediate surroundings, their friends and 
neighbours would have held similar attitudes and so the young people would 
normalise the acceptance of misuse. This can be contrasted with the 
participants in Chapter 7 who would have received substance misuse 
training, but more importantly they would be in regular contact with people 
from different communities and recognise that different attitudes can exist in 
communities. 
 
There were suggestions from the interviews on how to reduce the level of 
misuse. This is important because the results from Chapters 2 and 3 show 
that benzodiazepine use and misuse are not decreasing among adolescents 
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less than 18 years. Changes suggested were to tighten restrictions on 
benzodiazepine prescribing, educating the public on the dangers of 
benzodiazepine misuse, and to offer patients non-pharmacological 
alternatives such as CBT (section 7.3.6.3). The first of these suggestions has 
been proposed by the Irish government as described in Chapter 1 (3). 
Proposals include making possession of benzodiazepines without a 
prescription illegal, a requirement for benzodiazepine quantities to be written 
in words and figures on prescriptions, and monitoring of benzodiazepines not 
prescribed under a government-subsidised scheme. Examination of the 
scientific literature failed to find research on the effect of benzodiazepine 
awareness campaign on levels of prescribing or misuse; however two 
reviews indicated that public awareness campaigns were capable of 
reducing prescribing levels (350, 351). Campaigns have also been 
successful in reducing the use of dependence-forming substances such as 
alcohol and cigarettes, but one review states that the negative effects of 
substance use must be prominent (352).  
 
The benefit of alternative therapies such as CBT have been shown in 
economic evaluations in insomnia and anxiety (353, 354), however these 
studies compared CBT against standard treatment and so further research 
should be performed to compare CBT with benzodiazepine treatment. Future 
work in this area should investigate the utility of these, and implement them if 
they are found to be beneficial. 
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8.2 Limitations 
There are limitations to the work presented here. Descriptions of the 
limitations of individual chapters are provided already (sections 2.4.2, 3.4.1, 
4.4.2, 5.4.2, 6.4.2, and 7.4.1) so general limitations will be discussed here.  
 
The studies from Chapters 4 and 5 were conducted using data from clients 
attending a substance misuse centre, while the studies from Chapters 6 and 
7 were interview-based, so for different reasons they were not generalisable 
to all young people in Ireland. The treatment centre clients represent a 
section of the general population; those who have been referred for 
substance misuse. This means that the results of these chapters cannot 
represent substance misuse nationally; however they can provide a means 
of monitoring trends in substance misuse. For example, the top five misused 
substances reported were alcohol, tobacco, cannabis, benzodiazepines, and 
cocaine while the top five misused substance amongst clients in Table 5.2 
were the same. 
 
As is the nature with qualitative studies, the interviews in Chapters 6 and 7 
cannot be generalised externally to the national population. However, thick 
description was used to maximise the transferability of the work. The findings 
of the chapters were also compared with scientific literature to validate the 
findings. 
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8.3 Future Work 
Future work from this thesis would focus on testing interventions suggested 
by the work of this thesis that could reduce benzodiazepine and other misuse 
in young people. A public awareness campaign to highlight the dangers of 
misusing benzodiazepines could be developed and implemented. Research 
into the effectiveness of such a campaign would involve surveying 
adolescents before the campaign and after the campaign about their 
knowledge of benzodiazepines. Such a survey would ask participants about 
their perceptions of benzodiazepine misuse in their community, 
benzodiazepines’ dependence-forming ability, and the uses of prescribed 
benzodiazepines and the side effects associated with prescribed 
benzodiazepines. Such a survey should capture if a campaign changed the 
perception of benzodiazepines by adolescents. 
 
The Good Practice Guidelines for Clinicians are 12 years old, and updating 
the guidelines to reflect recent insights into best practice in benzodiazepine 
prescribing and the treatment of benzodiazepine dependence is important. 
The production of new guidelines would remind GPs of the potential dangers 
associated with benzodiazepine prescribing and would also help them to 
confidently treat patients with iatrogenic dependence and dependence from 
other source of benzodiazepines. 
 
Further research needs to be conducted into the applicability of CBT in 
assisting benzodiazepine treatment.  CBT can be used for insomnia and 
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anxiety but the effectiveness of CBT for these conditions in adolescence 
needs to be clarified. The potential for CBT to reduce relapse levels in those 
undergoing treatment for benzodiazepine treatment should be explored. 
 
8.3.1 Conclusion 
This thesis has added to the understanding of youth substance misuse in 
Ireland. Substance misuse has decreased for the three most commonly 
misused substances, but the fourth, benzodiazepines has not changed in the 
12 year period from 2000 to 2012. Benzodiazepine prescribing to young 
people has increased and a large minority of those patients are prescribed 
hypnotics which is not in line with national benzodiazepine guidelines. 
Benzodiazepine misusers attending a treatment centre in Cork are more 
likely to come from urban areas, and regular misusers are more likely to 
regularly misuse multiple substances than those that do not regularly misuse. 
It has contextualised the problems as seen by the client and those who are 
trying to help them. Family attitude and community perception can influence 
the level of youth benzodiazepine misuse. It has also highlighted the 
recommendations favoured by those intimately involved in youth 
benzodiazepine misuse to reduce benzodiazepine misuse amongst young 
people but which may also reduce benzodiazepine prescribing nationwide. 
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10.1  Appendix I - Controlled drugs schedules in Ireland 
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Schedule 1 
• 1-(1,3-Benzodioxol-5-yl)-2-(1-pyrrolidinyl)-pentanone  
• 1-Benzylpiperazine 
• Bufotenine 
• Cannabinol (except where contained in cannabis or cannabis resin) 
• Cannabinol derivatives 
• Cannabis and cannabis resin (hashish) 
• Cathinone 
• Coca leaf 
• Concentrate of poppy-straw 
• [2,3–Dihydro–5–methyl–3–(4–morpholinylmethyl)pyrrolo[1, 2, 3–de]–
1,4–benzoxazin–6–yl]–1–naphthalenylmethanone 
• 3–Dimethylheptyl–11–hydroxyhexahydrocannabinol 
• Eticyclidine 
• Etryptamine  
• 1-(2-Fluorophenyl)-2-methylaminopropan-1-one 
• 1-(3-Fluorophenyl)-2-methylaminopropan-1-one 
• 1-(4-Fluorophenyl)-2-methylaminopropan-1-one 
• 9-(Hydroxymethyl)–6, 6–dimethyl–3–(2–methyloctan–2–yl)–6a, 7, 10, 
10a–tetrahydrobenzo[c]chromen–1–ol 
• [9–Hydroxy–6–methyl–3–[5–phenylpentan–2–yl] oxy–5, 6, 6a, 7, 8, 9, 
10, 10a octahydrophenanthridin–1–yl] acetate 
• Khat (being the leaves of Catha edulis (Celastraceae)) 
• Lysergamide 
• Lysergide (and other N-alkyl derivatives of lysergamide) 
• Mescaline 
• Methcathinone (added by 2010 Regulations) 
• 1-(4-Methoxyphenyl)-2-(methylamino)propan-1-one 
• 2-Methylamino-1-(3,4-methylenedioxyphenyl)butan-1-one  
• 2-Methylamino-1-(3,4-methylenedioxyphenyl)propan-1-one 
• -Methyl-4-(methylthio)phenethylamine 
• 1-(4-Methylphenyl)-2-methylaminopropan-1-one 
• Psilocin 
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• Raw opium 
• Rolicyclidine 
• Tenocyclidine 
• N,N-Diethyltryptamine 
• N.N-Dimethyltryptamine 
• N-(1-Benzyl-4-piperidyl) propionanilide 
• N-[1(2-Thenyl)- 4-piperidyl] propionanilide 
• 2.5-Dimethoxy-∝, 4-dimethylphenethylamine 
• N-Hydroxytenamphetamine 
• 4-Methyl-aminorex 
 
Schedule 2 
• Acetorphine 
• Acetylmethadol 
• Alfentanil 
• Allylprodine 
• Alphacetylmethadol 
• Alphameprodine 
• Alphamethadol 
• Alphaprodine 
• Anileridine 
• Benzethidine 
• Benzylmorphine 
• Betacetylmethadol 
• Betameprodine 
• Betamethadol 
• Betaprodine 
• Bezitramide 
• Carfentanil 
• Clonitazene 
• Cocaine 
• Codoxime 
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• Desomorphine 
• Dextromoramide 
• Diampromide 
• Diethylthiambutene 
• Difenoxin 
• Dihydroetorphine  
• Dihydromorphine 
• Dimenoxadole 
• Dimepheptanol 
• Dimethylthiambutene 
• Dioxaphetyl butyrate 
• Diphenoxylate 
• Dipipanone 
• Drotebanol 
• Ecgonine 
• Ethylmethylthiambutene 
• Etonitazene 
• Etorphine 
• Etoxeridine 
• Fentanyl 
• Furethidine 
• Heroin 
• Hydrocodone 
• Hydromorphinol 
• Hydromorphone 
• Hydroxypethidine 
• Isomethadone 
• Ketobemidone 
• Levomethorphan 
• Levomoramide 
• Levophenacylmorphan 
• Levorphanol 
• Lofentanil 
• Medicinal opium 
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• Metazocine 
• Methadone 
• Methyldesorphine 
• Methyldihydromorphine 
• Metopon 
• Morpheridine 
• Morpine 
• Morphine methobromide  
• Myrophine 
• Nabilone 
• Nicomorphine 
• Noracymethadol 
• Norlevorphanol 
• Normethadone 
• Normorphine 
• Norpipanone 
• Oripavine 
• Oxycodone 
• Oxymorphone 
• Pethidine 
• Phenadoxone 
• Phenampromide 
• Phenazocine 
• Phencyclidine 
• Phenomorphan 
• Phenoperidine 
• Piminodine 
• Piritramide 
• Proheptazine 
• Properidine 
• Racemethorphan 
• Racemoramide 
• Racemorphan 
• Remifentanil 
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• Sufentanil 
• Tapentadol 
• Thebacon 
• Thebaine 
• Tilidine 
• Trimeperidine 
• 4-Cyano-2-dimethylamino-4,4-diphenylbutane 
• 4-Cyano-1-methyl-4-phenylpiperidine 
• 2- Methyl-3-morpholino-1, 1-diphenylpropanecarboxylic acid 
• 1-Methyl-4-phenylpiperidine-4-carboxylic acid 
• 1-Phenylcyclohexylamine 
• 4 Phenylpiperidine-4-carboxylic acid ethyl ester 
• 4-(1-Phenylcyclohexyl) morpholine 
• 1-Piperidinocyclohexanecarbonitrile 
• 1-[1-(2-Thienyl)cyclohexyl] pyrrolidine 
• 4-[1-(-2-Thienyl)cyclohexyl]morpholine 
• Substances 
• Acetyldihydrocodeine 
• Amineptine 
• Amphetamine 
• Amphetaminil 
• Benzphetamine 
• Buprenorphine 
• Butorphanol 
• Codeine 
• Dexamphetamine 
• Dextropropoxyphene 
• Dihydrocodeine 
• Ethylmorphine (3-ethylmorphine) 
• Fenethylline 
• Glutethimide 
• Lefetamine 
• Mecloqualone 
• Methaqualone 
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• Methylamphetamine 
• Methylphenidate 
• Nalbuphine 
• Nicocodine 
• Nicodicodine (6-nicotinoyldihydrocodeine) 
• Norcodeine 
• Phendimetrazine 
• Phenmetrazine 
• Pholcodine 
• Propiram 
• Quinalbarbitone 
• N-Ethylamphetamine 
• Zipeprol 
 
Schedule 3 
• Cathine 
• 1-(3-Chlorophenyl)-4-(3-chloropropyl)piperazine 
• 1-(3-Chlorophenyl)piperazine 
• Chlorphentermine 
• Diethylpropion 
• Ethchlorvnol 
• Ethinamate 
• Flunitrazepam 
• 4-Hydroxybutanoic acid 
• Ketamine 
• Mazindol 
• Mephentermine 
• Meprobamate 
• Methyprylone 
• Pemoline 
• Pentazocine 
• Phentermine 
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• Pipradrol 
• Temazepam 
 
Schedule 4 
• Alprazolam 
• Aminorex 
• Bromazepam 
• Brotizolam 
• Camazepam 
• Chlordiazepoxide 
• Clobazam 
• Clonazepam 
• Clorazepic Acid 
• Clotiazepam 
• Cloxazolam 
• Delorazepam 
• Diazepam 
• Estazolam 
• Ethyl loflazepate 
• Fencamfamin 
• Fenproporex 
• Fludiazepam 
• Flurazepam 
• Halazepam 
• Haloxazolam 
• Ketazolam 
• Loprazolam 
• Lorazepam 
• Lormetazepam 
• Medazepam 
• Mefenorex 
• Mesocarb 
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• Midazolam 
• Nimetazepam 
• Nitrazepam 
• Nordazepam 
• Oxazepam 
• Oxazolam 
• Pinazepam 
• Prazepam 
• Propylhexedrine 
• Pyrovalerone 
• Selegiline 
• Tetrazepam 
• Triazolam 
• Zolpidem 
 
Schedule 5 
• (a) Any preparation of one or more of the substances to which this 
paragraph applies (not being a preparation designed for 
administration by injection) when compounded with one or more other 
ingredients and which contains a total of not more than 100 
milligrammes of the substance or substances (calculated as base) per 
dosage unit and which in the case of an undivided preparation has a 
total concentration of not more than 2.5 per cent of the substance or 
substances (calculated as base). 
(b) The substances to which this paragraph applies are 
acetyldihydrocodeine, codeine, ethylmorphine (3-ethylmorphine), 
nicocodine, nicodicodine (6-nicotinoyldihydrocodeine), norcodeine, 
pholcodine and their respective salts. 
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• Any preparation of dihydrocodeine (not being a preparation designed 
for administration by injection) containing, per dosage unit, not more 
than 10 milligrammes of dihydrocodeine (calculated as base) and 
which in the case of an undivided preparation has a concentration of 
not more than 1.5 per cent of dihydrocodeine (calculated as base). 
 
• Any preparation of cocaine containing not more than 0.1 per cent of 
cocaine calculated as cocaine base, being a preparation which is 
compounded with one or more other ingredients in such a way that 
the cocaine cannot be readily recovered. 
 
• Any preparation of medicinal opium or of morphine containing, in 
either case, not more than 0.2 per cent of morphine calculated as 
anhydrous morphine base, being a preparation which is compounded 
with one or more other ingredients in such a way that the opium or 
morphine cannot be readily recovered. 
 
• Any preparation of dextropropoxyphene, being a preparation designed 
for oral administration, containing not more than 135 milligrammes of 
dextropropoxyphene (calculated as base) per dosage unit or with a 
total concentration of not more than 2.5 per cent, (calculated as base) 
in undivided preparations. 
 
• Any preparation of difenoxin containing, per dosage unit, not more 
than 0.5 milligrammes of difenoxin and a quantity of atropine sulphate 
equivalent to at least 5 per cent of the dose of difenoxin. 
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• Any preparation of diphenoxylate containing, per dosage unit, not 
more than 2.5 milligrammes of diphenoxylate calculated as base, and 
a quantity of atropine sulphate equivalent to at least 1 per cent of the 
dose of diphenoxylate. 
 
• Any preparation of propiram containing, per dosage unit, not more 
than 100 milligrammes of propiram calculated as base and which is 
compounded with at least the same amount, by weight, of 
methylcellulose. 
 
• Any powder of ipecacuanha and opium comprising 10 per cent 
powdered opium, 10 per cent powdered ipecacuanha root, both well 
mixed with the remaining 80 per cent consisting of any other 
powdered ingredient which contains no controlled drug. 
 
• Any mixture containing one or more of the preparations specified in 
this Schedule, being a mixture of which none of the other ingredients 
is a controlled drug. 
 
Schedule 8 
Part 1 - Drugs for pain relief in hospital 
• Morphine sulphate 
• Codeine phosphate 
Part 2 - Drugs for palliative care 
• Morphine sulphate 
• Hydromorphone 
• Oxycodone 
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• Buprenorphine 
• Fentanyl 
• Methylphenidate 
• Codeine phosphate 
Part 3 - Drugs for purposes of midwifery 
• Pethidine 
Part 4 - Drugs for neonatal care in hospital 
• Morphine sulphate Fentanyl 
• Fentanyl 
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10.2  Appendix II - Draft Misuse of Drugs (Amendment) 
Regulations, 2013 
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10.3  Appendix III – Substance use in young persons in 
Ireland 
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10.4  Appendix IV – MINORS rating of reviewed studies 
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                                         MINORS rating of reviewed studies 
   A score of 0 is given if the item is not reported, 1 if reported but not adequate, and 2 if reported and adequate 
 
  
Study 1. A 
clearly 
stated 
aim 
2. Inclusion of 
consecutive 
patients 
3. Prospective 
collection of 
data 
4. Endpoints 
appropriate 
to 
 the aim of 
the study 
8. 
Prospective 
calculation of  
the study 
size 
Total 
Currie 2 2 2 2 2 10 
Curtin 2 0 0 2 0 4 
Flanagan 2 2 2 2 0 8 
Hibell 2004 2 2 2 2 2 10 
Hibell 2008 2 2 2 2 2 10 
Hibell 2012 2 2 2 2 2 10 
Kabir 2 2 2 2 0 8 
Kelleher 0 2 2 2 0 6 
Manning 2 2 2 2 0 8 
McNeill 1 2 2 2 0 7 
Moran 0 0 2 2 0 4 
Morgan 2 2 2 2 0 8 
O’ Cathail 2 0 2 2 0 6 
OTC 2 2 2 2 2 10 
Palmer 1 0 2 2 0 5 
Share 2 2 2 2 2 10 
Smyth 2 2 2 2 0 8 
UNICEF 2 0 2 2 0 6 
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10.5  Appendix V – Ethical approval for study in Chapter 3 
 
  
281 
 
 
 
 
 
 
  
282 
 
 
 
10.6  Appendix VI – Ethical approval for studies in Chapter 4 
and 5 
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10.7  Appendix VII – Sample National Drug Treatment 
Reporting System form 
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10.8  Appendix VIII – Sample Initial Assessment form 
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10.9  Appendix IX – Ethics approval for Chapter 6 research 
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10.10 Appendix X – Information sheet and consent form for 
Chapter 6 research 
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Information Sheet (Briefing for Participants) 
Purpose of the Study. As part of the requirements for my PhD at UCC, I have 
to carry out a research study. The study will look at why young people try 
benzodiazepines, and why they continue taking them after that. 
What will the study involve? The study will involve a single interview which 
should last between 30 and 60 minutes, allowing a small amount of extra time 
for explaining the aims of the study, your questions about the study and how you 
feel after the interview. 
Why have you been asked to take part? You have been asked because you 
have taken benzodiazepines in the past. 
Do you have to take part? Participation is voluntary. If you agree to participate 
you'll sign a consent form, and you'll get to keep a copy of this information sheet 
and the consent form. You can withdraw at any time even if you have agreed at 
first to participate. You can withdraw your permission to use your interview 
within two weeks of the interview; if you withdraw permission, then the interview 
will be permanently deleted.  
Will your participation in the study be kept confidential? Yes. I will ensure 
that no clues to your identity appear in the thesis. Any extracts from what you 
say that are quoted in the thesis will be entirely anonymous.  
What will happen to the information which you give? The data will be kept 
confidential for the duration of the study. On completion of the thesis, the data 
will be retained for 5 years from the date of the interview.  
What will happen to the results? The results will be presented in my thesis. 
They will be seen by my supervisors, a second marker and an external 
examiner. The thesis may be read by future students. The study may be 
presented at scientific conferences and/or published in an academic journal. 
What are the possible disadvantages of taking part? It is unlikely for there to 
be negative consequences if you take part. Although unlikely, it is possible that 
talking about your experiences in this way may cause some form of distress. 
What if there is a problem? At the end of the interview, I will discuss with you 
how you found the experience and how you are feeling. If you subsequently feel 
distressed, you should contact me, the researcher or the seek support from your 
local counsellor. 
Who has reviewed this study? Approval has been granted to do this study by 
the Cork Research Ethics Committee of the Cork Teaching Hospitals. 
Any further queries? If you need any further information, you can contact the 
researcher, Kevin Murphy, by telephone (0863993086) or email, 
kev.mur21@gmail.com 
If you agree to take part in the study, please sign the consent form overleaf 
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Consent Form 
 
I ___________________________________ agree to participate in Mr. Kevin 
Murphy's research study. 
The purpose of the study has been explained to me and I understand it. 
I am participating voluntarily. 
I give permission for my interview with Mr. Murphy to be tape-recorded. 
I understand that I can withdraw from the study, without repercussions, at any 
time whether before it starts or while I am participating. 
I understand I can withdraw my permission to use the data within two weeks of 
the study, in which case the material I have provided will be deleted. 
I understand that anonymity will be ensured in the write-up by disguising my 
identity. 
I understand that disguised extracts from what I say may be quoted in the thesis 
and any subsequent publications if I give permission below: 
(Please tick one box) 
• I agree to quotation/ publication of extracts from my data □ 
• I do not agree to quotation/ publication of extracts from my 
data □ 
 
 
Signed_____________________________ Date: _________________ 
 
Parent (if necessary)________________________ Date: _________________ 
 
Parent (if necessary)________________________ Date: _________________ 
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10.11 Appendix XI – Ethical approval for Chapter 7 research 
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10.12 Appendix XII – Information sheet and consent form for 
Chapter 7 research 
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Information Sheet (Briefing for Participants) 
Purpose of the Study. As part of the requirements for my PhD at UCC, I have 
to carry out a research study. The study will look at why young people try 
benzodiazepines, and why they continue taking them after that. 
What will the study involve? The study will involve a single interview which 
should last between 30 and 60 minutes, allowing a small amount of extra time 
for explaining the aims of the study, your questions about the study and how you 
feel after the interview. 
Why have you been asked to take part? You have been asked because you 
are a drugs worker/counsellor that has treated/is treating a young person that 
has taken benzodiazepines in the past. 
Do you have to take part? Participation is voluntary. If you agree to participate 
you'll sign a consent form, and you'll get to keep a copy of this information sheet 
and the consent form. You can withdraw at any time even if you have agreed at 
first to participate. You can withdraw your permission to use your interview 
within two weeks of the interview; if you withdraw permission, then the interview 
will be permanently deleted.  
Will your participation in the study be kept confidential? Yes. I will ensure 
that no clues to your identity appear in the thesis. Any extracts from what you 
say that are quoted in the thesis will be entirely anonymous.  
What will happen to the information which you give? The data will be kept 
confidential for the duration of the study. On completion of the thesis, the data 
will be retained for 5 years from the date of the interview.  
What will happen to the results? The results will be presented in my thesis. 
They will be seen by my supervisors, a second marker and an external 
examiner. The thesis may be read by future students. The study may be 
presented at scientific conferences and/or published in an academic journal. 
What are the possible disadvantages of taking part? It is unlikely for there to 
be negative consequences if you take part. Although unlikely, it is possible that 
talking about your experiences in this way may cause some form of distress. 
What if there is a problem? At the end of the interview, I will discuss with you 
how you found the experience and how you are feeling. If you subsequently feel 
distressed, you should contact me, the researcher at the number below. 
Who has reviewed this study? Approval has been granted to do this study by 
the Cork Research Ethics Committee of the Cork Teaching Hospitals. 
Any further queries? If you need any further information, you can contact the 
researcher, Kevin Murphy, by telephone (0863993086) or email, 
kev.mur21@gmail.com 
If you agree to take part in the study, please sign the consent form overleaf… 
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Consent Form 
 
I ___________________________________ agree to participate in Mr. Kevin 
Murphy's research study. 
The purpose of the study has been explained to me and I understand it. 
I am participating voluntarily. 
I give permission for my interview with Mr. Murphy to be tape-recorded. 
I understand that I can withdraw from the study, without repercussions, at any 
time whether before it starts or while I am participating. 
I understand I can withdraw my permission to use the data within two weeks of 
the study, in which case the material I have provided will be deleted. 
I understand that anonymity will be ensured in the write-up by disguising my 
identity. 
I understand that disguised extracts from what I say may be quoted in the thesis 
and any subsequent publications if I give permission below: 
(Please tick one box) 
• I agree to quotation/ publication of extracts from my data □ 
• I do not agree to quotation/ publication of extracts from my 
data □ 
 
 
Signed_____________________________ Date: _________________ 
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Information Sheet (Briefing for Participants) 
Purpose of the Study. As part of the requirements for my PhD at UCC, I have 
to carry out a research study. The study will look at the challenges faced by 
General Practitioners prescribing benzodiazepines/Z-type nonbenzodiazepines 
to people less than 18 years of age. 
What will the study involve? The study will involve a single interview which 
should last between 30 and 60 minutes, allowing a small amount of extra time 
for explaining the aims of the study, your questions about the study and how you 
feel after the interview. 
Why have you been asked to take part? You have been asked because you 
are a General Practitioner in the Cork/Kerry area. 
Do you have to take part? Participation is voluntary. If you agree to participate 
you'll sign a consent form, and you'll get to keep a copy of this information sheet 
and the consent form. You can withdraw at any time even if you have agreed at 
first to participate. You can withdraw your permission to use your responses 
within two weeks of the focus group; if you withdraw permission, then your 
responses will be permanently deleted.  
Will your participation in the study be kept confidential? Yes. I will ensure 
that no clues to your identity appear in the thesis. Any extracts from what you 
say that are quoted in the thesis will be entirely anonymous.  
What will happen to the information which you give? The data will be kept 
confidential for the duration of the study. On completion of the thesis, the data 
will be retained for 5 years from the date of the interview.  
What will happen to the results? The results will be presented in my thesis. 
They will be seen by my supervisors, a second marker and an external 
examiner. The thesis may be read by future students. The study may be 
presented at scientific conferences and/or published in an academic journal. 
What are the possible disadvantages of taking part? It is unlikely for there to 
be negative consequences if you take part. Although unlikely, it is possible that 
talking about your experiences in this way may cause some form of distress. 
What if there is a problem? At the end of the interview, I will discuss with you 
how you found the experience and how you are feeling.  
Who has reviewed this study? Approval has been granted to do this study by 
the Cork Research Ethics Committee of the Cork Teaching Hospitals. 
Any further queries? If you need any further information, you can contact the 
researcher, Kevin Murphy, by telephone (0863993086) or email, 
kev.mur21@gmail.com 
If you agree to take part in the study, please sign the consent form 
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Consent Form 
 
I ___________________________________ agree to participate in Mr. Kevin 
Murphy's research study. 
The purpose of the study has been explained to me and I understand it. 
I am participating voluntarily. 
I give permission for my responses in the focus group to be tape-recorded. 
I understand that I can withdraw from the study, without repercussions, at any 
time whether before it starts or while I am participating. 
I understand I can withdraw my permission to use the data within two weeks of 
the study, in which case the material I have provided will be deleted. 
I understand that anonymity will be ensured in the write-up by disguising my 
identity. 
I understand that disguised extracts from what I say may be quoted in the thesis 
and any subsequent publications if I give permission below: 
(Please tick one box) 
I agree to quotation/ publication of extracts from my data □ 
I do not agree to quotation/ publication of extracts from my data  □ 
 
 
 
Signed_____________________________ Date: _________________ 
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